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Abstract 
Polyadenylation is a universal step in the production of all metazoan mRNAs except 
histone mRNA. Despite being universal, previous experiments have implicated it in 
the regulation of inflammation. An inflammatory system using RAW 264.7 murine 
macrophage cells was established with bacterial lipopolysaccharide (LPS) used as a 
stimulus. After improving the poly(A) tail test (PAT) method of measuring poly(A) tail 
lengths, it was applied to inflammatory mRNAs during the inflammatory response. 
Poly(A) tail length was shown to vary over the course of the inflammatory response, 
and for Tnf, this was even true of initial poly(A) tail size, which is widely believed to 
be uniform for the majority of mRNAs. The adenosine analogue cordycepin (3’-
deoxyadenosine) was shown to have anti-inflammatory effects on mRNA, in line 
with existing literature, and is likely to be the anti-inflammatory component of 
Cordyceps militaris ethanol extract. Inhibition of either import of cordycepin into 
cells or phosphorylation of cordycepin was sufficient to abolish its anti-inflammatory 
effects. Adenosine treatment led to repression of Il1b mRNA, but did not repress 
other mRNAs tested that were cordycepin-sensitive. This suggests that cordycepin 
does not simply act by mimicking the effect of adenosine, and that the two 
compounds have distinct modes of action. Inhibiting deamination of cordycepin 
potentiated its effects. We also observed that pre-mRNA levels of inflammatory 
genes were decreased by cordycepin treatment, indicative of effects on 
transcription. Other groups have reported that cordycepin interferes with NF-B 
signalling. As NF-B is an important transcription factor for the induction of 
inflammatory genes, this would provide a basis for explaining our observation that 
cordycepin represses at the transcriptional level. However, we did not observe any 
changes in NF-B signalling, with degradation of IB completely unimpeded by 
cordycepin treatment. Notably, cordycepin did shorten the Tnf poly(A) tail, and the 
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observed inhibition of polyadenylation is consistent with observations that 
cordycepin led to decreased efficiencies of mRNA 3’ cleavage and transcription 
termination for Tnf. Such effects on polyadenylation and 3’ processing of mRNA 
were hypothesised to particularly affect unstable mRNAs that depend on longer 
poly(A) tails for avoiding decay and/or mRNAs with a high rate of transcription. 
However, comparison of microarray data to data from RNA-seq of RNA from 4-
thiouridine labelling experiments showed that cordycepin-sensitivity did not 
correlate with mRNA stability or transcription rate. Long noncoding RNAs (lncRNAs) 
were found to be enriched in cordycepin-treated cells. If some of those lncRNAs 
have regulatory roles in inflammation, cordycepin’s effects may be mediated 
through them. Lastly, cordycepin significantly altered pain behaviour in a rat model 
of osteoarthritis (OA), supporting its continued use as a lead compound for 
exploration of new OA therapeutics. 
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1 Introduction 
There are many forms of gene regulation at the epigenetic, transcriptional, and post-
transcriptional levels. One of the key steps in posttransciptional gene regulation is 
the 3’ processing of mRNA. It is an integral step in the production of a mature 
eukaryotic mRNA transcript. It involves cleavage of the mRNA 20-40 nt downstream 
of a poly(A) signal in the 3’ UTR, followed by the addition of a poly(A) tail at the 
point of cleavage (Proudfoot 2011). This happens for all metazoan mRNAs with the 
exception of histone mRNA. The poly(A) tail facilitates export of transcripts from the 
nucleus, aids mRNA association with factors that promote translation initiation, and 
serves a protective role for the mRNA (Matthew Brook and Gray 2012; Burgess et al. 
2010; Kahvejian et al. 2005). While mRNA 3’ processing is a universal process, it was 
recently suggested that it may have a specific role in regulating inflammation 
(Kondrashov et al. 2012). Inflammation is a key part of the innate mammalian 
immune system, mediating host defence against pathogenic threats and responding 
to tissue damage. It must be carefully regulated in order to respond sufficiently to 
resolve threats and damage, but not be so active that it causes collateral damage to 
the host. In the case of the latter, inflammatory diseases result (Barnes et al. 2010; 
Karin 2006; Puntmann, Taylor, and Mayr 2011; Hummasti and Hotamisligil 2010). 
Cordycepin, an adenosine analogue, is a polyadenylation inhibitor derived from 
caterpillar fungi prized in Far Eastern traditional medicine. Cordycepin is said to have 
anti-inflammatory properties (among many others), and this has been shown both in 
cell culture systems as well as animal disease models (X. Yang et al. 2015; H. Kim et 
al. 2011; Rottenberg et al. 2005; H. G. Kim et al. 2006; Shin, Lee, et al. 2009; Y. Li et 
al. 2016). Briefly, this project aimed to investigate the role of polyadenylation in the 
inflammatory response, and to gain insight into how cordycepin’s anti-inflammatory 
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effects are mediated – whether through inhibition of polyadenylation or through 
other mechanisms. 
1.1 Polyadenylation 
1.1.1 Mechanics of nuclear polyadenylation 
In metazoan gene expression, 3’ cleavage and polyadenylation of pre-mRNA at the 
end of transcription is a critical step. With the exception of histone mRNA, it occurs 
for all transcribed mRNAs. Sequences in the 3’ UTR are recognised and bound by 
various processing factors following which a cleavage reaction occurs, yielding two 
fragments. The 5’ fragment yielded is polyadenylated immediately 3’ of the site of 
cleavage, i.e. a chain of adenosine phosphate residues (the poly(A) tail), is added to 
produce the mature mRNA molecule. The 3’ fragment of the cleavage reaction is 
degraded (Proudfoot 2011; Kuehner, Pearson, and Moore 2011). While there is 
variation e.g. between yeast and metazoan systems, there is significant similarity 
and homology between proteins that participate in the process (Shatkin and Manley 
2000; Zhao, Hyman, and Moore 1999). Here, I will describe the metazoan system. 
Polyadenylation is governed by cis-elements in the 3’UTR which interact with a host 
of trans-acting factors that facilitate the cleavage and polyadenylation reactions 
(Tian and Graber 2012). These factors, summarised in Table 1.1, include the 
cleavage and polyadenylation specificity factor (CPSF), cleavage factors Im and IIm 
(CF Im and CF IIm, respectively), cleavage stimulating factor (CstF), Symplekin, 
WDR33, FIP1L1, and a poly (A) polymerase (PAP). In cases for which commonly used 
names differ from official HUGO gene nomenclature, I will use the official names, 
but both sets of names are shown in Table 1.1. 
A consensus hexamer, most commonly AAUAAA, is found some 15-30 nt upstream 
of the cleavage site in the mRNA 3’ UTR. This sequence is recognised by WDR33 and 
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CPSF4 (Chan et al. 2014; Schönemann et al. 2014), and not by CPSF1, as previously 
thought (Keller et al. 1991; Murthy and Manley 1995). An upstream element (usually 
UGUA) associates with CF Im (Q. Yang, Gilmartin, and Doublié 2011), and a U/GU-
rich element located 20-40 nt downstream of the cleavage site associates with CstF 
(Takagaki and Manley 1997; Perez Canadillas et al. 2003; Beyer, Dandekar, and Keller 
1997). Symplekin is thought to serve as a scaffolding protein that links CstF and CPSF 
(Takagaki and Manley 2000). Two constituent proteins of CF IIm, CLP1 and PCF11, 
were found to be present in the 3’ processing complex at very low levels 
(substoichiometric) compared to CPSF, CstF, and CF Im (Shi et al. 2009).  
Protein Name Other names 
CPSF complex 
CPSF1 CPSF160 
CPSF2 CPSF100 
CPSF3 CPSF73 
CPSF4 CPSF30 
FIP1L1 hFip1 
CstF complex 
CSTF1 CstF50 
CSTF2 CstF64 
CSTF3 CstF77 
CF Im complex 
CPSF6 CF Im 68 
CPSF7 CF Im 59 
NUDT21 Cf Im 25; CPSF5 
CF IIm complex 
PCF11 hPcf11 
CLP1 hClp1 
Other Known Polyadenylation Factors 
SYMPK Symplekin 
PAPOLG PAP-γ 
PAPOLA PAP-α 
PABPC1  
PABPC4  
PABPN1  
WDR33  
 
Table 1.1. List of general 
polyadenylation factors thought 
to function in most cell types. 
Official HGNC names for Homo 
sapiens are given in the first 
column, synonyms are given in 
the second column. Table adapted 
from (Shi et al. 2009) 
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Addition of antibodies against CLP1 to HeLa nuclear extracts reduced cleavage 
activity, but not polyadenylation activity (de Vries et al. 2000). Together, these 
findings suggest that Cf IIm may transiently associate with the rest of the 3’ 
processing machinery to stimulate cleavage activity, possibly by linking CPSF and CF 
Im (de Vries et al. 2000). The exonuclease Xrn2 degrades the 3’ product after mRNA 
cleavage, resulting in transcriptional termination (West, Gromak, and Proudfoot 
2004). Further data from HeLa cells demonstrates roles for PCF11 in mediating 
efficient transcription termination and degradation of the 3’ cleavage product (West 
and Proudfoot 2008). In mammals, a distal G-rich auxiliary downstream element has 
also been identified, although it is not clear which factor(s) it interacts with. Lastly, 
most cleavage sites have a CA dinucleotide immediately 5’ of the cleavage site (with 
mRNA being cleaved immediately after the A). This dinucleotide sequence can be 
clinically relevant e.g. in the case of the human prothrombin gene. The prothrombin 
mRNA 3’ UTR has a CG dinucleotide, rather than the more common CA, which has 
been shown to result in a lower efficiency of cleavage in vitro (F. Chen, MacDonald, 
and Wilusf 1995). In ~1-2% of the Caucasian population the CG dinucleotide is 
mutated to CA, and is thought to be a cause of thrombophilia experienced by 
individuals with the mutation (Poort et al. 1996; Cattaneo et al. 1999). In these 
cases, the processing of the prothrombin mRNA is enhanced, as seen in cell culture 
conditions and transgenic mice (Gehring et al. 2001; Danckwardt et al. 2004; 
Kuwahara, Kurachi, and Kurachi 2004). The resulting increase in prothrombin 
expression (at the level of both mRNA and protein) provided the basis for a model to 
explain the contribution of the mutation to the pathogenesis of thrombophilia. 
While CPSF3 was reported to be the endonuclease that performs the cleavage 
(Mandel et al. 2006), it seems both CPSF3 and CPSF2 contribute to endonucleolytic 
activity (Kolev et al. 2008). Upon cleavage of the mRNA, a poly(A) polymerase 
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processively adds adenosine phosphate residues to form the poly(A) tail, typically 
thought to be 200-250 nt in length. The polyadenylation reaction is stimulated by 
FIP1L1 (Kaufmann et al. 2004). There are a number of canonical and non-canonical 
poly(A) polymerases (ncPAPs), which are discussed in section 1.1.3. PABPN1, a 
poly(A) binding protein (PABP), stimulates poly(A) tail extension and is thought to 
have a role in controlling its length (Kuhn et al. 2009). Nucleophosmin (NPM1) 
deposition on the poly(A) tail is also involved in poly(A) tail length control, with 
NPM1 knockdown resulting in hyperadenylation of mRNA in HeLa cells (Sagawa et 
al. 2011). 
1.1.2 Control of poly(A) tail length 
It is generally thought that a new mRNA is made in the nucleus with a poly(A) tail of 
200-250 nt. The mechanism proposed for the control of the length involves 
interactions between CPSF, the poly(A) polymerase (PAP) doing the polyadenylation, 
and PABPN1 (Kuhn et al. 2009). Initially, binding of PABPN1 to the nascent poly(A) 
tail and of CPSF to the poly(A) signal allows them to stimulate PAP activity. However, 
once the critical length is reached (~250 nt), PABPN1 then disrupts stimulation of 
PAP by CPSF, and so PABPN1 is proposed to perform the role of measuring and 
limiting the length of the poly(A) tail. PABPN1 has also been shown to have a role in 
splicing. While splicing is generally understood to occur co-transcriptionally (Tilgner 
et al. 2012; Carrillo Oesterreich, Preibisch, and Neugebauer 2010; Khodor et al. 
2011; Ameur et al. 2011), some splicing occurs following polyadenylation. In human 
cells, PABPN1 depletion decreased the splicing efficiency of a subset of pre-mRNAs 
that undergo splicing after polyadenylation (Muniz, Davidson, and West 2015). 
Knockdown of PAPOLA and PAPOLG also decreased the splicing efficiency, even for a 
synthetic construct whose cleavage and polyadenylation did not depend on cellular 
machinery i.e. the poly(A) polymerases’ role in facilitating splicing was independent 
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of the process of polyadenylation. IP experiments also showed PABPN1 depletion 
reduced association of splicing factors with terminal introns. 
The RNA binding protein ZC3H14 is important in neural function (Pak et al. 2011) 
and also has a role in controlling poly(A) tail lengths (Kelly et al. 2014). In mouse 
neuroblastoma cells, depletion of Pabpn1 led to shortening of total poly(A) tail 
length, while depletion of ZC3H14 led to longer poly(A) tails. Adult survival of flies 
lacking Nab2 (orthologue of ZC3H14) was very low, but those that did survive 
exhibited defects in development and locomotion. These could be rescued by 
neuron-specific transgenic expression of human ZC3H14, indicating an evolutionarily 
conserved role of this RNA binding protein. In yeast, the PABPs Pab2 and Nab2 have 
opposing roles in the nuclear decay of pre-mRNA (Grenier St-Sauveur et al. 2013). 
Pab2 facilitates exosomal degradation of pre-mRNA while Nab2 impedes it, affording 
the pre-mRNA more time to complete posttranscriptional splicing, ‘escape’ the 
Pab2-mediated exosomal decay, and be exported into the cytoplasm. Thus, nuclear 
PABPs can influence poly(A) tail length but can also serve other roles in regulating 
gene expression. 
While the 250 nt length in animals is generally accepted as the initial poly(A) tail size 
of a newly transcribed mRNA, there appear to be a few exceptions to the rule. 
Mammalian histone mRNA completely lacks a poly(A) tail (Marzluff, Wagner, and 
Duronio 2008; Marzluff 2005). eNOS mRNA in endothelial cells has been shown to 
be differentially polyadenylated in the nucleus in response to certain stimuli (Weber 
et al. 2005; Kosmidou et al. 2007). Under basal conditions, eNOS mRNA has a short 
poly(A) tail of <25 nt, but in response to statins or laminar shear stress, the mRNA is 
synthesised with a much longer poly(A) tail. The longer eNOS poly(A) tail is 
accompanied by greater mRNA half-life, greater representation of the mRNA in 
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higher polysome fractions (suggestive of increased translational activity), and 
greater mRNA levels in the cytoplasm (Weber et al. 2005; Kosmidou et al. 2007). 
A cis element termed the poly(A) limiting element (PLE) was found in the terminal 
exon of a number of mRNAs whose initial poly(A) tail sizes were discrete and limited 
to <20 nt (Das Gupta et al. 1998; Gu, Das Gupta, and Schoenberg 1999). The PLE was 
originally identified in Xenopus albumin pre-mRNA, but placing the PLE-containing 
part of the mRNA into a β-globin reporter construct transfected into mouse 
fibroblasts produced β-globin mRNA with <20 nt poly(A) tails, indicating 
conservation of the limiting mechanism between species (Das Gupta et al. 1998). 
Other mRNAs with PLE sequences and <20 nt poly(A) tails include transferrin and 
HIV-EP2, and removal of the PLE sequence in reporter constructs led to mRNAs with 
long poly(A) tails (Gu, Das Gupta, and Schoenberg 1999). It was later found that U2 
auxiliary factor (U2AF) binds to the PLE and has a role in modulating poly(A) tail 
length control by the PLE (Gu and Schoenberg 2003). Interestingly, it was found that 
the PLE increases mRNA levels in the cytoplasm by enhancing the efficiency of mRNA 
3’ processing in reporter constructs. PLE-containing RNA was cleaved in HeLa 
nuclear extract 80% faster than control RNA (J. Peng, Murray, and Schoenberg 
2005). Furthermore, PLE-containing β-globin mRNA with a short tail <20 nt was 
shown to be as stable as non-PLE-containing β-globin mRNA with a poly(A) tail size 
of 100-200 nt. These β-globin reporter constructs had the last part of the terminal 
exon removed and a synthetic polyadenylation element added at this point. Thus, 
regulatory elements in the β-globin 3’ UTR (which confer considerable mRNA 
stability (Peixeiro et al. 2011)) would not be present, and therefore would not be 
able to influence the stability of the mRNA produced. 
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1.1.3 Poly(A) polymerases and other types of polyadenylation 
In humans, 8 poly(A) polymerase (PAP) enzymes have been identified. The three 
canonical PAP enzymes are PAPα, PAPβ, and PAPγ (PAPOLA, PAPOLB, and PAPOLG 
respectively), with PAPOLA and PAPOLG thought to be the two main enzymes 
involved in nuclear polyadenylation of mRNA. Non-canonical PAPs (ncPAPs) include 
MTPAP (mitochondrial PAP), TUT1 (STAR-PAP), PAPD4 (GLD2), PAPD5 (GLD4), and 
PAPD7. Canonical PAPs are nuclear enzymes, as are some ncPAPs. However, a 
number of ncPAPs perform roles outside of the nucleus. Additionally, some ncPAPs 
also have terminal nucleotidyl transferase activity that is not limited to addition of 
adenosines. PAPD4 is a cytoplasmic PAP with importance in germline development 
and synaptic plasticity in a number of species (Sartain et al. 2011; Kwak et al. 2008; 
Rouhana et al. 2005; Benoit et al. 2008; Barnard et al. 2004). MTPAP is the only 
known mitochondrial PAP, and polyadenylates mitochondrial RNAs. PAPD5 
polyadenylates aberrant pre-rRNA to bring about its degradation (Shcherbik et al. 
2010), uridylates histone mRNA to bring about its degradation (Mullen and Marzluff 
2008), and performs 3’ oligoadenylation for snoRNAs with possible implications for 
their stability (Berndt et al. 2012). PAPD5 is also implicated in the regulation of TP53 
(p53) mRNA levels and protein expression (Burns and Richter 2008), which might be 
a cytoplasmic role (more on this in section 1.1.3.1). In yeast, the Trf4p/Air2p/Mtr4p 
polyadenylation (TRAMP) complex is a nuclear surveillance complex that serves to 
polyadenylate aberrant nuclear transcripts, leading to their exosomal degradation 
(Wyers et al. 2005; Vaňáčová et al. 2005; LaCava et al. 2005). This role of 
polyadenylation (performed by Trf4p – a non-canonical PAP and orthologue of 
PAPD5) appears to be more in line with polyadenylation’s prokaryotic origins, in 
which it promotes degradation. In mammals, a TRAMP-like complex includes PAPD5, 
demonstrating evolutionary conservation of the decay mechanism and a role for this 
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non-canonical PAP (Sudo et al. 2016; Shcherbik et al. 2010). It should be noted, 
however, that the phenomenon of polyadenylation in the nucleus to mediate 
exosomal decay of aberrant transcripts is not exclusively performed by ncPAPs. 
Work in human cells has revealed an exosomal nuclear decay pathway in which 
PAPα and PAPγ (canonical PAPs), together with PABPN1 and exosomal subunits, 
perform this role (Bresson and Conrad 2013). Since these poly(A) polymerases 
appear to have multiple roles, it is conceivable that these depend on binding 
partners. It was noted that this decay pathway did not affect efficiently exported 
RNAs. A model could therefore be constructed wherein the coupling of 3’ processing 
to nuclear export takes RNAs away from the polyadenylation-dependent 
degradative nuclear environment, and into the cytoplasm where the poly(A) tail 
serves other roles. A subset of long noncoding RNAs (lncRNAs) were among those 
found to be subject to this PABPN1-involved, polyadenylation-dependent turnover 
(Beaulieu et al. 2012). Further work is required for characterisation of PAPD7.  
A cytoplasmic role of Trf4-1 for promoting decay in Drosophila was recently reported 
(Harnisch et al. 2016). 3’ mRNA decay intermediates were found to have terminal 
oligoadenylations i.e. the mRNA had already experienced some 3’ decay such that its 
3’ end was upstream of the poly(A) site, but then non-template As had been added 
to this end. These modifications were due to the cytoplasmic activity of Trf4-1, and 
knockdown of Trf4-1 and the Dcp2 decapping enzyme led to a significant 
accumulation of 3’ decay intermediates cf Dcp2 knockdown alone, illustrating the 
role of Trf4-1 in promoting decay. Some ncPAPs are capable of performing 3’ end 
uridylation of mRNA, and are thus classed as terminal nucleotidyl transferases 
(TUTs) (Lim et al. 2014; Kwak and Wickens 2007; Rissland, Mikulasova, and Norbury 
2007; Martin and Keller 2007). Terminal uridylation of mRNA is another modification 
that can influence cytoplasmic mRNA decay. In yeast and mammalian systems, it 
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promotes decay (Slevin et al. 2014; Malecki et al. 2013), while it may have the 
opposite function in Arabidopsis (Sement et al. 2013). Uridylation can occur after the 
poly(A) tail, with shorter tails being better substrates for uridylation than longer tails 
(Lim et al. 2014). Non-polyadenylated mRNAs like siRNA-directed cleavage products 
and histone mRNA decay intermediates can also be uridylated (Slevin et al. 2014; 
Shen and Goodman 2004).  
1.1.3.1 Cytoplasmic polyadenylation 
Polyadenylation can occur in the cytoplasm for mRNAs that have already been 
transcribed and exported from the nucleus via the process of cytoplasmic 
polyadenylation. Generally, the role of cytoplasmic polyadenylation is to ‘activate’ 
translation of certain mRNAs that are stored in the cytoplasm in a repressed state 
with a short poly(A) tail (Weill et al. 2012; Villalba, Coll, and Gebauer 2011). For an 
mRNA to be regulated in this way, it would have to (after export from the nucleus) 
recruit deadenylases and factors that repress translation, be stored in the 
cytoplasm, and then be recognised by cytoplasmic polyadenylation machinery. This 
process is governed by interplay between cis elements in the 3’ UTR and trans-acting 
factors (Charlesworth, Meijer, and de Moor 2013). These include the same poly(A) 
signal as is used in nuclear polyadenylation (recognised by cytoplasmic CPSF 
complex), the cytoplasmic polyadenylation element (CPE) (recognised by CPE 
binding proteins (CPEBs)), and the Pumilio binding element (PBE) (bound by Pumilio 
(PUM2)). 
Cytoplasmic polyadenylation was originally found in germ cell and embryonic 
development across a number of different species, and is known to play crucial roles 
in these processes (Sartain et al. 2011; Luitjens et al. 2000; Wilt 1973; Fox, Sheets, 
and Wickens 1989; Standart and Dale 1993; Vassalli et al. 1989; Lim et al. 2016). 
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However, cytoplasmic polyadenylation has also been found to play roles in somatic 
cells, with the nervous system being one example. N-methyl-D-aspartate (NMDA) is 
an agonist for the NMDA receptor (NMDAR). NMDAR is thought to be important in 
synaptic plasticity and memory (F. Li and Tsien 2009). Treating mammalian neurons 
with NMDA led to a rapid increase in poly(A) tail size of NR2A mRNA . This increase 
was reduced by PAPD4 depletion, and NMDA treatment promoted phosphorylation 
of CPEB and dissociation of poly(A) ribonuclease (PARN) – these are both events 
associated with the transition from a repressed to activated state of mRNAs 
regulated by cytoplasmic polyadenylation. Additionally, PAPD4 has been shown to 
be important in Drosophila for long-term memory (Kwak et al. 2008), and Orb2 
(Drosophila somatic CPEB) is required for asymmetric cell division during 
neurogenesis (Hafer et al. 2011). 
Cytoplasmic polyadenylation is also important in the regulation of cell cycle. In HeLa 
cells, total mRNA and mRNA with short poly(A) tails were separated into fractions 
for cells in S phase and cells in G2/M phase (Novoa et al. 2010). The ratio of total to 
short poly(A) tail for each mRNA was then evaluated and compared between cells 
from the two different phases. Hundreds of mRNAs displayed a change in this ratio, 
and polyadenylation of some of these transcripts was affected by knockdown of 
CPEB1 and CPEB4. A more recent study in HeLa cells compared differentially 
expressed genes (DEGs) between S and M phases (J.-E. Park et al. 2016). A small set 
of key cell cycle regulators, including CDK1, experienced a significant decrease in 
poly(A) tail length in M phase, with coincident translational repression. However, 
this group represented just 8 genes out of the 777 DEGs, suggesting greater 
importance of polyadenylation-independent regulation of gene expression in the cell 
cycle. In mouse primary fibroblasts, cells’ ability to enter senescence was prevented 
by knockdown or ablation of CPEB1 (Groisman et al. 2006; Burns and Richter 2008). 
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Additionally, translational activation of TP53 (p53) – a master cell cycle regulator and 
tumour suppressor – mRNA was found to be dependent on CPEB1, and knockdown 
of CPEB1 led to TP53 mRNA with short poly(A) tails. PAPD5 was found to be 
associated with CPEB1 and TP53 mRNA, and knockdown of PAPD5 reduced TP53 
mRNA polyadenylation and protein expression (Burns and Richter 2008). Taken 
together, these data implicate cytoplasmic polyadenylation in the regulation of the 
cell cycle and specifically TP53 mRNA. 
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is an 
important transcription factor in the process of inflammation (see sections 1.3.2.1.1 
and 1.3.2.1.3). A kinase upstream of NF-κB activation is mitogen-activated protein 
kinase kinase kinase 7 (MAP3K7 or TAK1). TAK1 has been shown to be regulated by 
CPEB, with CPEB-depleted macrophages displaying elevated production of pro-
inflammatory cytokines (Ivshina et al. 2015). In this way, CPEB plays an important 
role in the control of the inflammatory response, although polyadenylation was not 
implicated in the study. 
1.1.3.2 Mitochondrial polyadenylation 
In mammals, mitochondrial RNAs are produced as polycistronic RNAs that are then 
processed by endoribonucleases to yield separate, intronless mRNAs. For several 
mitochondrial mRNAs, this cleavage leaves a 3’ end with an incomplete stop codon, 
with either a terminal UA or just U (S. Anderson et al. 1981). For these mRNAs, 
polyadenylation, performed by MTPAP, completes the UAA stop codon (Nagaike et 
al. 2005). A homozygous MTPAP mutation (N478D) in fibroblasts led to loss of 
polyadenylation but retention of oligoadenylation (Wilson et al. 2014). The enzyme 
was shown to have severely compromised polyadenylation activity in vitro. 
Fibroblasts with the mutation displayed a reduction in protein synthesis, and 
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reduction in levels of oxidative phosphorylation complexes I and IV. The loss of 
mitochondrial transcript polyadenylation and decreased levels of oxidative 
phosphorylation complexes I and IV was rescued by overexpression of wild-type 
MTPAP. So mitochondrial polyadenylation is an important posttranscriptional 
regulatory mechanism, and its dysregulation can lead to decreased mitochondrial 
protein synthesis and reduction in respiratory chain complexes. 
1.1.4 Biological importance and role of the poly(A) tail 
PABPs, through binding the poly(A) tail, perform a number of biologically important 
roles. Normally, they facilitate export of mRNAs from the nucleus. However, PABPN1 
can also enhance the decay of some hyperadenylated mRNAs that are not efficiently 
exported.  
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mRNAs are generally bound by the cytoplasmic poly(A) binding protein, PABPC1, on 
the poly(A) tail, while the 5’ cap is bound by eIF4E, as part of the cap binding 
complex, comprising eIF4E, eIF4G, and eIF4A (Mangus et al. 2003). Interactions 
between eIF4G and PABP facilitate formation of the closed-loop complex (Figure 
1.1). This complex is important for the formation of ribosomal initiation complexes 
(Kahvejian et al. 2005).  
Most eukaryotic mRNA degradation is thought to require shortening of the poly(A) 
tail (deadenylation) by deadenylase complexes (PAN2-PAN3, Ccr4-Not) to some 
critical length, whereupon the mRNA then becomes susceptible either to decapping 
(i.e. hydrolytic removal of the mRNA 5’ cap structure) followed by 5’-3’ 
exonucleolytic decay (C.-Y. A. Chen and Shyu 2011), or exosomal decay in the 3’-5’ 
direction. Some mRNAs contain regulatory cis elements that increase deadenylation 
and decay rates. AU-rich elements are a well-studied example of such sequences, 
and are found in many mRNAs encoding growth factors and inflammatory mediators 
(P. Anderson 2010; Stumpo, Lai, and Blackshear 2010; Khabar 2010). The AU-rich 
sequence UUAUUUAU, for example, is bound by tristetraprolin (TTP) in TNF mRNA 
and mediates instability (Stoecklin et al. 2004; Mahtani et al. 2001) – see section 
1.3.2.1.3 for more detail. This sequence also appears to play a role in TNF 
translational repression (Han, Brown, and Beutler 1990; Kontoyiannis et al. 1999), 
discussed more in section 1.3.2.1.1.1. 
Data from TAIL-seq, a high throughput poly(A) tail analysis technique, revealed that 
poly(A) tail length correlated positively with mRNA half-life (Chang et al. 2014). 
However, it did not correlate with ribosome binding. Rather, data suggested that a 
very short or no poly(A) tail was detrimental for translation, but beyond a critical 
length of ~25 nt, further increases in poly(A) tail size had no bearing on translation. 
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High throughput analysis in Arabidopsis showed a modest negative correlation 
between poly(A) tail length and mRNA half-life (Kappel et al. 2015). Data yielded 
from PAL-seq, a similar technique to TAIL-seq, found either weak negative or 
variable correlations between poly(A) tail length and mRNA half-life in 3T3, HeLa, 
and yeast (Subtelny et al. 2014). PAL-seq data also showed that a strong positive 
correlation between poly(A) tail length and translational efficiency did exist for cells 
in early developmental stages, but not for cells that had passed this phase. This fits 
with existing knowledge that non-polyadenylated, maternally-derived mRNAs in 
Xenopus oocytes can be translationally unmasked and activated by cytoplasmic 
polyadenylation. It should be noted, however, that in these cases, translational 
efficiency was inferred from ribosome binding i.e. translation initiation. Changes in 
the rate of translation elongation are not considered, so these correlations rest on 
the assumption that translation elongation is constant and independent of poly(A) 
tail length changes, which may not be the case. A third, similar recently published 
technique, PAT-seq, found little or no correlation between mean poly(A) tail length 
for a given mRNA and its read count or protein abundance (Harrison et al. 2015). 
In an in vitro decay system, it was shown that PABP depletion led to a several-fold 
increase in the decay rate of mRNAs (Bernstein, Peltz, and Ross 1989). This could be 
rescued by addition of exogenous PABP, and the decay rate of non-polyadenylated 
RNA was independent of the presence of PABP. Thus, the poly(A) tail and PABP, 
together, have a protective role, and it could be the case that the closed-loop 
complex reduces accessibility of the mRNA ends to decay machinery. However, the 
relationship between PABP and mRNA turnover is more complex than that, as it can 
also promote deadenylation and therefore decay, via TOB1 recruitment (Ezzeddine, 
Chen, and Shyu 2012). In summary, the poly(A) tail, through interaction with PABP, 
is important for nuclear export, translation, and mRNA lifetime.   
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Figure 1.2. Life cycle of an mRNA. As RNA polymerase II (RNAP II) 
transcribes the DNA, the nascent mRNA is subject to splicing. The poly(A) 
signal and nearby cis elements are recognised by mRNA 3’ processing 
machinery that cleaves the mRNA and polyadenylates the 5’ fragment. 
The 3’ product is degraded. The poly(A) tail is bound by poly(A) binding 
protein (PABP) and the mRNA is exported from the nucleus where it can 
adopt the closed-loop formation, favouring translation. The poly(A) tail 
can be removed by deadenylation and restored through cytoplasmic 
polyadenylation. Once shortened beyond a critical length, it is subject to 
degradation either by decapping and 5’-3’ exonucleolytic decay by XRN1, 
or by 3’-5’ exosomal decay. 
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1.1.5 Alternative polyadenylation 
Some mRNAs have multiple poly(A) sites, and so cleavage and polyadenylation can 
take place at different sites to yield different products. This process is termed 
alternative polyadenylation (APA), of which there are four main types: 
1. APA at tandem 3’ UTR sites 
2. APA at alternative terminal exons 
3. APA at intronic sites 
4. APA at exonic CDS sites 
APA at tandem 3’ UTR sites (1) produces mRNAs that vary solely in the length of 
their 3’ UTR, but are otherwise identical. The other three types of APA produce 
mRNAs which differ in both coding and 3’ UTR sequences. APA at alternative 
terminal exons (2), while termed APA, is a result of alternative splicing, which 
determines the terminal exon of the transcript. APA at cryptic poly(A) site in an 
intron or exon (3 and 4) can lead to production of truncated protein isoforms with 
altered coding and 3’ UTR sequence.  
Research has implicated APA and its regulation in cancer (Xia et al. 2014; Mayr et al. 
2009; Sandberg et al. 2008). Specifically, this generally involves a switch to proximal 
poly(A) sites, resulting in shorter 3’ UTRs which lack regulatory sequences e.g. 
miRNA binding sites for negative regulation. APA is also found to be important in the 
immune system, with T-cell activation leading to global 3’UTR shortening (Gruber et 
al. 2014). APA changes are also relevant in the activation of macrophages (Shell et al. 
2005), and PTGS2 (COX2) regulation (Cornett and Lutz 2014; Hall-Pogar et al. 2007). 
1.1.6 Measuring poly(A) tails 
Given the importance of poly(A) tails, tools and techniques have been developed in 
order to study them and assess length. However, accurately studying poly(A) tail 
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length is not a simple task. If comparing full length mRNAs, differences in poly(A) tail 
sizes can be difficult to detect, given that these would be on a much smaller scale 
relative to the entire length of the mRNA. Traditional replication-based sequencing 
methods are not suitable for use in determining poly(A) tail lengths due to problems 
with slippage on homopolymeric sequences (Viguera et al. 2001; Clarke et al. 2001). 
Briefly described below are some of the commonly used methods, which include 
northern blotting, poly(A) tail test (PAT), and 3’ end labelling.  
Northern blotting: 
1) A DNA probe that anneals at a known position of the 3’ UTR of the mRNA of 
interest (e.g. 300 nt upstream of the cleavage site) is allowed to hybridise to 
the RNA. RNase H treatment will then cleave at the site of hybridisation 
between RNA and the DNA probe, yielding fragments whose lengths are 
equal to 300 nt (distance between where the probe annealed and the 
cleavage site) plus the length of the poly(A) tail (which may vary across a 
range in the pool of mRNAs). 
2) The above is done, but, in addition to the specific oligo, oligo (dT) is added 
to the reaction, and so the poly(A) tail is removed. The product of the RNase 
H treatment should just be 300 nt. Only a single product should be produced 
(since the region of variable size – the poly(A) tail – has been removed). 
3) Cleavage products are cleaned up, run on a gel and visualised by northern 
blotting. The difference in size between the polyadenylated and 
deadenylated samples corresponds to the length of the poly(A) tail. 
This method has the advantage of specificity, but requires the use of radiation, high 
starting input of RNA, and lacks sensitivity, with mRNAs of low abundance being 
difficult to detect using this method. Also, the image quality is inferior to that of 
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agarose gels (see below), and the oligo (dT) has the potential to anneal to A-rich 
tracts instead of the poly(A) tail, leading to cleavage at an unintended location. 
Poly(A) test (PAT): 
There are a number of different PCR-based poly(A) test (PAT) methods, including 
RACE-PAT, ePAT, sPAT, and Klenow PAT, of which some are described in a recent 
review (Jalkanen, Coleman, and Wilusz 2014). The one described here is RNA 
ligation-mediated PAT (Figure 1.3): 
1) RNA is prepared in duplicate – one set is subjected to an RNase H/oligo (dT) 
treatment to remove poly(A) tails (deadenylated sample). The other set is 
untreated, and so retains poly(A) tails of mRNAs (non-deadenylated 
sample). 
2) RNA has a DNA adapter ligated to its 3’ end (“PAT anchor”). 
3) An oligo complementary to the PAT anchor (“PAT-R1”) is used to perform a 
specific reverse-transcription reaction to synthesise cDNA from all RNA to 
which the PAT anchor was successfully ligated.  
4) A PCR reaction is done, using a forward primer than anneals in the 3’UTR (at 
a known location), and PAT-R1 as the reverse primer. The PCR product 
length will be equal to the sum of the distance between the forward primer 
priming site and the cleavage site; the length of the poly(A) tail (for non-
deadenylated samples); and the length of the ligated PAT anchor sequence. 
Deadenylated samples should give rise to a single PCR product. 
5) PCR products are run on an agarose gel and visualised under UV by EtBr or 
SYBR Safe stain. The difference in size between deadenylated and non-
deadenylated samples corresponds to the size of the poly(A) tail. 
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Figure 1.3. Schematic overview of the RNA ligation-mediated 
PAT procedure. A 3’-blocked adapter (“PAT anchor”) is ligated to 
the 3’ ends of RNA. Reverse transcription is done using a primer 
complementary to PAT anchor (PAT-R1) to generate PAT cDNA. 
PCR is performed using a forward primer that anneals to the 3’ 
UTR of the gene of interest, and PAT-R1 as the reverse primer. 
The PCR products are analysed on an agarose gel. 
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This technique is more sensitive than northern blotting due to the amplification 
involved in the PCR, and does not require the use of radiation. The image quality 
obtained on the agarose gel is superior to that of a northern gel. However, high 
input RNA quantities are still required, especially if oligo (dT)/RNase H treatment is 
to be done, and the use of PCR can lead to artefacts and off-target amplification.  
3’ End-labelling 
1) A radioactive pCp base is ligated to the 3’ end of total RNA. 
2) A cocktail of RNases digests all RNA that is not poly(A). 
3) Free poly(A) tails are then run on a long TBE-urea PAGE gel, and then placed 
in a cassette with a phosphorimaging screen at -80°C for up to a week. 
4) The screen is then imaged on the phosphorimager. 
This technique allows for the measurement of global poly(A) tail sizes within a 
sample. It requires a much lower input quantity of RNA than the other two methods, 
but is a long process and uses radiation. No information on the poly(A) tails of 
individual mRNAs is obtained, unless a purification step is performed on the RNA to 
isolate a specific mRNA (Schoenberg et al. 1989). This requires a very high starting 
quantity of RNA, however, and use of the technique is limited to highly abundant 
mRNAs. 
The methods discussed have their advantages and disadvantages. Our group 
primarily uses PAT and 3’ end-labelling, results and optimisation of which can be 
found in later sections. A significant limitation of these methods is that they do not 
yield high-throughput genome-wide data. PAT can only be done for a single mRNA 
i.e. one forward primer per tube. 3’ end labelling only provides a single result – the 
entire mix of poly(A) tails in a sample, with no way of separating the data into which 
poly(A) tails came from which mRNAs. Simply using RNA-seq is not an option, as 
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homopolymeric sequences result in slippage of the DNA polymerase, leading to 
misalignment and replication errors (Viguera et al. 2001; Clarke et al. 2001). 
During the course of my project, other groups developed and published novel 
techniques for this very purpose of high-throughput poly(A) tail measurement. TAIL-
seq, whose methodology is described briefly in Figure 1.4, requires a very large input 
quantity of RNA, but yields genome-wide distribution of poly(A) tail sizes within an 
RNA sample.  
Other high throughput techniques exist including PAL-seq, PAT-seq, and mTAIL-seq 
(Harrison et al. 2015; Subtelny et al. 2014; Lim et al. 2016). These techniques use 
either a splint oligo with T bases (to anneal to poly(A) tails) for 3’ adapter ligation, or 
a similar oligo with T bases which serves as the template to extend the 3’ end of the 
mRNA to which it is annealed. In either case, this results in biasing towards 
polyadenylated mRNAs, and so mRNAs that are deadenylated or have non-A 
terminal modifications such as uridylation or guanylation will not be represented in 
the library. PAL-seq requires non-conventional use of the Illumina instrument in such 
a way that voids the manufacturer guarantee. While PAT-seq provides information 
on gene expression, poly(A) site usage, and changes in poly(A) tail length 
distribution, it does not yield data on actual poly(A) tail size. TAIL-seq has limitations 
of its own, but none of the above apply to it. 
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Figure 1.4. Overview of the TAIL-seq library generation procedure. Total 
RNA is subjected to two rRNA-removal steps and then has a biotinylated 
adapter ligated to the 3’ end of RNAs. This is then subjected to a partial 
RNase T1 digest, following which the 3’-most fragment of all digested 
RNAs (which has the biotinylated sequence) is purified by streptavidin 
pulldown, 5’-phosphorylated, and run on a gel for size selection (300-
1000 nt). This size-selected, 5’-phosphorylated RNA then has the 5’ 
adapter ligated and is reverse transcribed to cDNA. PCR is then done 
using primers that have overhanging index sequences.  
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1.2 Cordycepin 
Cordycepin (3’-deoxyadenosine) is an adenosine analogue that lacks the 3’ hydroxyl 
group (Figure 1.5), and therefore functions as a chain terminator if phosphorylated 
and incorporated into a growing polynucleotide chain. It is extracted from parasitic 
caterpillar fungi that have been used in Far Eastern traditional medicine for treating 
a range of ailments, with its purported benefits including anti-inflammatory, anti-
diabetic, anti-cancer, and anti-obesity properties, among others (Jeong et al. 2010b; 
Takahashi et al. 2012; S.-J. Lee et al. 2010). Over the last two decades, evidence has 
started to emerge to support the potential therapeutic benefits of both purified 
cordycepin itself, and extracts prepared from the entire fungus. 
1.2.1 Cordycepin and transcription 
As an adenosine analogue, it is conceivable that cordycepin triphosphate could be 
used by RNA polymerase II in place of ATP, thereby terminating transcription. 
Indeed, this was found to occur in vitro (Desrosiers et al. 1976; Shigeura and Boxer 
1964), but data from cells were at odds with these findings. Incubation of HeLa cells 
with cordycepin revealed that pre-mRNA levels (produced by RNA polymerase II) 
were not significantly affected by cordycepin, suggesting that transcription is 
unaffected (Siev, Weinberg, and Penman 1969; Penman, Rosbash, and Penman 
1970). More recently, it was confirmed that cordycepin indeed does not affect the 
transcription of housekeeping mRNAs in tissue culture (Kondrashov et al. 2012). 
Therefore, cordycepin is not an inhibitor of mRNA transcription in intact cells.  
Previous data also showed that 45S pre-rRNA (produced by RNA polymerase I) was 
significantly decreased in cordycepin-treated cells, at concentrations of cordycepin 
that had no effect on pre-mRNA. To attempt to explain these findings, which were 
not limited to HeLa cells, the sensitivity of both RNA polymerases I and II were 
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compared in vitro (Desrosiers et al. 1976). However, both enzymes were determined 
to be sensitive to cordycepin with similar kinetic values obtained for both. The 
varying effects of cordycepin on the production of different RNA types could 
therefore not be ascribed to the intrinsic susceptibility of the polymerases. More 
recent findings on the effects of cordycepin on signal transduction suggest that the 
sensitivity of RNA pol I to cordycepin may be mediated by effects on signal 
transduction.  
 
1.2.2 Cordycepin and mTOR signalling 
As mentioned, cordycepin treatment in HeLa cells led to decreased levels of pre-
rRNA. It should be noted that this reduction was accompanied by a decrease in tRNA 
levels. In more recent years, cordycepin has been found to inhibit mammalian target 
of rapamycin (mTOR) signalling (Wong et al. 2010). A simplified overview of mTOR 
signalling, and cordycepin’s proposed involvement, is shown in Figure 1.6. 
Cordycepin Adenosine 
Figure 1.5. Chemical structure of cordycepin. The only difference between 
the structure of adenosine and cordycepin is the absence of the 3’ hydroxyl 
group in cordycepin. This property would make it a chain terminator, if 
incorporated into a growing polynucleotide strand. 
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Corydcepin was found to activate AMP-activated protein kinase (AMPK) and cause 
dephosphorylation of eIF4E-binding protein (4EBP1). Dephosphorylated 4EBP1 binds 
eIF4E, thereby inhibiting its binding to the mRNA 5’ cap structure to initiate 
translation. mTORC1 phosphorylates 4EBP1 to relieve this repression and facilitate 
translation initiation. This was blocked by cordycepin. 
  
mitogens 
PIP2+PIP
 
Inhibition (phosphorylation) 
of 4EBP1 increases 
translation 
PI3K 
PTEN 
PDK1 
AKT 
mTORC1 mTORC2 
AMPK 
cordycepin 
4EBP1 
PIP+PIP2 
Figure 1.6. Simplified PI3 kinase/Akt signalling pathway showing 
proposed interaction with cordycepin. Cordycepin appears to inhibit 
mTOR signalling via activation of AMPK, but the detailed mechanism by 
which this occurs is unknown. See references for more detail (Memmott 
and Dennis 2009; Huang and Manning 2009; Wong et al. 2010).  
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mTOR signalling plays a role in the activities of RNA polymerases I and III (Mayer and 
Grummt 2006). Initiation of transcription by Pol I is dependent upon Transcription 
Initiation Factor I (TIF-I) A, TIF-IB/SL1, and Upstream Binding Factor (UBF). Signalling 
through the mTOR pathway leads to phosphorylation of UBF and TIF-IA, enabling 
their association with Pol I. Inhibition of mTOR signalling leads to both inactivation 
of TIF-IA and partial nuclear exclusion. Therefore, reduced Pol I transcription 
through inhibition of mTOR signalling provides a plausible model to account for the 
previously observed reduction in pre-rRNA. The same can apply for the observation 
of decreased tRNA levels, following cordycepin treatment. Pol III is responsible for 
production of tRNA, and mTOR signalling is also involved in its activity. In yeast, the 
TOR inhibitor rapamycin was shown to decrease Pol III activity, which was 
determined to occur through the negative regulator Maf1 (Zaragoza et al. 1998; 
Oficjalska-Pham et al. 2006). Maf1 represses Pol III activity when in a 
dephosphorylated state. Rapamycin treatment leads to dephosphorylation of Maf1, 
which results in its accumulation in the nucleus and facilitates repression of Pol III. 
This phenomenon was later found to be true in humans, as well, with mTORC1 
directly phosphorylating human MAF1 (which represses Pol III in a 
hypophosphorylated state, as in yeast) (Michels et al. 2010; Shor et al. 2010). To 
summarise, reduction in levels of pre-rRNA and tRNA, but not pre-mRNA, following 
cordycepin treatment could be explained by its more recently discovered inhibitory 
effects on mTOR signalling. 
1.2.3 Cordycepin and polyadenylation 
As mentioned above, cordycepin does not inhibit transcription in cells (Penman, 
Rosbash, and Penman 1970; Siev, Weinberg, and Penman 1969). It was, however, 
shown to be an efficient chain terminator of polyadenylation (Rose, Bell, and Jacob 
1977). Its status as a known polyadenylation inhibitor was exploited in several 
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studies for studying mRNA 3’ processing. Through the use of cordycepin 
triphosphate for in vitro polyadenylation reactions, insight was gained into the 
cleavage and polyadenylation of mRNA (Ryner and Manley 1987; Zarkower et al. 
1986), and it was also determined that a complex exists that recognises the poly(A) 
signal and is required for cleavage and polyadenylation (Zarkower and Wickens 
1987). This study also found that this complex is normally transient but becomes 
stabilised when associated with cleaved RNA with a cordycepin-terminated tail. 
Another study made the same observation, noting that this stabilisation of the 
complex was observed both with cordycepin and non-hydrolysable ATP analogues 
(Zhang and Cole 1987). With in vitro effects well established, data from a number of 
cell types show reduced poly(A) tail size following cordycepin treatment, confirming 
that effects on polyadenylation are present (Ioannidis et al. 1999; Kondrashov et al. 
2012; Wong et al. 2010). 
Since polyadenylation is required for nearly all mRNAs, it is surprising that inhibiting 
this process can cause a specific reduction in the expression of inflammatory genes 
(Kondrashov et al. 2012). In human primary airway smooth muscle (ASM) cells 
treated with tumour necrosis factor (TNF), inflammatory gene expression measured 
by RT-qPCR was greatly increased. Pretreatment of the cells with cordycepin 
resulted in a much lower degree of induction in the mRNA levels of such genes, 
while housekeeping mRNA levels were unaffected. Other adenosine analogues were 
tested in place of cordycepin, and only the one that was also known to be a 
polyadenylation chain terminator was able to replicate its effects. In addition, 
knocking down poly(A) polymerase α (PAPOLA) also reduced the expression of 
inflammatory genes. 
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1.2.3.1 Polyadenylation and cordycepin’s mechanism 
Removal of the poly(A) tail is often the first and rate-limiting step in the process of 
mRNA decay (C.-Y. A. Chen and Shyu 2011), and many inflammatory mRNAs are 
inherently unstable owing to regulatory sequences in their 3’ UTRs (P. Anderson 
2010; Stumpo, Lai, and Blackshear 2010). Therefore, if cordycepin inhibits 
polyadenylation (thus shortening or even removing the rate-limiting step of 
deadenylation), it could be hypothesised that intrinsically unstable mRNAs (like 
those produced from inflammatory genes) would be particularly sensitive. This 
model provides an explanation for the specificity of cordycepin’s effects in reducing 
the induction of inflammatory genes (Kondrashov et al. 2012). 
Another model can be formed around the observation that cordycepin arrests the 
cleavage complex in vitro (Zarkower and Wickens 1987). In stabilising the 3’ 
processing complex, cordycepin-terminated RNAs may be sequestering the 
constituent factors, thereby preventing proper processing of other transcripts. This 
hypothesis is further supported by the finding that cordycepin caused transcription 
termination defects – a sign of decreased pre-mRNA cleavage efficiency (Luo, 
Johnson, and Bentley 2006; West, Proudfoot, and Dye 2008; Richard and Manley 
2009). For genes being induced (e.g. inflammatory genes in response to an 
inflammatory stimulus), mRNA production could be hampered by a reduced 
availability of 3’ processing factors if they have high processing factor requirements. 
Such requirements could either be due to suboptimal cis elements around the 
poly(A) site; or simply because transcription becomes so fast that very many factors 
are required to process the large number of nascent transcripts. Additionally, there 
is evidence to show that proper mRNA 3’ processing is required for efficient 
recycling of transcription factors to the promoter to initiate the next round of 
transcription (Mapendano et al. 2010). By interfering with 3’ processing, cordycepin 
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may inhibit transcription of affected genes. In this way, cordycepin could specifically 
inhibit the induction of any genes for which rapid transcriptional increase is required 
(e.g. inflammatory genes in response to a pro-inflammatory stimulus (Kondrashov et 
al. 2012)). Housekeeping genes, on the other hand, may have a transcription rate 
that is sufficiently low to not be limited by the availability of 3’ processing factors or 
inefficient recycling of transcription factors. 
The above represents just three possible explanations of how cordycepin could 
affect gene expression by inhibiting polyadenylation. As discussed in section 1.1.3, 
poly(A) polymerases are diverse in their functions and polyadenylation is a varied 
process. With polyadenylation existing in nuclear, cytoplasmic, and mitochondrial 
forms, cordycepin may have multiple effects. Additionally, it may affect 
polyadenylation in the context of nuclear polyadenylation-mediated decay. Indeed, 
treatment of human cells with cordycepin led to nuclear accumulation of stable 
transcripts with shorter tails that, under control conditions, are hyperadenylated 
and degraded (Bresson and Conrad 2013). 
1.3 Inflammation 
Inflammation is a response of the innate immune system to infection and tissue 
injury. The term refers to a complex biological process whose purpose is to defend 
the host by eliminating invading pathogens, repairing damaged tissues, and 
restoring homeostasis. A number of cell types are involved, but I will focus 
specifically on macrophages, since studies have found this cell type to be sensitive to 
cordycepin (H. G. Kim et al. 2006; Shin, Lee, et al. 2009). 
Inflammation is tightly controlled with large regulatory networks in place. There 
needs to be a sufficient degree of inflammation to deal with the harmful stimulus, 
but not so much that the inflammation causes collateral damage to the host. 
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Improper regulation of inflammation is known to give rise to a host of diseases and 
conditions, including rheumatoid arthritis, asthma, and Crohn’s disease (Barnes et al. 
2010; Bradley 2008; Suzuki and Yamamoto 2015). 
1.3.1 Inflammation and pain 
The process of inflammation is also tied to the sensation of pain (Kidd and Urban 
2001). Nociception is the response of specific sensory neurons (nociceptors) to 
noxious stimuli, generally resulting in pain sensation. In normal tissues, the feeling of 
pain generally has to do with the nature of the stimulus. However, in inflamed 
tissue, pain can arise spontaneously without an external stimulus. When there is an 
external stimulus, pain in inflamed tissues can be enhanced (hyperalgesia), and pain 
can even result from innocuous stimuli that do not result in pain in normal tissue 
(allodynia). There are a number of ways in which inflammation results in pain 
sensation, some of which I will briefly describe. Tissue injury results in the release of 
inflammatory mediators of which some can activate peripheral nociceptors directly 
e.g. bradykinin, while others, e.g. neural growth factor (NGF), activate inflammatory 
cells and trigger the release of pain-inducing (algogenic) agents. Furthermore, 
release of inflammatory mediators recruits cells of the immune system that, in turn, 
release more inflammatory mediators and further contribute to the establishment 
of an inflammatory environment. Inflammation in peripheral tissues can also lead to 
the phenomenon of central sensitisation in the spinal dorsal horn, whereby changes, 
including altered neurotransmitter production, result in increased excitability of CNS 
neurons and persistent pain. Finally, neurotrophic growth factors, including NGF and 
brain-derived neurotrophic factor (BDNF), are produced in greater quantities during 
inflammation (Woolf et al. 1997; Cho et al. 1997). These play roles in central 
sensitisation, and cause hyperalgesia (through directly activating nociceptors and 
also indirectly through activation of mast cells) (Kerr et al. 1999; Lewin, Rueff, and 
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Mendell 1994; Aloe and Levi-Montalcini 1977). In short, inflammation is closely 
linked to pain sensation. 
1.3.2 Macrophages 
Macrophages are white blood cells derived through the myeloid lineage from 
haematopoietic stem cells (HSCs). They are mononuclear, and often defined by their 
capacity for phagocytosis. They play roles in host defence against tissue injury and 
infection, as well as tissue repair and homeostasis (Wynn, Chawla, and Pollard 
2013). Macrophages are found in all tissues. Formerly, macrophages were thought 
to arise predominantly from recruitment of circulating monocytes in the blood and 
their subsequent differentiation into macrophages (van Furth and Cohn 1968). 
However, it has more recently been found that the majority of tissue-resident 
macrophages originate during embryonic development (Epelman, Lavine, Beaudin, 
et al. 2014; Hashimoto et al. 2013; Epelman, Lavine, Randolph, et al. 2014). During 
inflammation, circulating monocytes that are recruited to tissues and differentiated 
into macrophages may behave differently to embryonically-derived tissue-resident 
macrophages. For instance, in cardiac tissue, embryonic macrophages seem to serve 
a more reparative role while macrophages derived from HSCs are more 
inflammatory in nature (De Wit et al. 2003; Epelman, Lavine, Randolph, et al. 2014; 
Aurora et al. 2014).  
Definition and classification of macrophages becomes difficult when considering the 
specialisation of tissue-resident macrophages in distinct anatomical sites and the 
fact that macrophages are remarkably plastic cells. They are involved in the 
induction as well as the resolution of inflammation, and can change their activity 
and gene expression programmes to exhibit different phenotypes depending on the 
microenvironmental context and the specific stimuli that they encounter. Indeed, 
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transcriptional profiling of tissue-resident macrophages from different organs done 
through the Immunological Genome Project revealed highly diverse profiles (Gautier 
et al. 2012). For this reason, it can be dangerous to think of them as a single cell 
type. Rather, macrophages are cells that are capable of occupying a large range of 
biological states depending on a number of factors (Hume 2015). 
Macrophages are thought to be activated in two ways. Classical activation produces 
the M1 macrophage subtype, and alternative activation produces the M2 activated 
subtype (which has the M2a, M2b, and M2c subcategories) (Italiani and Boraschi 2014; 
Laskin 2009). M1 macrophages are activated by signals including lipopolysaccharide 
(LPS) and TNF (following priming by IFNγ (IFNG)), have a pro-inflammatory 
phenotype, and are associated with tissue destruction. Factors produced by M1 
macrophages include reactive oxygen/nitrogen species, TNF, IL-1, IL-6, and 
chemokines. They also have increased cell surface MHC class II expression through 
which they display antigens to helper T cells, thereby playing a role in adaptive 
immunity. M2 macrophages, which are activated by signals including IL-4, IL-13, and 
transforming growth factor beta 1 (TGF-β1, TGFB1), generally have a more anti-
inflammatory phenotype, and are associated with wound healing and tissue repair. 
Factors produced by M2 macrophages include IL-10, TGFβ, and epidermal growth 
factor (EGF). These classifications, which have been greatly simplified, here, can be 
useful. However, it should be remembered that macrophages, in an organism-wide 
context, are too complex and diverse to fit into these two categories and 
macrophage biologists are working on a common framework for macrophage-
activation nomenclature (Murray et al. 2014).  
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1.3.2.1 Macrophage receptors and signalling 
Macrophages can sense infection and sterile tissue damage, and, in response, 
mediate inflammatory processes to remove the threat and restore homeostasis. 
Pattern recognition receptors (PRRs) recognise particular molecular structures that 
broadly fit into two categories: pathogen-associated molecular patterns (PAMPs) 
and damage-associated molecular patterns (DAMPs). Examples of macrophage PRRs 
include Toll-like receptors (TLRs), capable of interacting with PAMPs and DAMPs, 
retinoic acid-inducible gene 1 (RIG-I) which detects viral dsRNA, and nucleotide-
binding oligomerisation domain-containing protein 2 (NOD2) which detects the 
muramyl dipeptide structure found in certain bacteria (Hayden, West, and Ghosh 
2006). 
PAMPs represent molecular structures that are unique to pathogens and are subject 
to surveillance by the innate immune system of the host via PRRs (Tang et al. 2012). 
They are therefore exogenous signals. Examples include LPS (more detail in section 
1.3.2.1.1) and flagellin (part of the bacterial flagellum). 
DAMPs, by contrast, are the host’s own endogenous molecular structures whose 
detection by PRRs signals danger and damage (Piccinini et al. 2010). Some DAMPs 
are intracellular molecules that are normally absent from the extracellular 
environment, and therefore are not ‘seen’ by extracellular PRRs (Tang et al. 2012). 
As a result of cellular stress or tissue injury, or cell necrosis, such DAMPs are 
released into the extracellular space where they can be recognised by extracellular 
PRRs and elicit sterile inflammation (G. Y. Chen and Nuñez 2010). Examples of 
DAMPs include mitochondrial DNA, nuclear proteins, and histones. While DAMPs 
have roles in immunity and tissue repair, excessive levels of DAMPs are implicated in 
diseases. The DAMP high mobility group box 1 (HMGB1) is present at elevated 
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concentrations in the serum and plasma of patients with sepsis (H. Wang et al. 
1999). Antibodies against HMGB1 increased the survival of septic mice, suggestive of 
a causal relationship. 
1.3.2.1.1 LPS signalling through TLR4 
Lipopolysaccharide (LPS) is an archetypal PAMP found on the surface of gram-
negative bacteria. It can trigger the innate immune system through the TLR4 
receptor. TLR4 requires carriers and co-receptors to recognise LPS. In the 
extracellular space, LPS interacts with the soluble, shuttle protein LPS-binding 
protein (LBP). LBP in the bloodstream forms a complex with LPS (Jack et al. 1997) 
and transfers monomeric units of LPS to CD14 (a co-receptor of TLR4 expressed in 
immune cells) (Wright et al. 1990). CD14 – a GPI-anchored cell surface protein 
(which also exists in a soluble form) –facilitates the transfer of LPS to the TLR4/MD-2 
receptor complex. The importance of LBP and CD14 is illustrated in mouse studies – 
deficiency in either protein led to a shift in sensitivity to LPS by 2-3 orders of 
magnitude (Haziot et al. 1996; Moore et al. 2000; Wurfel and Wright 1997), and LBP 
was essential for a rapid inflammatory response to LPS challenge or gram-negative 
bacterial infection (Jack et al. 1997). MD-2 is a soluble protein, which forms part of 
the receptor complex with TLR4. It can exist in soluble form (and bind LPS), or in a 
pre-formed complex with TLR4 (as described above). LPS binding occurs with a 
higher affinity for the TLR4-MD-2 complex than for soluble MD-2 alone (Akashi et al. 
2003). The TLR4-MD-2-LPS complex forms a dimer, as confirmed by a crystal 
structure (B. S. Park et al. 2009). Downstream signalling is mediated through the 
intracellular Toll/IL1R homology (TIR) domain of TLR4, involving the recruitment of 
adapter proteins. These adapter proteins include myeloid differentiation primary 
response gene 88 (MyD88), TIR domain-containing adapter protein (TIRAP), TIR 
domain-containing adapter inducing IFN-β (TRIF), TRIF-related adapter molecule 
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(TRAM), and sterile α and HEAT-Armadillo motifs-containing protein (SARM). TLR4 is 
the only TLR member able to activate both the MyD88-dependent and TRIF-
dependent pathways. 
1.3.2.1.1.1 MyD88-dependent pathway 
The MyD88-dependent pathway (Figure 1.7) leads to activation of transcription 
factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
and activator protein 1 (AP1). Three mitogen-activated protein kinases (MAPKs) are 
phosphorylated in the MyD88-dependent pathway. These are p38, c-Jun N-terminal 
kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK 1/2). Pro-
inflammatory cytokines are induced by this pathway. 
Following recognition of TLR4 as described above, MyD88 and TIRAP are recruited to 
the intracellular domain of TLR4. This leads to the recruitment of IL-1 receptor-
associated kinase (IRAK) 4 and 1, and TNF receptor-associated factor 6 (TRAF-6). 
TRAF-6, in complex with ubiquitin-conjugating enzyme 13 (UBC13) and ubiquitin-
conjugating enzyme variant 1 isoform A (UEV1A) activates mitogen-activated 
protein kinase kinase kinase 7 (MAP3K7 aka TAK1). TAK1 activates IκB kinase (IKK), 
which phosphorylates inhibitor of kappa B alpha (IκBα), leading to its dissociation 
from NF-kB, ubiquitination and proteasomal degradation, allowing nuclear 
translocation of NF-κB. TAK1 also activates mitogen activated protein kinase (MAPK) 
pathways, namely JNK, p38, and ERK 1/2, all of which contribute to the 
inflammatory process. A conserved sequence UUAUUUAU is found in the 3’ UTR of a 
number of human and murine inflammatory mRNAs including TNF (Caput et al. 
1986). As mentioned in section 1.1.4, this sequence is bound by TTP and mediates 
instability of the TNF mRNA. The role of TTP in regulating TNF mRNA stability is 
discussed in section 1.3.2.1.3. This sequence mediates translational repression, and 
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derepression occurs in response to endotoxin (LPS) (Han, Brown, and Beutler 1990). 
Dexamethasone specifically inhibits LPS-induced JNK activity in macrophages and led 
to decreased TNF production, but no change in TNF mRNA accumulation (Swantek, 
Cobb, and Geppert 1997). Overexpression of MAPK10 (JNK3, Stress activated 
protein kinase beta (SAPKβ)) was able to overcome the dexamethasone-mediated 
translational repression of TNF. A kinase-dead mutant of JNK3 mimicked the effect 
of dexamethasone, with no translational derepression of TNF observed after LPS 
stimulation (while TNF mRNA accumulation was unaffected). These data highlight an 
important role of JNK signalling in facilitating the inflammatory response. p38 
phosphorylates and activates several transcription factors, including activating 
transcription factor 2 (ATF2), and a number of downstream kinases including MAP 
kinase activated protein kinase 2 (MAPKAPK2) (MK2) (Guha and Mackman 2001). 
The role of p38-induced MK2 activation in inflammation is discussed in section 
1.3.2.1.3. Experiments done in monocytes show that inhibition of MAPK Erk kinase 
(MEK), which phosphorylates ERK 1/2, led to a decrease in LPS-induced production 
of a number of inflammatory cytokines including TNF and IL-1β (Scherle et al. 1998). 
Activation of the MAPK pathways also contributes to pro-inflammatory gene 
activation through the induction of the transcription factor AP-1.  
In addition to the above, the MyD88 pathway also involves induction of IκBζ and 
interferon regulatory factor 5 (IRF5). IκBζ is a member of the IκB family that is 
localised in the nucleus. It is important for the induction of the pro-inflammatory 
cytokine IL-6 (Yamamoto et al. 2004), the antimicrobial protein LCN2 (Kohda, 
Yamazaki, and Sumimoto 2016), and also the anti-inflammatory cytokine IL-10 
(Hörber et al. 2016). IRF5, which interacts with and appears to be activated by 
MyD88 and TRAF-6, is important for the induction of TNF, IL-6, and IL-12B (Takaoka 
et al. 2005). 
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1.3.2.1.1.2 TRIF-dependent pathway 
TLR4 activation of the TRIF-dependent (or MyD88-independent) pathway occurs 
later when the receptor is endocytosed and trafficked to the endosome, where the 
TIR domain of TLR4 forms a complex with other adapter molecules such as TRIF and 
TRAM (Kagan et al. 2008). The activation of this pathway is responsible for the late-
phase activation of NF-κB and MAPKs and the production of inflammatory cytokines 
and Type I interferons, which serve roles in the host response to bacterial and viral 
infections (Perry et al. 2005). Transcriptional activation of Type I interferons is 
accomplished through joint action of IRF3 (which is phosphorylated in the pathway) 
and NF-κB.  
Figure 1.7 TLR4 signalling through the MyD88 pathway. 
Following LPS stimulation, signalling through TLR4 via the MyD88 
pathway culminates in the induction of pro-inflammatory 
cytokines with activation of NF-κB, AP-1 and IRF5. 
Figure taken and adapted from (Lu, Yeh, and Ohashi 2008). 
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The TRAM and TRIF adapters are recruited and TRIF is able to interact with receptor-
interacting protein 1 (RIP1). RIP 1 mediates the late-phase activation of NF-κB and 
MAPKs (Cusson-Hermance et al. 2005; Ofengeim and Yuan 2013). In addition to NF-
κB and MAPKs, IRF3 is activated (T. Kawai et al. 2001). This occurs through TRAF-3, 
which can associate with TRAF family member-associated NF-κB activator (TANK), 
TANK binding kinase 1 (TBK1) and IKKi (Oganesyan et al. 2006). Once activated, IRF3 
and NF-κB activate transcription of target genes, including Type I interferons 
(Moynagh 2005). 
Endotoxin stimulation of MyD88-deficient macrophages still activates MAPKs and 
NF-κB, albeit with delayed kinetics (Taro Kawai et al. 1999), ostensibly through the 
TRIF-dependent pathway. However, such macrophages did not experience an 
induction of pro-inflammatory cytokine production following LPS challenge. This 
suggests that, aside from NF-κB and MAPK activation, other MyD88-dependent 
events are prerequisites for the induction of inflammatory gene expression. 
1.3.2.1.2 NF-κB signalling in inflammation 
The NF-κB transcription factor family comprises five members (Oeckinghaus and 
Ghosh 2009): 
 p105 (produced from NFKB1 gene), which is constitutively processed to p50 
 p100 (produced from NFKB2 gene), which is processed to p52 under tight 
control 
 p65 (aka RelA, produced from RELA gene) 
 RelB (produced from RELB gene) 
 c-Rel (produced from REL gene) 
Heterodimers and homodimers of this family constitute NF-κB transcription factors 
that are able to bind to the NF-κB consensus binding sequence and regulate gene 
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expression by either activating or repressing transcription. NF-κB-responsive genes 
are numerous and diverse, but many are pro-inflammatory, and so NF-κB is an 
important mediator in the inflammatory process and a potential therapeutic target. 
Target genes whose expression is driven by NF-κB include TNF, IL-1, and IL-6 
(Oeckinghaus and Ghosh 2009). A lack of proper control in NF-κB signalling can give 
rise to disease (Courtois and Gilmore 2006; Ben-Neriah and Karin 2011). 
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Signals that activate NF-κB include PAMPs e.g. LPS through TLR4 (see section 
1.3.2.1.1), DAMPs e.g. HMGB1 through TLR4 (S. Kim et al. 2013), and cytokines e.g. 
TNF through TNF receptor-1 (TNFR1) (Wajant and Scheurich 2011) or IL-1β through 
IL-1 receptor, type I (IL1R). The NF-κB pathway downstream of TLR4 signalling is 
shown in Figure 1.8. As mentioned in previous sections, NF-κB is kept inactive in the 
cytoplasm by members of the IκB family (May and Ghosh 1997; Whiteside and Israël 
1997). IκB family members have ankyrin repeats that allow them to bind the N-
terminal Rel homology domain (RHD) of NF-κB family members. In binding NF-κB, 
IκBs can mask the nuclear localisation signal (NLS), thereby excluding NF-κB from the 
nucleus (and target genes). 
Nuclear vs cytoplasmic localisation only represents one level of control, however. 
NF-κB is also regulated through modulation of its capacity to bind DNA and its 
transcriptional activity (Guan, Hou, and Ricciardi 2005). NF-κB proteins can be 
subjected to several post-translational modifications (PTMs) that can affect these 
properties (Karin and Ben-Neriah 2000; Christian, Smith, and Carmody 2016). All NF- 
κB proteins have an N-terminal RHD. p65, c-Rel, and RelB all have a C-terminal 
transactivation domain (TAD), also. p105 and p100 (the precursors from which p50 
and p52 are formed, respectively) have an N-terminal RHD, and also ankyrin repeats 
closer to the C-terminus that give the proteins an inhibitory IκB-like function in the 
cytoplasm. This inhibitory action is lost upon processing of p105 and p100 to p50 
and p52 which retain only the N-terminal RHD. p50 and p52 have DNA-binding 
activity, but do not have a TAD. As such, they function as transcriptional repressors 
when homodimeric (Bohuslav et al. 1998; Guan, Hou, and Ricciardi 2005).] 
Phosphorylation at S276 in p65 is one of the best studied examples of NF-κB 
regulation by phosphorylation. The catalytic subunit of protein kinase A (PKAc) is 
kept in an inactive cytoplasmic complex with IκBα and p65 (Zhong et al. 1997). 
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Signals that lead to IκB degradation then allow PKAc to phosphorylate p65 at S276. 
This modification both promotes interaction of p65 with the p300/CBP (cAMP 
response element-binding protein (CREB) binding protein) coactivators, thus 
enhancing transcriptional activity, and also leads to acetylation at K310 which also 
increases transcriptional activity (Zhong et al. 1998; L.-F. Chen et al. 2005). IL-1β 
stimulation in liver cancer cells led to PI 3-kinase-dependent phosphorylation and 
transactivation of p65 (Sizemore, Leung, and Stark 1999). Inhibition of PI 3-kinase 
decreased p65 phosphorylation and caused a decrease in NF-κB-dependent gene 
expression with no effect on IκB degradation, NF-κB nuclear translocation, or even 
NF-κB binding to DNA. This demonstrates the importance of PTMs as an 
independent modulator of NF-κB activity. 
1.3.2.1.3 Regulation of inflammatory cytokine mRNA stability  
A number of mRNAs involved in the immune response and inflammation such as TNF 
and prostaglandin-endoperoxide synthase 2 (PTGS2 or COX-2) contain AU-rich 
elements (AREs) in their 3’ UTRs (P. Anderson 2008; Caput et al. 1986; Tudor et al. 
2009). ARE sequences can confer instability upon the mRNA through interactions 
with ARE-binding proteins (ARE-BPs) that promote its turnover. One such protein is 
tristetraprolin (TTP), which binds its targets and mediates their rapid decay through 
recruitment of Not1 and Caf1 deadenylase subunits (Brooks and Blackshear 2013). 
Xrn1 exonuclease and decapping complex proteins and the exosome are also 
possibly recruited (Hau et al. 2007). Under normal, unstimulated conditions, TTP 
causes the rapid degradation of its ARE-containing target mRNAs, and so those 
mRNA levels are kept low. The amount of ARE content in inflammatory genes’ 3’ 
UTRs is said to direct the course and kinetics of the inflammatory response, as genes 
are expressed in three distinct temporal phases (Hao and Baltimore 2009). mRNAs 
expressed earlier had greater ARE content, while those expressed in later phases 
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had less. In this study by Hao & Baltimore, it is interesting to note that using TNF as a 
stimulus in fibroblasts had little or no effect on the measured half-lives of mRNAs 
with high ARE content. Using LPS to stimulate bone marrow derived macrophages, 
however, resulted in a marked increase in the stability of such mRNAs. It may be, 
therefore, that regulation at the level of mRNA stability in inflammation is 
dependent on the cell type (or possibly just the stimulus). 
  
Stimulus 
 (e.g. LPS) 
MKK3, MKK4, MKK6 
p38 
MAPKAPK-2 (MK2) 
TTP 
ARE-containing 
mRNAs 
e.g. TNF 
TTP 
P 
P 
Bound by 14-3-3 proteins, 
moved to cytoplasm in 
inactive state 
PP2A Later dephosphorylation 
by PP2A restores TTP 
repressive activity 
Figure 1.9. Simplified p38 signalling pathway overview. p38 activation 
leads to phosphorylation of TTP via MAP kinase activated protein kinase 
2 (MAPKAPK-2) (MK2). Phosphorylated TTP is bound by 14-3-3 proteins 
and localises in the cytoplasm but remains inactive, unable to destabilise 
mRNAs like TNF with AREs in their 3’ UTR, allowing such mRNAs to 
accumulate. Phosphorylated TTP can later be dephosphorylated by 
protein phosphatase 2A (PP2A) whereupon it regains its ability to 
destabilise ARE-containing mRNAs. This contributes to the decline in the 
levels of such mRNAs. 
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TNF is a key pro-inflammatory cytokine in the inflammatory response, and plays a 
large role in rheumatoid arthritis – evidence of this is provided by the fact that many 
successful therapies for rheumatoid arthritis target TNF (Brennan et al. 1989; P. C. 
Taylor, Taylor, and Feldmann 2009). A number of its effects are mediated through 
the activation of NF-κB-dependent gene expression through IκB degradation as 
described in the previous section. TNF contains AREs in its 3’ UTR, and so levels are 
kept low by TTP in unstimulated cells. The role of TTP in regulating TNF mRNA levels 
is shown by TTP deficiency in a mouse model. These mice develop a syndrome 
whose symptoms include inflammatory arthritis, dermatitis, and autoimmunity, and 
TNF levels are found to be higher, with mRNA half-life being increased (Carballo 
1998). Administration of antibodies against TNF to mice prevents the onset of nearly 
all symptoms (G. A. Taylor et al. 1996). Other 3’ elements are also responsible for 
TNF mRNA dynamics, such as the constitutive decay element (CDE), which is bound 
by Roquin and Roquin2, which recruit the Ccr4-Caf1-Not deadenylase complex to 
the mRNA (Leppek et al. 2013). 
The p38 MAP kinase pathway (Figure 1.9), activated by signals including LPS, causes 
phosphorylation of TTP by MAP kinase activated protein kinase 2 (MAPKAPK2 or 
MK2) (Chrestensen et al. 2004). In this first phase of p38-TTP interplay, the 
phosphorylated TTP is bound by 14-3-3 proteins and becomes localised in the 
cytoplasm (M. Brook et al. 2006; Johnson et al. 2002). In this form, it is inactive and 
no longer able to repress ARE-containing mRNAs like TNF (Stoecklin et al. 2004), 
resulting in a rapid accumulation of such mRNAs. Phosphorylation of TTP by MK2 
inhibits its ability to recruit the CAF1 deadenylase complex and deadenylate ARE-
containing mRNAs (Marchese et al. 2010). In a second phase, the phosphatase PP2A, 
which competes with 14-3-3 proteins for phosphorylated TTP, dephosphorylates TTP 
(L. Sun et al. 2006). At this point, TTP regains its capacity to destabilise ARE-
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containing mRNAs and is already localised in the cytoplasm to perform this role. In 
this phase, levels of ARE-containing mRNAs decline as part of the resolution of 
inflammation. TTP dynamics in p38 signalling is discussed in depth in this review 
(Sandler et al. 2008). In addition to regulation of TNF mRNA described above, the 
mRNA of other pro-inflammatory mediators including PTGS2, IL-10, IL-6, and IL-1α is 
also stabilised by p38 through inhibition of TTP-mediated decay (Tudor et al. 2009). 
IL-1β mRNA is also subject to ARE-mediated regulation. Like TNF mRNA, it is a target 
of TTP, with TTP destabilising it. TTP-deficient dendritic cells displayed elevated 
levels of IL-1β mRNA compared to wild type dendritic cells, both with and without 
LPS stimulation (Bros et al. 2010). Stability of IL-1β mRNA is increased, along with 
that of several other ARE-containing mRNAs, by p38 signalling (Frevel et al. 2003). 
KH-type splicing regulatory protein (KSRP) is an ARE-binding protein that promotes 
mRNA decay (Chou et al. 2006). Astrocytes from KSRP null mice displayed increased 
levels of IL-1β mRNA both with and without stimulation by TNF, and also an increase 
in mRNA stability compared to astrocytes from wild type control mice (X. Li et al. 
2012). 
1.3.3 Anti-inflammatory effects of cordycepin 
A number of studies have shown that cordycepin has anti-inflammatory effects in 
cells (H. Kim et al. 2011; Jeong et al. 2010b; Shin, Moon, et al. 2009; Y. Li et al. 2016; 
Kondrashov et al. 2012; Shin, Lee, et al. 2009). In a system of ASM cells stimulated 
with TNF, cordycepin did not prevent degradation of IκB or translocation of NF-κB 
into the nucleus (Kondrashov et al. 2012). In RAW 264.7 cells, a murine macrophage 
cell line, NF-κB nuclear translocation was reduced by cordycepin (H. G. Kim et al. 
2006). In HEK 293 cells, NF-κB nuclear translocation was not prevented by 
cordycepin, but, at higher concentrations, NF-κB DNA binding and transcriptional 
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activities were reduced (Ren et al. 2012). Another group examined rat nucleus 
pulposus (NP) cells in the context of intervertebral disc degeneration (IDD) (Y. Li et 
al. 2016). IDD is thought to be a contributing factor to the development of low back 
pain, and a strong pro-inflammatory environment provided by NP cells is heavily 
implicated in IDD. Treatment of NP cells with LPS increased expression and 
production of a number of cytokines, which was reduced by cordycepin treatment. 
In these cells, phosphorylation of IκBα and p65 was decreased by cordycepin. It was 
noted that cordycepin did not affect MAPK signalling, however. 
 The therapeutic potential suggested by these studies has been tested in vivo in 
animal models of disease. In a study in which mice were infected with Trypanosoma 
brucei, a reduction in cerebral inflammation and pro-inflammatory cytokine levels in 
the brain was observed upon cordycepin treatment (Vodnala et al. 2009). Anti-
inflammatory activity of cordycepin has also been observed in several other animal 
models of disease, including lung injury, cerebral ischemia/reperfusion injury, and 
asthma (X. Yang et al. 2015; M. Chen et al. 2012; H. Kim et al. 2011; Cheng et al. 
2011).  
In a study of nociception in rats, rats had a range of inflammatory mediators injected 
into their spines a week prior to administration of the hyperalgesic agent 
prostaglandin E2 (PGE2). The enhancement of pain sensation caused by the 
inflammatory mediators was significantly relieved by administration of cordycepin 
(Ferrari et al. 2015). 
Microglia are brain-resident macrophages and play an important role in CNS repair 
and homeostasis (Gehrmann, Matsumoto, and Kreutzberg 1995). Their overactivity 
and increased production of inflammatory mediators is implicated in the progression 
of neurodegenerative diseases (González-Scarano and Baltuch 1999; Heneka et al. 
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2015; Liu and Hong 2003). Mounting evidence supporting a role for brain 
inflammation in Alzheimer’s disease has led to significant interest in targeting 
inflammation to treat the disease (Heneka et al. 2015). Murine microglia stimulated 
with LPS exhibited increased production of inflammatory mediators, and typical 
signalling events including increased phosphorylation of p38, ERK1/2, and JNK MAP 
kinases; IκB degradation; and NF-κB (p65) translocation to the nucleus (Jeong et al. 
2010a). Pretreatment of cells with cordycepin prior to addition of LPS, compared to 
LPS alone, resulted in decreased production of inflammatory mediators, reduced 
phosphorylation of aforementioned MAP kinases, stabilisation of IκB, and nuclear 
exclusion of NF-κB (measured both by Western blotting and immunocytochemistry). 
A more recent study made similar observations (Jie Peng et al. 2015). With in vivo 
work already showing that cordycepin protected against cerebral 
ischaemia/reperfusion injury (Cheng et al. 2011), these findings in microglia further 
support the therapeutic potential of cordycepin for neurodegenerative conditions.  
1.4 Osteoarthritis – a therapeutic application of cordycepin? 
Osteoarthritis (OA) is a joint disease that affects about a third of the population over 
the age of 45 in England. It is characterised by a number of hallmark features that 
include cartilage damage, synovial inflammation, and bone changes. The breakdown 
of articular cartilage results from the degradation of extracellular matrix by 
chondrocytes. OA is largely thought of as a non-inflammatory disorder. However, 
research has shown that inflammation is an integral component of OA progression 
contributing to the development of its symptoms (Berenbaum 2013). The inflamed 
synovium (synovitis) releases pro-inflammatory cytokines that can lead to further 
cartilage degradation. OA is characterised by an increase in anabolic activity in the 
subchondral bone. Osteoblastic (bone forming) and osteoclastic (bone degrading) 
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activities become unbalanced and increased bone deposition results in sclerosis of 
the subchondral bone (bone beneath the articular cartilage) and formation of 
osteophytes. Osteophytes (new bone formation) appear at the joint margins, 
subchondral bone thickens, joint capsule enlarges, mild synovitis and effusion are 
also observed (Johnston 1997; Sunita Suri and Walsh 2012; Wenham and Conaghan 
2010). It remains yet to be confirmed whether subchondral bone sclerosis is a cause 
or consequence of cartilage loss in OA. The increased thickness and density of the 
subchondral bone and osteophyte formation may be a result of a disordered repair 
process to increase joint stability. An overview of these changes in the joint 
physiology is shown in Figure 1.10.  
Articular cartilage is found at the junction between two or more bones. It functions 
as a shock absorber and facilitates movement at the joint. In the case of a healthy 
joint, articular cartilage is neither innervated nor does it have a blood supply, while 
the adjacent bone, on the other hand, has both a blood supply and nerves. It has 
been shown that blood vessels grow up from the subchondral bone, breaching the 
tidemark (a transitional zone which marks the division between articular cartilage 
and calcified cartilage above the subchondral bone) and invading the normally 
aneural and avascular articular cartilage in OA (Walsh et al. 2010; S. Suri et al. 2007). 
The route by which they do this is usually within the vascular channels that extend 
up from the subchondral bone marrow spaces through the calcified cartilage and 
into the non-calcified articular cartilage. The separation between bone and cartilage 
is thus lost and both nerves and blood vessels invade the cartilage from the bone, 
leading to joint pain.  
Chondrocytes are the only cell types found in the articular cartilage. These cells are 
normally responsible for maintaining the cartilage by balancing matrix production 
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and degradation. In OA, the chondrocytes become hypertrophic and this balance is 
shifted towards matrix degradation, resulting in a reduction of cartilage, and 
chondrocytes also die by apoptosis (van der Kraan and van den Berg 2012; Akkiraju 
and Nohe 2015). In some cases, the cartilage is completely lost, leaving only bone on 
either side of the joint margin. 
The subchondral bone, i.e. the layer of bone directly under the cartilage, undergoes 
notable remodelling in OA. Normal bone structure is in part maintained through the 
balance of osteoclasts (bone-degrading cells) and osteoblasts (bone-producing cells). 
In OA, the balance is disturbed, leading to aberrant bone structure (Sunita Suri and 
Walsh 2012). Osteophytes are also a common occurrence in OA. These are 
protrusions of bone that form along joint margins, and can contribute to the disease 
progression through malalignment of the bones at the joint (Felson et al. 2005).  
The synovium encases the synovial fluid within the synovial cavity. This provides the 
nutrients and external factors required for maintenance of the cartilage. 
Inflammation of the synovium (synovitis) is one of the hallmark features of OA 
Figure 1.10. Changes in knee physiology in osteoarthritis.  
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(Haywood et al. 2003). Synovial inflammation contributes to the disease in part 
through the activity of synovial macrophages and fibroblast-like synoviocytes (FLS). 
While the degree of inflammation can vary between patients, pro-inflammatory 
cytokines such as TNF and IL-1β produced by synovial macrophages can promote 
degradation of the cartilage (Rahmati, Mobasheri, and Mozafari 2016). 
Macrophages in the synovial lining also have a role in the formation of osteophytes 
(Blom et al. 2004). FLS cells can also promote a pro-inflammatory environment that 
leads to cartilage destruction (A. R. Sun et al. 2016; Philp, Davis, and Jones 2016). In 
OA, synovial fluid may contain calcium pyrophosphate dehydrate (CPPD) crystals 
which are capable of activating the NLRP3 inflammasome in macrophages which, 
following caspase-1 proteolytic activation, enhances IL-1β and IL-18 secretion (Jin et 
al. 2011). Basic calcium phosphate (BCP) crystals, which can also be found in OA 
synovial fluid, have been shown to induce IL-1β secretion by macrophages through 
the NLRP3 inflammasome in vitro. 
Together, the changes in subchondral bone, cartilage, and the synovium contribute 
to the pain associated with OA and the progression of the disease. Given that 
inflammation plays a part in the destruction of the cartilage, cordycepin may have 
therapeutic benefit in reducing pain in OA patients. In human chondrocytes from OA 
patients, IL-1β-driven increases in proinflammatory cytokine production were 
inhibited by cordycepin pretreatment (Ying et al. 2014), and degradation of IκB by IL-
1β was also prevented by cordycepin in these cells. Cordycepin was also able to 
inhibit the impairment of osteogenesis (bone formation) by oxidative stress in bone 
marrow mesenchymal stem cells (BM-MSCs) (F. Wang et al. 2015). Reactive oxygen 
species (ROS) are important in the differentiation of osteoclasts (N. K. Lee et al. 
2005). Consistent with its role in opposing the effects of oxidative stress in BM-
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MSCs, cordycepin was found to scavenge ROS generation and inhibit 
osteoclastogenesis (Dou et al. 2016).  
1.5 Project aims and outcomes 
The aim of my PhD project was twofold: to investigate the role of polyadenylation in 
the inflammatory response, and to gain insight into how cordycepin’s anti-
inflammatory effects were mediated. This was to be measured in RAW 264.7 
macrophages, using LPS as a stimulus to induce an inflammatory response. Addition 
of LPS to RAW 264.7 cells did, indeed, result in increased inflammatory gene 
expression measured over a 2 hour period after addition of LPS. Adding cordycepin 
either 1 hour before LPS or 10 minutes after LPS led to a pronounced decrease in 
inflammatory mRNA levels (for both mature transcripts and pre-mRNA). This was 
confirmed on a genome-wide scale through microarray and cluster analysis. It was 
found that Tnf mRNA (whose levels are >100-fold increased following LPS treatment) 
experiences an increase in poly(A) tail size following LPS treatment, while 
housekeeper mRNA poly(A) tail size is unaffected. Performing this experiment with 
the nuclear fraction, to assess initial poly(A) tail size of newly synthesised mRNA, 
also showed an increase in Tnf poly(A) tail size, indicating that nuclear 
polyadenylation may be dynamic in the inflammatory response. The Tnf poly(A) tail 
size increase is noticeably reduced in the presence of cordycepin. Inhibition of 
cordycepin’s import into the cell or its phosphorylation abrogated its anti-
inflammatory effects. Taken together, these data suggest that, in a macrophage 
system, polyadenylation is dynamic in response to an inflammatory stimulus, and 
that cordycepin has specific anti-inflammatory effects that it elicits intracellularly, 
possibly through effects on polyadenylation. These data support the case for 
cordycepin as a potential therapeutic for diseases in which inflammation is involved. 
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Work done by James Burston (with whom I collaborated) in a rat model of 
osteoarthritis showed that cordycepin reduced pain behaviour associated with OA, 
but I was unable to see changes in inflammatory cytokine mRNA in the synovium. 
This suggests these mRNAs are not the therapeutic target in this case, or at least not 
in that tissue. However, the effects on pain behaviour still add weight to the 
therapeutic potential of cordycepin.
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2 Materials and methods 
2.1 Cell work 
2.1.1 Cell culture 
RAW 264.7 mouse macrophage cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma, cat no 6429) supplemented with 10% foetal bovine serum 
(FBS) (Sigma, cat no F9665-500ml). Cells were split into fresh flasks whenever they 
reached ~80% confluence. All experiments were done on cells between passage 20 
and 40. 
NIH-3T3 mouse fibroblasts were cultured in DMEM supplemented with 10% 
newborn calf serum (NBCS). For serum induction experiments, 106 cells were seeded 
in 10 cm plates (TPP, cat no 93100), then had medium changed to DMEM + 0.5% 
NBCS after 24 hours. 24 hours after this change of medium, cells were stimulated 
with addition of 10% NBCS. The experiment using NIH-3T3 cells from which data is 
presented in this thesis (Figure 3.7) was performed by Cornelia de Moor. 
2.1.2 Cell stimulation with lipopolysaccharide (LPS) and treatments with 
compounds 
RAW 264.7 cells were seeded into 15 cm plates (TPP, cat no 93150) 10 cm plates 
(TPP, cat no 93100), 6 cm plates (TPP, cat no 93060), 6-well plates (TPP, cat no 
92006), or 12-well plates (TPP, cat no 92012). Seeding densities ranged from 2×103-
6×104 cells/cm2. 24 hours after seeding, the medium was aspirated, cells were 
washed in the same volume of phosphate-buffered saline (PBS) as the medium, and 
then DMEM + 0.5% FBS was added. ~24 hours after this, the experiment would take 
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place, with LPS (Sigma, cat no L6761) being added at a final concentration of 1 μg/ml 
for the desired duration. For some experiments, the LPS was added ~24 hours after 
seeding, without any change of medium. 
For samples that were to be treated with cordycepin (≥98% pure) from Cordyceps 
militaris (Sigma, C3394), the cordycepin dissolved in DMSO (stock concentration 20 
mM) was added to all plates (20μM final concentration unless otherwise indicated) 1 
hour before, at the same time as, or 10 minutes after the addition of LPS to any 
plate. Fungal extracts (preparation described below) were treated as 1000-fold 
concentrated stocks, and so were added at 1/1000 of the volume of medium in 
which the cells were seeded. Pentostatin (Sigma, cat no SML0508) was added at the 
same time as cordycepin at 1nM concentration. Adenosine (Sigma, cat no A4036) 
was added at the same time and concentration as cordycepin. The adenosine 
transporter inhibitor S-(4-Nitrobenzyl)-6-thioinosine (NBTI) (Sigma, cat no N127) and 
the adenosine kinase inhibitor 5-Iodotubericidin (ITu) (Sigma, cat no I100) were 
added 15 minutes prior to cordycepin treatment. 
2.1.3 Preparation of fungal ethanol extracts for use in cell culture 
Cordyceps militaris fungi were from Hainan SHUNTIAN Biological Technology Co Ltd; 
Ophiocordyceps sinensis tablets (500 mg biomass per tablet) were from Mycology 
Research Laboratories Ltd; and Pleurotus ostreatus, Agaricus bisporus, and 
Flammulina velutipes were purchased from Sainsbury’s supermarket. The fungus or 
starting material was ground and 1g dissolved in 20 ml ethanol. This suspension was 
then placed on a tube roller for 1 hour and then allowed to stand for 15 minutes. 
Supernatant was then divided into several 2 ml tubes, which were centrifuged at 
10,000 g at 4°C for 30 minutes. Supernatant was pooled and filtered in a laminar 
flow hood for sterility. This sterile mix was then divided into several tubes (500 µl 
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per tube) and spun in a vacuum concentrator until dry. Once all the ethanol had 
evaporated, 25 µl of DMSO was added to each tube, thoroughly mixed, and then all 
liquid was combined to obtain a single, homogeneous mixture. This was divided into 
aliquots and stored at -20°C for further use. 
2.1.3.1 Assessing cordycepin and 3’ deoxyinosine concentration in fungal extracts 
by liquid chromatography/mass spectrometry (LC/MS) (performed by 
Wahyu Utami) 
LC/MS analysis was performed by Wahyu Utami – the method described below is 
taken from her PhD thesis (Utami Wahyu 2015): 
“Analyses of samples were carried out on an Agilent 1100 HPLC system (Agilent, 
Santa Clara, CA, USA) with auto sampler maintained at 8°C. Separations were 
achieved on a Luna C-18, 3 µm (2 × 150 mm) column with Security Guard (4 × 2 mm) 
(Phenomenex, Macclesfield, UK) at 40°C. The standards and the samples were 
eluted using a gradient mobile phase containing of 5 mM DMHA in water:methanol 
(95:5 v/v) (A), and 5 mM DMHA in methanol: water (80:20 v/v) (B). Mobile phase A 
was adjusted to pH 7 using acetic acid. The gradient condition was: 0-5 min, 10-20% 
B; 5-10 min, 20-28 % B; 10-22, 28-40 % B; 22-25, 40-10 % B; 25-35 min, 10 % B. The 
volume of sample injected to the column was 5 µL. The flow rate was set at 200 
µL/min. 
MS data were acquired on Waters Quattro Ultima triple quadrupole mass 
spectrometer (Waters, Milford, MA, USA) in negative electrospray ionisation (ESI) 
mode. Source temperature was at 125°C, with nitrogen as drying and nebulising gas 
and argon as collision gas. Multiple reactions monitoring (MRM) scan was used with 
dwell time 0.1 s. The MS system and data were processed by Waters MassLynx™ 
Software.” 
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2.1.4 Statistical tests for comparing cell treatments 
Statistical tests were performed using GraphPad Prism version 6 for Windows 
(GraphPad Software, La Jolla California USA). 2-way ANOVA was performed with 
means between different conditions compared to each other within each group. For 
Figure 5.5, this means comparing the mean values for 0 nM pentostatin to the mean 
values for 1 nM pentostatin within each separate cordycepin concentration tested. 
For Figure 5.9, it means comparing the mean values for both C+10 and C-60 to the 
control mean (DMSO) within each separate timepoint. Default options were left 
unchanged, and recommended tests were used following the ANOVA. For Figure 
5.5, the recommended test was Sidak’s multiple comparisons test, and for Figure 
5.9, it was Dunnett’s multiple comparisons test. 
2.2 RNA work 
2.2.1 RNA isolation 
At the end of any experiment, cells were harvested as follows: 
Cells in 10cm/15cm plates Cells in 6-well or 12-well plate 
 Put plates on ice, aspirate medium from cells, and 
wash twice with ice-cold PBS (Oxoid, cat no BR0014G) 
 Add 5 ml ice-cold PBS and scrape 
cells using cell scraper (Greiner 
Bio-One, cat no 541070) 
 Add lysis buffer from RNA 
isolation kit* directly to cells on 
plate, then transfer lysate to 
fresh tube 
 Transfer cell suspension to fresh 
15 ml tube and spin at 775 g for 2 
minutes 
 Aspirate supernatant and add 
lysis buffer from RNA isolation 
kit* to cell pellet 
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RNA was then isolated from the lysates using an RNA isolation kit, following 
manufacturer’s protocol (except DNase treatment was done for 1 hour rather than 
15 minutes), and stored at -20°C. *All experiments done before November 2015 
used the NucleoSpin RNA kit (Macherey Nagel, cat no 740955), while experiments 
done thereafter used the ReliaPrep™ kit (Promega, cat no Z6012). The two kits 
performed equally well in our experience – the switch was made purely due to the 
ReliaPrep™ kit being cheaper. 
2.2.2 RNA isolation from nuclear and cytoplasmic fractions 
Fractionation experiments were done using a 15 cm plate for each timepoint. At the 
end of the experiment, cells were washed twice with ice-cold PBS, and then scraped 
in 5 ml ice-cold PBS with a cell lifter (Corning, cat no 07-200-364). All centrifugation 
was done at 4°C. The cell suspension was spun at 700 g for 5 minutes, the 
supernatant was discarded, and the pellet resuspended in 1 ml PBS. This suspension 
was centrifuged at 500 g for 5 minutes and supernatant was discarded. The pellet 
was resuspended in 400 µl of buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM 
EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) and incubated on ice for 15 minutes. 
25 µl of 10% NP-40 was then added to the suspension which was vortexed for 10 
seconds and placed on ice for 5 minutes. This mix was then centrifuged at 16,000 g 
for 1 minute, resulting in pelleted nuclei and a cytoplasmic supernatant. 
Approximately 60% of the supernatant was collected in a new tube (in order to 
avoid nuclear contamination by trying to collect all of the supernatant), and had an 
equal volume of 100% isopropanol added. This was then centrifuged at 16,000 g for 
30 minutes. While spinning, the remaining supernatant was discarded, and the 
nuclear pellet was washed three times with 400 µl buffer A to remove remaining 
cytoplasmic material. When the cytoplasmic centrifugation was complete, 
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supernatant was aspirated yielding a cytoplasmic pellet. Cytoplasmic and nuclear 
pellets then had the appropriate amount of lysis buffer added from the RNA 
isolation kit. For the NucleoSpin kit, the lysis buffer volume used was 350 µl. For the 
ReliaPrep™ kit, the volume used was 100 µl for up to 5×105 cells, 250 µl for 5×105-
2×106 cells, and 500 µl for any more than that. RNA was isolated from lysates 
following the manufacturer’s protocol but with a 1 hour DNase treatment rather 
than the stated 15 minutes. Once eluted from the isolation kit, nuclear RNA was 
subjected to another DNase digestion using TURBO™ DNase (Ambion™, cat no 
AM2238), following manufacturer’s protocol. RNA was then extracted by a 
phenol/chloroform extraction and precipitated with ethanol and sodium acetate. 
After washing and redissolving the nuclear pellet, cytoplasmic and nuclear RNA 
isolation was complete. Fractionation was validated by RT-qPCR to check for 
enrichment of pre-mRNA in the nuclear RNA sample.  
2.2.3 4-thiouridine labelling for nascent mRNA capture performed by Richa 
Singhania 
Labelling transcripts in the cells: 250 µM 4-thiouridine (4SU) was added to RAW 
264.7 cells 15 minutes before harvesting the cells. 
To harvest, cells were placed on ice, washed twice with ice-cold PBS, and 
immediately lysed with 10 ml TriPure reagent and transferred to a fresh tube. 4SU-
labelled yeast RNA was added at this point as a spike-in for later analysis purposes 
(see below). 2 ml chloroform/isoamyl alcohol (24:1) was added and the tube was 
incubated on ice for 10 minutes before being centrifuged at >18,000 g for 10 
minutes. The top aqueous layer was removed and subject to an ethanol/sodium 
acetate precipitation, after which the pellet was redissolved in water, subjected to a 
TURBO DNase treatment following manufacturer’s protocol. 
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Biotinylating 4-thiouridine labelled RNA: DNase-treated RNA, having been cleaned 
up, was then heated at 65°C for 5 minutes before being placed on ice. The following 
were then added (final concentrations are indicated) to the RNA for a final volume 
of 400 µl per 40 µg RNA: Tris-HCl pH 7.4 (10 mM), EDTA (1 mM), EZ-Link™ HPDP-
Biotin (0.2 mg/ml) (Thermo, cat no 21341). This was then rotated at room 
temperature in the dark for 1 hour and 30 minutes, after which an equal volume of 
chloroform/isoamyl alcohol (24:1) was added and the aqueous phase was then 
collected using MaXtract column (Qiagen, cat no 129046). RNA was precipitated 
using isopropanol and NaCl, and pellet redissolved in water. 
Fractionating the RNA: Streptavidin paramagnetic beads (Promega, cat no Z5482) 
were pipetted into a tube (200 µl per 70 µg RNA), placed into a magnetic rack, and 
the buffer was replaced with 200 µl of fresh MPG buffer (1M NaCl, 10 mM EDTA, 
100 mM Tris-HCl pH 7.4). A known quantity of thiouridine-labelled RNA from S. 
pombe was added to the total RNA as a spike-in for data analysis purposes later (see 
below). RNA was heated at 65°C for 10 minutes, and then added to the beads and 
rotated at room temperature for at least 20 minutes. The tube was then placed on 
the magnetic rack – biotinylated nucleic acids are bound to the beads, while non-
labelled RNA is contained in the supernatant. Supernatant (unlabelled fraction) was 
transferred to a fresh tube and kept on ice. Beads were washed for 5 minutes with 
750 µl MPG buffer four times. The fourth wash was collected as a control fraction 
which should be free of RNA. 100 µl of 0.1 M DTT was added to the beads and 
rotated for 10 minutes to elute the bound, labelled RNA. The tube was placed onto 
the rack and supernatant (labelled RNA) collected in a fresh tube on ice. This was 
repeated and the second labelled RNA elution pooled with the first. 
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Final cleanup: the unlabeled fraction was precipitated with ethanol and sodium 
acetate and then redissolved in water. The labelled fraction was purified using 
RNeasy MinElute cleanup kit (Qiagen, cat no 74204). 
Yeast spike-in and analysis: fixed amounts of 4SU-labelled RNA isolated from S. 
pombe were added to the cell lysate in TriPure reagent prior to isolating total RNA 
and performing the fractionation, as mentioned previously. RNA samples were then 
sent for RNAseq on the NextSeq platform. Raw reads from the sequencer then had 
adapter sequences and low quality base calls trimmed. Remaining reads were 
mapped to the joined mouse and S. pombe genomes – the best matches were 
returned and ambiguous mappings were discarded. For both the 4SU-labelled RNA 
and the total RNA, the number of reads mapping to features in the genome was 
counted. In order to compare the numbers of transcripts between 4SU-labelled and 
total RNA samples, the numbers must be adjusted so that they are on the same 
scale. This was accomplished using the S. pombe RNA spike in – since this was of a 
known, fixed amount, the fraction of 4SU-labelled RNA relative to the total could be 
calculated. The resulting scaling factor was used to scale the fragments per kilobase 
per million mapped reads (FPKM) values of the 4SU-labelled fraction. The FPKM 
values could then be used to calculate transcription rates (4SU-labelled FPKM) and 
decay rates (4SU-labelled FPKM divided by total FPKM). 
2.2.4 Reverse transcription quantitative PCR (RT-qPCR) 
RNA was reverse transcribed to cDNA using SuperScript™ III reverse transcriptase 
(Invitrogen, cat no 18080-044). For each sample, 500 ng of RNA was used with 120 
ng of random hexamers (Invitrogen, cat no 48190-011), 0.5 mM dNTP mix 
(nucleotides supplied in separate tubes from Thermo, cat no R0182), 1x first strand 
buffer (supplied with kit), 5 mM DTT, and 0.5 μl of SuperScript™ III enzyme, in total 
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volume of 20 μl. Incubations were done as per the protocol. At the end of the 
reaction, 180 μl of water was added to dilute the cDNA 10-fold. The cDNA could 
then be used as template for qPCR. 
In later experiments, SuperScript™ IV (Invitrogen, cat no 18090050) was used. 
Reaction was performed as above, but first strand buffer was replaced with SSIV 
buffer. Incubations were done as per manufacturer’s protocol. 
Earlier qPCR was done on an Agilent MX3005P qPCR machine (Agilent, cat no 
401513-64000), while later work was done on a Qiagen Rotor-Gene Q qPCR machine 
(Qiagen, cat no 9001560).  
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MX3005P 
qPCR was done using Promega SYBR Green GoTaq® qPCR master mix (Promega, 
A6002). Reactions were done in a volume of 20 µl with 4 µl of cDNA, a final primer 
concentration of 0.25 µM, and 1X GoTaq® qPCR master mix. PCR programme: 
10 mins at 95°C 
30 seconds at 95°C 
30 seconds at 58°C 
30 seconds at 72°C 
60 seconds at 95°C 
30 seconds at 55°C 
30 seconds at 95°C 
Options selected in the MxPro software, when setting up the above programme: 
SYBR Green with dissociation curve, ‘SYBR’ box ticked.  
Rotor-Gene Q 
Reactions were done with 2 µl of cDNA, a final primer concentration of 1 µM, and 1X 
GoTaq® qPCR master mix in 10 µl total reaction volume. PCR programme: 
5 mins at 95°C 
10 seconds at 95°C 
20 seconds at 60°C 
20 seconds at 72°C 
Melt segment (default) 
Gain optimisation was performed at 60°C at start of run, and before melt. 
qPCR data were analysed using the 2-ΔΔCt method. 
×50 
This is the dissociation 
curve analysis segment 
×40 
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2.2.5 Microarray analysis (data analysis performed by Graeme Thorn) 
RNA was analysed from RAW 264.7 cells exposed to four treatment conditions (full 
details are given below): LPS stimulated and unstimulated cells both with and 
without a cordycepin pre-treatment (cells that were not pre-treated with cordycepin 
were pre-treated with DMSO instead). 
Four wells of a 6-well plate were seeded with RAW 264.7 cells in DMEM + 10% FBS. 
Cells were washed and medium replaced with DMEM + 0.5% FBS after 24 hours. A 
further 24 hours later, one pair of wells had DMSO added, and the other pair of 
wells had 20 µM cordycepin added. After a 60 minute incubation, two wells (one 
DMSO-treated well and one cordycepin-treated well) had LPS added at 1 µg/ml. 
Nothing was added to the other two wells. 60 minutes later, all cells were lysed and 
RNA extracted as described in section 2.2.1. To summarise, cells were pre-treated 
with DMSO or cordycepin and then either stimulated with LPS or not. Cell conditions 
were named ‘D0’, ‘D60’, ‘C0’, and ‘C60’ – D means DMSO pre-treated, C means 
cordycepin pre-treated, 0 means NOT stimulated with LPS, 60 means LPS-stimulated. 
This experiment was performed in biological quadruplicate (16 RNA samples in 
total), and these were then analysed on a SurePrint G3 Mouse Gene Expression 
8x60K microarray kit (Agilent, cat no G4852A). Each slide for the microarray has 8 
array slots. As we had 16 samples, 2 slides were used with 2 biological replicates on 
each. 
Raw data were processed using limma (Ritchie et al. 2015) and affy R packages to 
read the data directly from the microarrays. Each individual microarray was then 
normalised using the ‘qspline’ option which matches the quantiles of intensities for 
each microarray. Estimates of measurement errors were taken from replicate arrays 
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using an empirical Bayes procedure, which calculates an estimated error based on 
duplicates on individual arrays. Probes for which intensity was greater than the 
background + error estimate were retained, while probes for which this criterion 
was not met were marked as “not above background”. Differences between the 
mean values were calculated between pairs of conditions: D0 vs D60, C0 vs D0, and 
C60 vs D60. Individual tests were performed if difference between conditions was 
significantly non-zero. P-values were corrected from individual p-values by 
Bonferroni procedure: p-values were multiplied by the number of comparisons 
made between conditions and capped at a maximum value of 1 (corrected p-val = 
max(1, p-val * #tests)). 
Gene ontology (GO) analysis for lists of genes generated from microarray data 
was performed using DAVID (https://david.ncifcrf.gov). The list of genes was 
uploaded to DAVID functional annotation tool along with a background list 
(containing all measurable genes on the microarray chip). The proportion of 
genes within a GO term out of the total number of genes in the list of interest 
was compared to the proportion of genes within the same GO term in the 
background list. The ratio between these two proportions represents the fold 
enrichment. The test for significance is based on Fisher’s exact test with p-
values then adjusted by Bonferroni procedure (the raw p-value is multiplied 
by the number of comparisons being made) to correct for multiple 
comparisons. 
2.2.6 Poly(A) tail measurement 
3’ end labelling using [5'-32P]Cytidine 3',5'-bis(phosphate) (32P-pCp) and RNA ligase 
was performed as described (Minvielle-Sebastia et al. 1991). Briefly, 32P-pCp was 
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ligated to the 3’ end of total RNA, following which the RNA and ligase mixture was 
subjected to RNase and proteinase K treatment to digest the enzyme and all non-
poly(A) RNA. A phenol/chloroform extraction and ethanol precipitation was done to 
then purify the remaining non-digested RNA (just poly(A) tails). These RNA samples 
were then run on a TBE-urea PAGE gel. The gel was then placed in a cassette with a 
phosphor screen and incubated at -80°C for 3-5 days before being imaged on a GE 
Storm 825 phosphorimager. 
The poly(A) tail test (PAT) assay is done to assess poly(A) tail length. 3 different types 
of PAT were used – RL1-PAT, RL2-PAT, and sPAT (I/T). RL1-PAT was an older method 
that was supplanted by RL2-PAT. sPAT (I/T) was tested against RL2-PAT for potential 
improvements, but was found to be an inferior method, and so RL2-PAT was kept as 
the method in use. 
For RL1-PAT, the 3’-blocked anchor oligo (‘PAT-R1 anchor’) was ligated to the 3’ end 
of an RNA sample. 50 pmol of anchor and 2 µg of RNA were combined in an 8 µl 
volume. This mix was incubated for 5 minutes at 65°C, and then had 10 units of T4 
RNA ligase 1 (NEB, cat no M0204S) added together with the supplied reaction buffer 
for a final concentration of 1X. The ligation mix was incubated at 37°C for 2 hours, 
then 15 minutes at 65°C to heat inactivate the enzyme. After this, reverse 
transcription was done directly on the resulting mix using SuperScript III. Reaction 
was done using 1 µM PAT-R1 (complementary to the ligated anchor oligo), 0.2 mM 
dNTP mix, 1x first strand buffer, 5 mM DTT, and 1 μl of SuperScript™ III enzyme, in 
total volume of 50 μl. Incubations done as per manufacturer’s protocol. 
During the ligation, the oligo receives a 5’-5’ adenylation (catalysed by the enzyme 
using ATP in the reaction buffer) to form an intermediate species (Figure 2.1). T4 
RNA ligase 1 used in RL1-PAT is capable of generating this intermediate, which can 
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then be ligated to the 3’ end of an acceptor RNA molecule. For RL2-PAT, T4 RNA 
ligase 2 truncated KQ (NEB, cat no M0373S) was used, which is incapable of 
generating the intermediate. It requires the donor oligo to already have the 
modification made. The enzyme can only ligate the pre-formed intermediate to an 
acceptor RNA molecule. The 5’-5’ adenylation can be done using Mth RNA ligase 
from the 5’ DNA adenylation kit (NEB, cat no E2610S), or oligos can be ordered with 
this modification already made. Since T4 RNA ligase 2 truncated KQ requires its 
substrates to be 5’-5’ adenylated already, and is incapable of ligating 5’-
phosphorylated substrates(Ho et al. 2004; Ho and Shuman 2002), endogenous RNA 
cannot supply the 5’ end for the RL2-PAT ligation reaction and endogenous RNAs are 
not ligated to each other by this enzyme. Additionally, RL2-PAT ligation is ATP-
independent. The ligation reaction used in RL2-PAT will be referred to as L2T.
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Enzyme Step 1 Step 2 Step 3 
T4 RNA ligase 1    
Mth RNA ligase    
T4 RNA ligase 2   
T4 RNA ligase 2 
truncated (KQ) 
   
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Step three – formation of phosphodiester 
bond between the donor oligo 5’ end and 
acceptor oligo (or mRNA) 3’ hydroxyl group 
Figure 2.1. Mechanism of RNA ligation. The ligation of an 
ssRNA or ssDNA oligo to ssRNA is completed in 3 steps. The 
table shows the ability of different enzymes to perform each 
step. An ssRNA donor oligo is depicted here, but is 
mechanistically interchangeable with ssDNA. 
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When assessing RL2-PAT as an alternative to RL1-PAT, Mth RNA ligase was used to 
perform the 5’-5’ adenylation on the PAT-R1 anchor oligo. After determining that 
RL2-PAT was superior to RL1-PAT, a new anchor was ordered with the modification 
already made. This anchor was termed ‘PAT-R1 anchor oligo (L2T)’ (Table 2.1). The 
RL2 ligation was performed using 0.5 µg RNA, 20 pmol 5’-rApp PAT anchor oligo, 
15% PEG 8000, and 10 units T4 RNA ligase 2 truncated KQ, with 1X supplied buffer in 
a 20 µl reaction volume. Note that this ligation is done in the absence of ATP. The 
ligation mix was incubated at 16°C overnight, following which a reverse transcription 
was done in the same way as is done for RL1-PAT, but all quantities were doubled, 
since the ligation mix volume for RL2-PAT is double that of RL1-PAT. 
Splint mediated PAT (sPAT) involves the use of a DNA ‘splint’ oligo, which is 
supposed to contribute to the sensitivity and accuracy of the assay. An overview of 
the ligation used in sPAT is shown in Figure 2.2. It uses a 3’-blocked RNA anchor 
oligo (whereas RL1-PAT and RL2-PAT both use a DNA anchor oligo) and a DNA splint 
which has a 5’ sequence complementary to the anchor followed by a string of T 
bases, designed to base pair to the poly(A) tail of mRNA. The splint, RNA sample, and 
the RNA anchor are mixed, heated, and then gradually cooled to room temperature. 
Under these conditions, the RNA anchor first base pairs to the splint. The non-paired 
T bases of the splint in this RNA-DNA hybrid then serve to guide the splint to the 3’ 
ends of mRNA, by base pairing with the last A bases in poly(A) tails. At this point, T4 
RNA ligase 2 is added, which repairs nicks in double-stranded RNA. This is not the 
same enzyme as that used in RL2-PAT (T4 RNA ligase 2 truncated). T4 RNA ligase 2 
ligates 5’-phosphorylated oligos and can perform all steps of the ligation process 
(Figure 2.1). Once the ligation incubation is complete, the ligation mix is subjected to 
a DNase I treatment to remove the DNA splint. The ligated RNA is then cleaned up 
 70 
by a phenol/chloroform extraction and ethanol precipitation, whereupon it can be 
reverse transcribed to PAT cDNA and used for PCR. 
  
AAA…AAA 
TTT 
Polyadenylated mRNA 
3’ anchor RNA oligo 
DNA splint oligo 
AAA…AAA 
Polyadenylated mRNA 
TTT 
Splint-anchor hybrid 
Combine in PCR tube 
Start at high temperature 
Decrease temperature 
Decrease temperature further 
mRNA and anchor both hybridised to splint – 
anchor is in close proximity to 3’ end of mRNA 
Perform ligation reaction 
Do DNase treatment to remove splint 
Clean up RNA 
AAA…AAA 
Ligated RNA ready to be reverse transcribed 
+ 
Figure 2.2. Overview of sPAT ligation. Total RNA is mixed with a 3’-blocked RNA 
anchor oligo and a splint. The splint has a 3’ stretch of T bases that are 
complementary to the poly(A) tail, and a 5’ stretch (red) that is complementary 
to part of the anchor oligo. After an initial melt phase in the thermocycler, the 
temperature is cooled enough to favour hybridisation between the splint and 
anchor only. The temperature is then cooled enough to favour hybridisation 
between the splint’s T stretch and poly(A) tails. The splint thus guides the anchor 
to the 3’ ends of mRNAs. The ligation reaction is then performed, a DNase 
treatment done to remove the splint, and the RNA is cleaned up, whereupon 
reverse transcription and PCR can be done as in RL1-PAT. 
AAA…AAA P 
TTT 
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The version of sPAT we tested deviated from the published protocol (Minasaki, 
Rudel, and Eckmann 2014). The RNA oligo sequence was adapted so that we could 
use our existing PAT-R1 primer to do the reverse transcription and PCR. The DNA 
splint sequence was modified to be complementary to our modified RNA oligo. In 
addition to a DNA splint with a stretch of T bases, a second splint was designed in 
which the T bases were replaced with an equal number of inosine bases. This was in 
order to avoid biasing against mRNAs with terminal uridylation. sPAT using the oligo 
(dT) splint is abbreviated to sPAT (T) and sPAT using the oligo(dI) splint is 
abbreviated to sPAT (I). The last change made was to not only perform the ligation 
as it was done in the original publication, but also to test sPAT with the L2T ligation 
method. Written below is the method using the L2T ligation. For the original sPAT 
ligation, details are in the original publication. 
1 µg of RNA was mixed with 20 pmol DNA splint and 3 pmol anchor in a 10 µl 
volume. This was then heated to 70°C for 5 minutes, then 60°C for 5 minutes, then 
42°C for 5 minutes, then 25°C for 5 minutes, and then held at 15°C. This programme 
should favour first the hybridisation of the splint to the anchor, and then the 
hybridisation of the overhanging splint-anchor hybrid to the 3’ end of mRNA. 10 
units of T4 RNA ligase 2 truncated KQ was then added to the mix, with 1X reaction 
buffer and 15% PEG 8000 in a total reaction volume of 20 µl, and this was incubated 
overnight at 15°C. Following this, the ligation mix was subjected to a DNase 
digestion using TURBO™ DNase (Ambion™, cat no AM2238), following 
manufacturer’s protocol, to remove the DNA splint. Following DNase treatment, the 
mix was subjected to a phenol/chloroform extraction and ethanol precipitation. The 
RNA pellet was redissolved in 20 µl water, and then subjected to reverse 
transcription using SuperScript III, in the same was as is done for RL2-PAT. 
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For all PAT types, once the reverse transcription was complete, the PCR step was 
done in the same way, using GoTaq G2 polymerase (Promega, cat no M7801). 
Reactions were done in a 50 µl volume with 1 µl PAT cDNA, 1X supplied buffer, 1.5 
mM MgCl2, 0.2 mM dNTP mix, 0.4 µM forward PAT primer, 0.4 µM reverse PAT 
primer (PAT-R1), and 1.25 units of GoTaq G2 polymerase. PCR programme: 5 
minutes initial denaturation at 95°C, followed by 40 cycles of 1 minute at 95°C, 1 
minute at 58°C, and 2 minutes at 72°C, and ending with a 10 minute final extension 
at 72°C. PCR products were then run on an agarose gel pre-stained with SYBR Safe 
(Invitrogen™, cat no S33102) at 4V/cm for 2.5-3 hours. 
Gene name Primer name Sequence (5’-3’) 
Expected 
deadenylated 
product size/bp 
Cxcl2 Cxcl2 PAT 1 TGGGGGTGGGGACAAATAGA 339 
Fosb Fosb 3F1 ATTGACTCCATAGCCCTCAC 189 
Rpl28 Rpl28 3F1 GCCACTTCTTATGTGAGGAC 259 
Tnf TNF PAT 1 CTCTACCTTGTTGCCTCCTCTT 215 
- 
PAT-R1 anchor 
(RL1) 
GGTCACCTTGATCTGAAGC-NH2 
- 
- 
PAT-R1 anchor 
(L2T) 
/rApp/GGTCACCTTGATCTGAAG/ddC/ - 
- sPAT anchor /5Phos/GGUCACCUUGAUCUGAAGC-NH2 - 
- sPAT I splint TCAGATCAAGGTGACCIIIIIIIII-NH2 - 
- sPAT T splint TCAGATCAAGGTGACCTTTTTTTTT-NH2 - 
- PAT-R1 GCTTCAGATCAAGGTGACCTTTTT - 
 
Table 2.1. List of PAT primers. Note sPAT anchor is entirely RNA. All other 
primers are DNA. Expected PCR product sizes resulting from PAT using cDNA 
synthesised from deadenylated RNA samples is shown. 
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After imaging the agarose gels on a Chemidoc XRS UV transilluminator (Biorad, cat 
no 1708265), the image was analysed using Quantity One 1-D analysis software 
(Biorad, cat no 1709602). Lanes in the image were framed and scanned, yielding a 
plot of physical distance migrated vs intensity for each lane, including one empty 
lane to measure background intensity. These data were exported and processed in 
Microsoft Excel as described below. 
Firstly, physical distance was plotted against the log2(base pairs) of the DNA 
fragments in the ladder (100 bp ladder, NEB cat no N3231S). Since the ladder 
fragments are of defined sizes, they can be used to derive a relationship between 
physical distance migrated and DNA length (bp). A fourth order polynomial trendline 
was fitted to the plot of physical distance vs log2(base pairs) for the ladder lane. The 
equation of the trendline was then used to convert physical distance migrated to 
DNA length (bp). Note that this was only done within the range of the data available 
i.e. the smallest and largest fragment sizes in the ladder (100 bp and 1517 bp 
respectively). All data points outside this range were removed. 
Secondly, the column representing background intensity values down the lane were 
subtracted from the intensity values for all sample lanes. The resulting background-
corrected intensity values were then all divided by their corresponding DNA size (bp) 
to account for the fact that longer DNA molecules will produce a stronger signal. 
Lastly, these intensity values in each lane were divided by the average intensity 
value of their respective lanes. This was done in order to normalise the data and be 
able to plot them on the same scale (in case more product was loaded in one lane 
compared to another). These were the final values to plot on the y-axis as ‘relative 
frequency’. The x-axis values at this point are ‘DNA size (bp)’. By subtracting the 
expected deadenylated PAT product size (Table 2.1) for whichever primer was used 
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from the DNA size (bp) values, the resulting x-values represent poly(A) tail length 
(bp). Thus, the final plot of poly(A) tail length vs relative frequency is obtained.  
2.2.7 High throughput poly(A) tail measurement: TAIL-seq 
  
Figure 2.3. Overview of the TAIL-seq library generation procedure. Total RNA is 
subjected to 2 rRNA-removal steps and then has a biotinylated adapter ligated to 
the 3’ end of RNAs. This is then subjected to a partial RNase T1 digest, following 
which the 3’-most fragment of all digested RNAs (which has the biotinylated 
sequence) is purified by streptavidin pulldown, 5’-phosphorylated, and run on a gel 
for size selection (300-1000 nt). This size-selected, 5’-phosphorylated RNA then has 
the 5’ adapter ligated and is reverse transcribed to cDNA. PCR is then done using 
primers that have overhanging index sequences.  
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TAIL-seq, originally developed by the Kim lab (Chang et al. 2014), allows for a global 
assessment of poly(A) tail lengths. An overview of the process is shown in Figure 2.3. 
Work was done to establish a working protocol for this technique, since the original 
group’s protocol was not producing results, in our experience. Below is the method 
we used, deviations from the original protocol are indicated. 
rRNA depletion: 50 µg of total RNA was subjected to 2 rounds of rRNA depletion 
using Ribo-Zero Gold kit (MRZH11124C, Epicentre) following manufacturer’s 
protocol with 10 µl rRNA removal solution used per round. 50 µg exceeds the 
capacity of the rRNA removal solution, which is why 2 rounds are used. 
3’ adapter ligation: After redissolving the RNA (now rRNA-depleted), the 
biotinylated 3’ adapter (RA3_biotin4) was ligated to the 3’ ends of all the RNA using 
T4 RNA ligase 2 truncated KQ, 20 pmol of the adapter, and 15% PEG 8000 in a 20 µl 
reaction volume. The ligation was done at 16°C overnight. This step differs from the 
original protocol, which used T4 RNA ligase 2 truncated (NEB, cat no M0242S), 10 
pmol of the 3’ adapter, no PEG 8000, a 10 µl reaction volume and the ligation 
temperature profile was 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and 
then hold at 4°C. 
Partial digestion: Following the ligation, the RNase T1 (Ambion, cat no AM2283) 
partial digest was done by assembling the 3’ adapter ligated RNA in 100 µl reaction 
volume with 1X sequencing buffer (supplied with kit). This mixture was incubated at 
50°C for 5 minutes then paused at 22°C, at which point 2 µl of RNase T1 was added. 
This digestion mixture was incubated at 22°C for 5 minutes in the original protocol, 
which we found to be insufficient, so we increased the duration (discussed in section 
3.4). After the digestion, precipitation/inactivation buffer was added to the mixture 
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and RNA was precipitated following manufacturer’s instructions and redissolved in 
50 µl water. 
Optimisation of the duration of the RNase T1 treatment (discussed in section 3.4) 
involved the use of synthetic RNA as a substrate. The synthetic RNA used (‘T3CAT-
xxsB1-M2’) was produced by in vitro transcription from a construct containing the 
chloramphenicol acetyltransferase gene under the control of a T3 promoter. Further 
details are available in the methods section of the publication for which it was made 
(de Moor and Richter 1999). 
Biotin/streptavidin pulldown, 5’-phosphorylation, and size selection: The 3’ most 
RNA fragments were purified using Dynabeads M-280 Streptavidin (Invitrogen, cat 
no 11206D). 50 µl of Dynabeads were used per 10 pmol biotinylated oligo. 
Manufacturer’s protocol was used up until the bead washing following binding of 
RNA to beads. At this point, a PNK (polynucleotide kinase) reaction was done while 
the RNA was still bound to the beads to phosphorylate the 5’ ends of the RNAs. This 
was done by preparing a 50 µl mix containing 2 µl of T4 PNK (NEB, cat no M0201S), 
1X PNK buffer (50 mM Tris-Cl pH 7.4, 10 mM MgCl2, 0.5% NP-40), and 0.4 mM ATP. 
This mix was then mixed with the beads and incubated at 37°C for 30 minutes. Note 
that the PNK buffer is NOT the buffer supplied with the kit. Following the PNK 
reaction, the beads were washed twice with 100 µl PNK buffer, and then had 13 µl 
of RNA loading dye (95% formamide, 10 mM Tris-HCl) added. This was mixed, 
heated at 95°C for 3 minutes, placed on the magnetic rack, and supernatant 
immediately collected. This elution step was repeated and the two 13 µl elution 
volumes pooled. Eluted RNA was then run on a TBE-urea PAGE gel and stained with 
SYBR gold (Invitrogen, cat no S-11494). A size selection was done by cutting the gel 
between 300 nt and 1000 nt (in the original protocol, this was 450-1500 nt), placing 
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the gel slice into a gel breaker tube (IST engineering, cat no 3388-100) stacked into a 
2 ml centrifuge tube and centrifuging at >16,000 g for 5 minutes. In the original 
protocol, the size selection was At the end of this, 800 µl of 0.3 M NaCl solution was 
added to the gel slice debris and rotated overnight at 4°C. The following day, the gel 
debris suspension in NaCl was divided between 2 Spin-X columns (Corning, cat no 
8162) and centrifuged at >16,000 g for 5 minutes. The flow through was then 
precipitated with 2-3 volumes of 100% ethanol and 0.3 M sodium acetate. The pellet 
was redissolved in 4.2 µl water. 
5’ adapter ligation: This RNA (now with the 3’ adapter in place, and 5’-
phosphorylated) then had the 5’ adapter ligated. T4 RNA ligase 1 (NEB, cat no 
M0204S) was used for this with 0.8 µl of the enzyme, 1mM ATP, 1X T4 RNA ligase 
buffer (supplied with kit) and 5 pmol of the 5’ adapter (RA5) in an 8 µl reaction 
volume. In the original protocol, the temperature profile for the ligation incubation 
was 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and hold at 4°C. We changed 
this to a single incubation temperature of 16°C overnight. 
Reverse transcription (RT): The RNA was reverse transcribed using SuperScript III 
(Invitrogen, cat no 18080093). Manufacturer’s protocol was followed using 4 pmol 
of the reverse transcription primer (RTP). 
PCR: When the library is generated, the fewest cycles that results in successful 
amplification should be used – this is because amplification becomes non-linear at 
higher cycle numbers. A small-scale PCR at several different cycle numbers was 
performed to find out what the ideal number of cycles was. PCR was done using 
Phusion polymerase (Thermo, cat no F-530L), RP1 forward primer, and RPI X reverse 
primer (where X denotes. The reaction was done in a 4 µl volume with 0.4 µl of RT 
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product, 0.2 mM dNTP mix, 0.5 µM primers and 0.04 µl of enzyme. 13-21 cycles 
were used with the following cycling conditions: 
98˚C 30s  
98˚C 10s 
13-19 
cycles 
60˚C 30s 
72˚C 45s 
72˚C 5 min  
After running the PCR products on the gel to determine what the lowest cycle 
number was that resulted in amplification, this number of cycles was used for a full-
scale PCR. The same cycling conditions were used as above, the volumes were all 
scaled up by a factor of 12.5 so that the reaction volume was 50 µl. 
Purification of DNA library: Once the PCR was complete, the library was purified by 
AMPure XP beads (Beckman Coulter, cat no A63880) following manufacturer’s 
protocol. 
Primer name Primer sequence (5’-3’) 
RNA 5’ Adapter 
(RA5) 
GUUCAGAGUUCUACAGUCCGACGAUC 
RNA 3’ Adapter 
(RA3 biotin 4) 
/5App/CTGACNNNNNNNNNNNNNNNTGGAATTCTCG
GGTGCCAAGGC/iBiodT//iBiodT//3ddC/ 
RNA RT Primer 
(RTP) 
GCCTTGGCACCCGAGAATTCCA 
RNA PCR Primer 
(RP1) 
AATGATACGGCGACCACCGAGATCTACACGTTCAGAGT
TCTACAGTCCGA 
RNA PCR Index 
Primers (RPIX) 
Any of Illumina’s proprietary TruSeq small RNA RNA 
PCR index primers between RPI 1 and RPI12 
 
 
 
 
  
Table 2.2. List of TAIL-seq primers. 
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Gene Primer name Sequence (5’-3’) 
Acod1 
Irg1-F1 ACTCCTGAGCCAGTTACCCT 
Irg1-R1 CTGTGACAGACTTGAGCATCAT 
Acod1 
(unspliced) 
un Irg-F TTCTCCACTTCCACGCATCA 
un Irg1-R CAGAAACTTGGACGCAGCAG 
Cxcl2 
Cxcl2-F TGAACAAAGGCAAGGCTAACTG 
Cxcl2-R ACATCAGGTACGATCCAGGC 
Gapdh 
Mouse GAPDH F AAGAAGGTGGTGAAGCAGGC 
Mouse GAPDH R ATCGAAGGTGGAAGAGTGGG 
Hprt 
Mouse HPRT F GGTGTTCTAGTCCTGTGGCC 
Mouse HPRT R AGTGCAAATCAAAAGTCTGGGG 
Il1b 
Mouse Il1b-F1 AGATGAAGGGCTGCTTCCAAA 
Mouse Il1b-R1 GGAAGGTCCACGGGAAAGAC 
Ptgs2 
Ptgs2 F GGTTCACCCGAGGACTGGGC 
Ptgs2 R GGGGGATACACCTCTCCACCAAT 
Rpl28 
Rpl28 Fw TACAGCACGGAGCCAAATAA 
Rpl28 Rev ACGGTCTTGCGGTGAATTAG 
Rpl28 
(unspliced) 
Rpl28 Fw2 CATCGTGTACACCTATTCCC 
Rpl28 Rev ACGGTCTTGCGGTGAATTAG 
Rpl28 
(unterminated) 
Rpl28 Rdthr 500 F1 ACATTCTGGTGGGTGTCAGC 
Rpl28 Rdthr 500 R1 TCTAAGGTCAGCAATTCACACTGA 
Rpl28 
(uncleaved) 
Rpl28 PAS F1 ACACGCCCGAAGCAATAAAG 
Rpl28 PAS R1 CAACCCTCACTCCAGATGAACA 
Tnf 
TNF Fw1 CTATGGCCCAGACCCTCACA 
TNF Rv1 CCACTTGGTGGTTTGCTACGA 
Tnf 
(unspliced) 
Mouse un Tnf-F1 ACACTGACTCAATCCTCCCC 
Mouse un Tnf-R1 AGCCTTGTCCCTTGAAGAGA 
Tnf 
(unterminated) 
Tnf Rdthr 750 F1 ATCCAAGCCTGCATATGTGATTA 
Tnf Rdthr 750 R1 TATTGAGGTGGGTGGATTGGAAA 
Tnf 
(uncleaved) 
Tnf PAS F1 TTTTGTTCCACGGGGGTCTT 
Tnf PAS R1 GGGAGCCGTGACTGTAATCG 
Table 2.3. List of qPCR primers. Primers are stacked as pairs. The top 
primer in each stack is the forward primer, the bottom is the reverse. 
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2.3 Protein work 
2.3.1 Western blot analysis 
At the end of the experiment, cells were placed on ice and washed twice with chilled 
PBS, and then scraped in 5 ml PBS with a cell lifter (Corning, cat no 07-200-364). This 
cell suspension was then centrifuged at 10,000 g for 1 minute at 4°C. The 
supernatant was discarded and the pellet resuspended in 500 µl ice-cold PBS, 
centrifuged as above, and supernatant discarded. To this pellet, 125 µl of ice-cold 
lysis buffer (1xPBS, 0.5% Igepal, 0.5% deoxycholate, 0.05% SDS, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 mM PMSF) was added, and pipetted up and 
down. This was centrifuged at 20,000 g for 10 minutes at 4°C and supernatant 
collected in a new tube. 10 µl of the supernatant was used for determining protein 
concentration by Bradford assay, and the rest had 3X SDS-PAGE loading buffer (0.2 
M Tris-HCl pH 6.8, 9%SDS, 30% glycerol, 2.1 M β-mercaptoethanol, 0.0125% 
bromophenol blue) added for a final concentration of 1X. 45 µg of protein in 1X SDS-
PAGE loading buffer was loaded per well on a 1mm 12% minigel (8.6cm × 6.8cm). 
After running the gel, proteins were blotted onto a PVDF membrane (Thermo, cat no 
88518). Membrane was rinsed twice with TBST (10 mM Tris/HCl, 150mM NaCl, 
0.05% Tween 20), incubated for 1 hour at room temperature while rocking in TBST 
containing 5% milk, rinsed three times with TBST, and then sealed in a small pouch 
with the primary antibody in milk. Primary antibodies used were mouse anti-IκBα 
(Cell signalling technology, cat no 4814) and mouse anti-symplekin (BD Biosciences, 
cat no 610644). This was then incubated for 1 hour at room temperature, with the 
pouch regularly rubbed to mix. The blot was then removed, rinsed three times with 
TBST, and then incubated with polyclonal goat anti-mouse secondary antibody 
(Dako, cat no P0447) in milk for 1 hour at room temperature in another small, sealed 
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pouch. The blot was then recovered, rinsed three times with TBST, and incubated for 
20 minutes in TBST on a rocker at room temperature. Chemiluminescence solution 
(GE, cat no RPN2106) was prepared and, after placing the blot onto a glass plate 
(protein side up), pipetted onto the blot just enough to cover the surface. After 
approximately 5 minutes, the blot was imaged on the LAS-4000 imager (GE, 
discontinued, cat no 28-9558-10). 
2.4 Animal work 
2.4.1 Rat osteoarthritis model pain behaviour assessment by James Burston 
The monosodium iodoacetate (MIA) model of osteoarthritis was used. On day 0, 
animals had either saline (one group) or MIA (two groups) injected into the knee of 
one hind leg. One MIA group had cordycepin mixed with food at 2 mg/kg every 
other day over the course of the experiment while the other MIA group and the 
saline group had DMSO (vehicle) mixed with food, instead. Pain behaviour was 
assessed on a number of days during this period, measured as weight bearing 
asymmetry between hind legs, and paw withdrawal thresholds when paws were 
pressed with Von Frey filaments of increasing force until the animal withdrew its 
paw. On day 14 post injection, animals were killed and tissues obtained for later use. 
2.4.2 RNA isolation from rat synovia 
A number of strategies were attempted to isolate RNA from synovia (discussed in 
results). The method that worked was the use of TRI Reagent (Sigma, cat no T9424) 
at 2 ml per 50 mg tissue. TRI Reagent was added to the synovium in a tube and 
immediately processed using a rotor-stator homogeniser for 15-30 seconds at room 
temperature, until a homogeneous suspension was obtained. The homogenates 
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were incubated at room temperature for 5 minutes after which 0.2 ml of 1-bromo-3-
chloropropane was added per 1 ml of monophasic lysis reagent. Samples were 
mixed by shaking and then centrifuged at 10,000 g for 15 minutes at 4°C. The 
aqueous layer was then transferred to a fresh tube and subjected to an 
isopropanol/sodium acetate precipitation. Pellet was redissolved in water.  
Gene Primer name Sequence (5’-3’) 
Actb 
 
Actb-F AGGCCATGTACGTAGCCATCCA 
Actb-R TCTCCGGAGTCCATCACAATG 
Il1b 
Il1b-F CACCTCTCAAGCAGAGCACAG 
Il1b-R GGGTTCCATGGTGAAGTCAAC 
Tnf 
Rat Tnf-F CCAGGAGAAAGTCAGCCTCCT 
Rat Tnf-R TCATACCAGGGCTTGAGCTCA 
Ptgs2 
Cox2-F GGCACAAATATGATGTTCGCA 
Cox2-R CCTCGCTTCTGATCTGTCTTGA 
  
  
Table 2.4. List of rat qPCR primers used. Primers are stacked as pairs. The 
top primer in each stack is the forward primer, the bottom is the reverse. 
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3 Optimising and developing methodologies for poly(A) 
tail measurements 
The poly(A) tail test (PAT) offers a means for assessment of the distribution of 
poly(A) tail sizes for a specific mRNA within an RNA sample. There are several 
varieties of the PAT method, but the types that this chapter is concerned with all 
include ligation of an oligonucleotide adapter to the 3’ end of RNA, reverse 
transcription to generate cDNA, and PCR using primers that flank the poly(A) tail. 
The method that was in use in our research group when this project began was RNA 
ligation-mediated PAT (RL1-PAT) (Rassa et al. 2000). RL1-PAT requires a large input 
quantity of RNA, which was not always possible for samples with low yields. I sought 
to make improvements to RL1-PAT, as it was. Additionally, RL1-PAT was compared 
to two alternative PAT methods in case they offered superiority – RL2-PAT and 
splint-mediated PAT (sPAT) (Minasaki, Rudel, and Eckmann 2014). 
Lastly, in collaboration with the Deep seq facility at the University of Nottingham, we 
attempted to establish the recently published TAIL-seq method for high-throughput 
poly(A) tail analysis (Chang et al. 2014). 
3.1 Deadenylation by oligo (dT)/RNase H treatment 
To determine if the correct product is amplified, RNA samples are used that have 
been subjected to an oligo (dT)/RNase H treatment to remove poly(A) tails. This 
should result in all PAT cDNAs that get amplified having a uniform poly(A) tail size 
close to zero. This means a single band will be observed on the gel, or 2 or more 
discrete, distinct bands in the case of alternative polyadenylation. Doing the oligo 
(dT)/RNase H treatment is therefore essential for testing new primers (to check that 
the expected deadenylated product is being amplified, and not an off-target 
product). In the event that different PAT products are yielded from different RNA 
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samples, repeating PAT on the samples’ deadenylated counterparts should yield the 
same product(s) as 1 or more discrete, distinct band(s), thus proving that differences 
observed are exclusively due to poly(A) tail size differences. For this reason, the oligo 
(dT)/RNase H treatment is a crucial part of the PAT methodology. 
After switching supplier of RNase H from Promega to NEB, our lab group was 
experiencing incomplete, unsatisfactory deadenylation with the oligo (dT)/RNase H 
treatment (Figure 3.1A). I tested multiple different permutations of the treatment to 
see if this could be rectified to yield complete deadenylation (Figure 3.1B). The 
treatments were all carried out under the same conditions, with the only differences 
being the quantity of oligo (dT) and RNase H enzyme used. Using 4 µg of oligo (dT) 
and 5U of enzyme consistently yielded properly deadenylated RNA, and so this 
combination of concentrations was adopted. The lowest combination of oligo (dT) 
and enzyme concentration (2 µg and 2.5 U respectively) appears to result in the 
same degree of deadenylation as using 4 µg of oligo (dT) and 5 U of enzyme in 
Figure 3.1B. However, such results were not consistent in further experiments, 
whereas 4 µg of oligo (dT) and 5 U of RNase H reliably caused deadenylation. 
Unexpectedly, the result of using 4 µg of oligo (dT) and 2.5 U of enzyme was less 
deadenylation than for the lowest combination of concentrations. This was probably 
an anomalous result. 
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Figure 3.1 Incomplete deadenylation using NEB RNase H was addressed by 
increasing oligo (dT) and RNase H quantities. RL1 PAT was performed using 
the Rpl28 3F1 primer with various cDNA samples and PAT products were run 
on agarose gels. (A) DA and non-DA denote deadenylated and non-
deadenylated PAT cDNA of RNA isolated from unstimulated RAW 264.7 cells. 
The deadenylation was performed using Promega or NEB RNase H (1.5 U of 
enzyme, 2 µg oligo (dT). (B) NEB RNase H deadenylation was performed on 
RNA from RAW 264.7 cells stimulated with LPS at 1 µg/ml for 30 minutes 
using a range of different oligo (dT) and NEB RNase H quantities. * indicates 
artefactual bands. 
Deadenylated Rpl28 product size: 259 bp 
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3.2 Appraising different ligation strategies 
As part of the PAT optimisation, different ligation strategies were used and 
compared to each other. I compared RL1-PAT, which uses the T4 RNA ligase 1 
enzyme, to RL2-PAT, which uses the T4 RNA ligase 2 truncated enzyme. The ligation 
in the RL2-PAT workflow is referred to as L2T. The sPAT method was also tested both 
with the original ligation and using the L2T ligation. Full details are in section 2.2.6. 
In order to see whether RL2-PAT offered advantages over the RL1-PAT method in 
use, reactions were incubated in parallel with 3 different input RNA quantities (2 µg, 
1 µg, and 0.5 µg). PAT anchor was 5’-adenylated using a 5’ DNA adenylation kit prior 
to use in the RL2-PAT workflow, while the normal, unaltered, PAT anchor (5’-
phosphorylated) was used for RL1. Following the ligation step, the reverse 
transcription was done in the same way, but all volumes were doubled for RL2-PAT, 
since the ligation reaction volume was double that of RL1-PAT. PAT-PCR was then 
done in exactly the same way for both, with 1 µl of cDNA. RL2-PAT was found to 
yield consistent PAT products across the 3 different input RNA quantities, while the 
distribution of PAT products generated with RL1-PAT appeared to vary between the 
different input RNA quantities (Figure 3.2A). qPCR on all the PAT cDNA samples was 
performed, and demonstrated that cDNA generation was consistent for RL2-PAT for 
all input RNA quantities used (Figure 3.2B). This consistency was not seen for RL1-
PAT, which also yielded considerably less cDNA than RL2-PAT, suggesting better 
ligation efficiency with L2T. Taken together, these data indicate that using the L2T 
ligation represents a significant improvement of the PAT method over the RL1 
method that had been in use before. For this reason, RL2-PAT using L2T ligation 
replaced the RL1-PAT procedure, and a new PAT anchor oligo was ordered with the 
5’-5’ adenylation modification already made.
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Figure 3.2. RL2 PAT yields more 
consistent results with a range of 
input RNA quantities, and more 
efficient cDNA generation. (A) RL1 
and RL2 PAT tests were performed 
for Tnf using RNA from RAW 264.7 
cells stimulated with LPS at 1 µg/ml 
for 30 minutes. Three input RNA quantities were used (2 µg, 1 µg, and 0.5 µg) 
for each ligation method (RL1 and RL2). PAT products were run on an agarose 
gel. The gel image was scanned using Quantity One software and profiles 
represented graphically. * indicates artefactual bands. (B) The PAT cDNA 
samples were also subjected to qPCR for Tnf, and the raw Ct value was 
measured. qPCR was performed on the Qiagen Rotor-Gene Q platform. Error 
bars represent standard deviations across three technical replicates. 
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After implementing the RL2 ligation in the PAT procedure, the sPAT method was 
published, which was tested against our newly adopted RL2-PAT method. In order to 
see if a combination of splint ligation and the ligation method used in RL2-PAT 
ligation could improve the ligation efficiency even further, the RNA anchor oligo was 
subjected to a 5’-5’ adenylation step prior to use in some samples i.e. sPAT using RL2 
ligation with 5’-5’ adenylated RNA anchor instead of the standard sPAT using T4 RNA 
ligase 2 with 5’-phosphorylated RNA anchor. sPAT using the RL2 ligation method will 
be referred to as L2T sPAT, while standard sPAT using T4 RNA ligase 2 with 5’-
phosphorylated RNA anchor will be referred to as T4 Rnl2 sPAT. 
Both types of sPAT were done (L2T and T4 Rnl2), and the gel image (Figure 3.3) 
shows that the L2T method produced a stronger signal. It was later noted that the 
DNase treatment had been accidentally omitted in this experiment, and so it was 
repeated alongside RL2-PAT for direct comparison. However, having observed that 
L2T ligation appeared to improve sPAT, we only compared RL2-PAT to L2T sPAT – T4 
Rnl2 sPAT was not included in the experiment. RL2-PAT produced results that were 
either similar to those for L2T sPAT or showed higher signal (Figure 3.4). qPCR was 
done on RL2-PAT and L2T sPAT cDNAs for a number of mRNAs across a range of 
different levels of abundance. RL2-PAT consistently resulted in a greater efficiency of 
cDNA generation (Figure 3.4). It was thus concluded that RL2-PAT was superior to 
L2T sPAT, and so the method was retained. 
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Figure 3.3. The L2T ligation improves sPAT compared to the T4 
Rnl2 sPAT ligation. sPAT protocol was followed with two different 
ligation strategies: the L2T ligation with a 5’-5’ adenylated RNA 
anchor oligo (L2T sPAT) or the standard sPAT ligation using T4 RNA 
ligase 2 with 5’-phosphorylated RNA anchor oligo (T4 Rnl2 sPAT). 
Both the I and T splints were used with 3 different input quantities 
of RNA: 1 µg, 0.5 µg, and 0.2 µg. RNA was from RAW 264.7 cells that 
had been stimulated for 30 minutes with LPS at 1 µg/ml. PAT 
products (Tnf) were run on an agarose gel. Note that the DNase 
treatment was forgotten. * indicates artefactual bands. 
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3.3 Identifying artefacts 
Very large, unexpected, PAT products are routinely observed when running the 
products on agarose gels, in addition to the products that appear around the 
expected size (Figure 3.7). Possible explanations for the presence of these 
unexpected species were that they were products with very large poly(A) tails, 
products with a downstream poly(A) site (i.e. alternative polyadenylation) and 
therefore longer 3’ UTR, or some sort of artefactual species. If these higher bands 
are due to alternative polyadenylation, then doing PAT on the samples’ 
deadenylated counterparts should yield a correspondingly large deadenylated PAT 
product in addition to the expected one. However, this is generally not observed 
(e.g. Figure 3.1A), and so this was unlikely. If the higher bands represented some 
sort of artefact formed through secondary structure, then running them on a gel 
under denaturing conditions should remove them. I attempted this by mixing 
different quantities of a PAT product with formamide buffer (49.5% final 
concentration for all samples loaded), heating, and running on a TBE-urea PAGE gel 
(Figure 3.5). This was done for 2 different PAT products (Rpl28 and Tnf), and the 
relative proportion of the higher bands increased with increasing PAT product being 
loaded, even though it was the exact same PAT product for each of the 3 quantities 
loaded. This was highly suggestive of the higher band representing an artefact 
whose formation was favoured by increasing concentration of the product. 
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Figure 3.5. An increase in PCR product:formamide ratio increases the 
prevalence of suspected multimeric bands. RL2-PAT was performed for 
Rpl28 and Tnf using RNA from RAW 264.7 cells stimulated with LPS at 1 µg/ml 
for 30 minutes. PAT products were run on a TBE-urea PAGE gel. Samples were 
in 49.5% formamide buffer and were heated at 90°C for >10 minutes then 
placed on ice prior to loading and running. Gel images were scanned using 
Quantity One software and profiles represented graphically. * indicates 
artefactual bands. 
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I ran those same products, again, on a TBE-urea PAGE gel, but with only 1 µl of PAT 
product loaded in 90% formamide buffer, and with heated running buffer in the 
electrophoresis tank to maximise the denaturing potential of the system. Doing this 
completely removed the appearance of the higher bands which were observed on 
agarose and when using 49.5% formamide buffer on TBE-urea PAGE (Figures 3.5 and 
3.6). A working model for the formation of these higher bands was conceived 
(Figure 3.7B), wherein the repetitive melting and reannealing in later stages of PCR 
leads to mispairing of strands with different poly(A)/poly(T) lengths, and looping out 
of excess A or T bases. Loops of excess A can then facilitate base pairing with loops 
of excess T from other mismatched duplexes to form a multimeric artefact. This 
model is consistent with the findings of an experiment in which oligo (dT) was able 
to remove higher bands. PAT cDNA from serum-stimulated NIH-3T3 cells were used 
for PAT to amplify Fosb – PAT for this mRNA in this cell type routinely results in 
higher bands. PAT products then had varying quantities of oligo (dT) added, were 
heated at 95°C, and then were run on an agarose gel. The gel photo and graphical 
scan show that the addition of oligo (dT) leads to disappearance of the higher bands 
(Figure 3.7A). Ostensibly this occurs by ‘titrating’ A loops, preventing their 
association with T loops. 
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Figure 3.6. Artefactual species are multimers and can be removed through 
fully denaturing PAGE. RL2-PAT was performed for Rpl28 and Tnf using RNA 
from RAW 264.7 cells stimulated with LPS at 1 µg/ml for 30 minutes. PAT 
products were run on an agarose gel, and on a TBE-urea PAGE gel. For PAGE, 
samples were in 95% formamide buffer, TBE in the gel tank was heated to 50
°C prior to running, and samples (in formamide buffer) were heated at 90°
C for >10 minutes immediately prior to loading and running. Gel images were 
scanned using Quantity One software and profiles represented graphically. * 
indicates artefactual bands. 
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Figure 3.7. Addition of oligo (dT) to PAT-PCR products can remove 
multimer species. (A) RL2 PAT was performed for Fosb on RNA samples from 
NIH-3T3 cells stimulated with DMEM + 10% NBCS for 110 minutes (following 
a 24 hour incubation in DMEM + 0.5% NBCS). 15 µl of PAT-PCR products 
were mixed with the indicated amount of oligo (dT), heated at 95°C for 10 
minutes then placed on ice prior to loading and running. Gel images were 
scanned using Quantity One software and profiles represented graphically. 
* indicates artefactual bands. (B) Working model for formation of the PAT 
multimer species. 
Deadenylated Fosb product size: 189 bp. 
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3.4 High-throughput poly(A) tail measurements – TAIL-seq 
TAIL-seq is a method that allows for the high-throughput measurement of poly(A) 
tail lengths, and other 3’ terminal modifications, within an RNA sample. We sought 
to establish the technique within our group in conjunction with the Nottingham 
deep sequencing facility. However multiple attempts to follow the TAIL-seq protocol 
(provided by Narry Kim’s group) failed to generate a library, and so we tried to 
troubleshoot the procedure by assessing how well individual steps within the 
protocol were working. An overview of the process is shown in Figure 2.3. 
By the point of eluting RNA from the streptavidin beads, the expected RNA 
recovered would be the 3’-most fragment yielded from the partial RNase T1 digest 
with the biotinylated 3’ adapter (RA3_biotin4) ligated to its 3’ end, and 
phosphorylated at its 5’ end (since a PNK reaction is performed on the beads after 
the wash steps and before eluting). As shown in Figure 3.8, only the unligated 3’ 
adapter (RA3_biotin4) was being recovered following the streptavidin pulldown. The 
RA3_biotin4 oligo can be seen in the ligation mix along with the rRNA-depleted NIH 
3T3 RNA – this indicates that at least some of the oligo did not ligate to the NIH 3T3 
RNA. If the ligation had been successful, I would have expected the bands for the 
rRNA-depleted NIH 3T3 RNA to shift up between the two lanes on the gel (before 
and after ligation). The RA3_biotin4 adapter is 45 nt in length, and the ladder shows 
clear separation of the 30 nt and 50 nt RNA fragments, and so a 45 nt change in RNA 
length should be clearly observable, at least around this lower part of the gel. This 
suggests a possible failure of the 3’ adapter ligation. Moreover, only a single band is 
observed on the gel after the streptavidin pulldown, corresponding to the 
RA3_biotin4 oligo. This strongly suggests that the 3’ adapter ligation did indeed fail, 
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since ligation products would have otherwise been recovered in the pulldown 
(irrespective of whether the RNase T1 digest had been successful or not). 
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Figure 3.8. Only unligated RA3 oligo is recovered after the streptavidin 
pulldown. Total RNA from unstimulated NIH 3T3 cells was isolated and 
subjected to rRNA removal. The resulting ribodepleted RNA was then used for 
the 3’ adapter (‘RA3 oligo’) ligation step, following original protocol (T4 RNA 
ligase 2 truncated, 10 pmol of the 3’ adaptor, no PEG 8000, a 10 µl reaction 
volume, 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and then hold at 
4°C). Once the ligation step was complete, the RNA was subjected to a partial 
RNase T1 digest (5’ digestion time), and a streptavidin pulldown performed. A 
PNK reaction was completed prior to eluting bound RNA from the streptavidin 
beads. Samples of RNA from multiple points in this procedure were run on a 
TBE-urea PAGE gel alongside the 3’ adapter (‘RA3_biotin4’) alone. 
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Our PAT protocol uses a very similar ligation step under different conditions that 
works well, so we sought to compare the efficiencies of the TAIL-seq ligation versus 
the L2T ligation used in the RL2-PAT method (see section 2.2.6 for details). After 
doing the ligation in both ways, the RNA ligation mixes were divided into two halves 
– one half was reverse transcribed using random hexamers, while the other was 
reverse transcribed using the “RT primer” (primer complementary to the 3’ adapter). 
Using random hexamers was expected to produce similar amounts of cDNA for all 
RNA ligation mixes, while reverse transcription (RT) using the RT primer would 
depend on the efficiency of the ligation. Comparison of the ratio of the Ct value for 
the two RT methods will give an indication of how well the ligation has worked 
between the different ligation methods. 
Surprisingly, the Ct values for the TAIL-seq ligation method and random hexamer RT 
were very high (Table 3.1). As a result, I was not able to directly compare the ligation 
efficiencies, but, since I obtained reasonable Ct values from all cDNAs made from 
our PAT ligation method, we elected to use this method for the TAIL-seq, also. 
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  Gapdh (high 
abundance) 
Tnf (mid-high 
abundance) 
Fosb (low 
abundance) 
RT 
method 
used 
Input 
RNA 
quantity 
L2T 
TAIL-
seq 
L2T 
TAIL-
seq 
L2T 
TAIL-
seq 
Random 
hexamers 
3 µg 14.02 35.08 19.37 No Ct 29.71 No Ct 
0.5 µg 18.62 32.34 23.60 No Ct 33.47 No Ct 
RT primer 
(RTP) 
3 µg 16.28 23.46 23.97 30.42 No Ct No Ct 
0.5 µg 20.29 34.06 28.34 No Ct No Ct No Ct 
 
  
Table 3.1. The ligation used in the PAT workflow successfully generated cDNA for 
TAIL-seq. 3 µg or 0.5 µg of total RNA from unstimulated RAW 264.7 cells had 
RA3_biotin4 3’ adapter ligated to the 3’ end of RNA in one of two ways: T4 RNA 
ligase 2 truncated KQ, 20 pmol of RA3_biotin4, and 15% PEG 8000 in a 20 µl 
reaction volume incubated overnight at 16°C overnight (‘L2T’); or T4 RNA ligase 2 
truncated, 10 pmol of RA3_biotin4, and no PEG 8000 in a 10 µl reaction volume 
incubated at 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and then held at 
4°C (‘TAIL-seq’). Ligation mixes were then reverse transcribed using either random 
hexamers or the RT primer specific to RA3_biotin4 (the ligated 3’ adapter). qPCR 
was done in technical triplicate for each reverse transcription mix for Gapdh, Tnf, 
and Fosb. Average Ct values are shown. 
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Following the RNase T1 partial digest, bands from the NIH-3T3 RNA are clearly 
visible (Figure 3.8). The quantity of RNA run on the gel at this point was very low 
compared to that of the previous two lanes, and so the signal is faint, but the bands 
between 50 nt and 80 nt, as well as the band just under 150 nt, can be observed at 
the same size as in the previous two lanes (undigested sample), possibly indicating 
limited digestion. For deep sequencing using Illumina technology, longer fragments 
of nucleic acids (>1,000 nt) experience a decreased efficiency of amplification during 
the process of cluster generation relative to that of shorter fragments (Quail et al. 
2009). This can lead to to an underestimation of longer fragments compared to 
shorter ones, since shorter ones will amplify more efficiently and result in 
proportionately more reads. For this reason, we wanted to ensure the digestion was 
not limited and sought to optimise it by testing different digestion durations. Using 
multiple aliquots of NIH-3T3 RNA that had been subjected to rRNA removal (the 
normal substrate for the RNase T1 partial digest step) to test multiple digestion 
durations was not viable, since the rRNA removal reactions were very expensive. For 
this reason, we used a synthetic RNA (‘T3CAT-xxsB1-M2’, henceforth referred to 
simply as ‘synthetic RNA’) as a substrate, instead, since this was expendable RNA 
from older work that was no longer required. The synthetic RNA was ~800 nt in 
length. 
The RNase T1 enzyme cleaves single-stranded RNA after G residues, and so poly(A) 
tails are impervious to RNase T1 digestion. Therefore, in order to avoid the problem 
mentioned above (longer fragments that do not amplify efficiently during cluster 
generation), we aimed to ensure that the RNase T1 would cleave non-poly(A) RNA 
approximately every 400 nt. In this way, the fragments obtained after the ligation 
and RNase T1 digestion would have a length amounting to ~400 nt plus the length of 
their poly(A) tails. This would allow for even RNAs with long poly(A) tails (>250 nt) to 
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still fall below the 1,000 nt limit (after RNase T1 digestion). For our synthetic RNA 
(~800 nt total size), we aimed to achieve an extent of digestion which yields a 
distribution of products with a peak around 400 nt. Figure 3.9 shows that a 10’ 
RNase T1 treatment of the synthetic RNA yielded a spread of products, with most 
RNA appearing to fall in the range of 300 nt to ~800 nt (just below the undigested 
0’control). The 30’ digestion duration resulted in a greater degree of digestion than 
the 10’ duration. Compared to the 10’ digestion, no significant amount of RNA is 
observed above the 500 nt band, RNA between 300 nt and 500 nt is fainter, and 
more RNA appears below the 300 nt band. For the 60’ RNase T1 digestion, the 
longest RNA fragments yielded are below the 300 nt band – a much greater extent 
of digestion than desired. The 10’ digestion was not quite extensive enough 
(significant signal observed just under the undigested RNA band), and the 30’ 
digestion appeared to be slightly too extensive (significantly fainter signal observed 
between 300 nt and 500 nt marker bands and more intense smear of shorter 
products below the 300 nt band compare to the 10’ digestion). Ultimately, a 
digestion duration of 15’ was chosen for the workflow. 
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Our attempt to generate a library for TAIL-seq using the original ligation strategy and 
RNase T1 duration was unsuccessful, as shown in Figure 3.10A – the only product 
observed in the small-scale PCR is a band is observed below the 100 bp marker 
band, possibly due to primer dimer. After implementing the L2T ligation (to ligate 
the RA3_biotin4 3’ adapter to the end of rRNA-depleted NIH-3T3 RNA) and the 15’ 
RNase T1 digestion in the TAIL-seq workflow, the library generation was 
reattempted and 13-17 cycles of PCR was sufficient to successfully generate a 
library, with products corresponding to the library ranging from 100 bp to >1,000 bp 
(Figure 3.10B). The fact that products larger than 1,000 bp were amplified suggests 
that the RNase T1 digestion duration may need further optimisation. 
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Figure 3.9. Increasing RNase T1 digestion time results in shorter 
RNA fragments. 3 µg of synthetic RNA produced from in vitro 
transcription was subjected to RNase T1 digestion for the indicated 
durations and run on a TBE-urea PAGE gel. 
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Figure 3.10. Changing the 3’ adapter ligation strategy and increasing the 
RNase T1 digest duration resulted in successful amplification of a library. 
(A) The original TAIL-seq workflow was followed with NIH 3T3 RNA, using 
the original protocol. 3’ adapter ligation conditions: T4 RNA ligase 2 
truncated, 10 pmol of the 3’ adaptor, no PEG 8000, a 10 µl reaction 
volume, 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and then hold 
at 4°C. RNase T1 digest duration: 5 minutes. After the small scale PCR, 
samples were run on an agarose gel after completing the indicated 
number of PCR cycles to assess whether a library had been amplified. (B) 
As above except for 15 minute RNase T1 digest and altered 3’ adapter 
ligation conditions: T4 RNA ligase 2 truncated KQ, 20 pmol of the adaptor, 
15% PEG 8000 in a 20 µl reaction volume, 16°C overnight. After the small 
scale PCR, samples were run on a TBE-urea PAGE gel after completing the 
indicated number of PCR cycles to assess whether a library had been 
amplified. 
B 
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13 15 17 19 20 21 
100 bp 
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3.5 Discussion 
Significant improvements were made to the PAT methodology through the 
identification of working deadenylation reaction conditions and use of the L2T 
ligation reaction in the RL2-PAT workflow. RL2-PAT was also superior to the sPAT 
method, even when it was combined with the L2T ligation. This is a beneficial 
outcome since sPAT is a longer and more expensive method than RL2-PAT, due to 
the need for an RNA oligo and DNase treatment step. RL2-PAT was implemented in 
the research group as the standard PAT method to use. Unless otherwise stated in 
the figure legends, all PAT presented in chapter 4 onwards is RL2-PAT and all 
products are run on agarose gels. Higher, unexpected bands that often appeared on 
PAT gels were identified as artefacts, and ways to remove them were found. It 
should be noted that the addition of oligo (dT) did not reliably and reproducibly 
remove these artefacts, but fully denaturing TBE-urea PAGE did. None of the PAT 
data in chapter 4 onwards use TBE-urea PAGE, however, as those data were all 
generated before TBE-urea PAGE was shown to remove artefacts. Progress was 
made on establishing TAIL-seq for use by our research group. We were unable to 
obtain usable data, so further adjustments to the workflow are necessary. However, 
a library was successfully created and data generated validated the technique in 
principle, which shows progress from the initial experience of not being able to even 
generate the library before steps in the workflow were altered. Further work should 
lead to the proper establishment of the technique, which would provide a means to 
analyse poly(A) tails on a genome-wide scale.  
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4 Inflammation and polyadenylation in RAW 264.7 cells 
Our group previously reported that inhibiting polyadenylation results in a decrease 
in inflammatory gene expression (Kondrashov et al. 2012). Many mRNAs involved in 
inflammation are inherently unstable due to regulatory cis elements in their 3’ UTRs, 
with AU-rich elements (AREs) being a well-studied example of such elements (P. 
Anderson 2010; Stumpo, Lai, and Blackshear 2010; Hao and Baltimore 2009). Part of 
ARE function includes recruitment of deadenylase machinery via trans-acting factors 
that removes the poly(A) tail. This is often regarded as the first and rate-limiting step 
of mRNA decay (C.-Y. A. Chen and Shyu 2011), and so a model can be conceived 
wherein the time taken to remove the poly(A) tail represents a delay before the 
mRNA can be degraded. Thus, regulation of poly(A) tail size could be particularly 
important for those mRNAs that are inherently unstable (like inflammatory mRNAs) 
and thus “depend” on the delay to exist long enough to be translated. 
Previous experiments in our group studying polyadenylation and inflammation were 
done in human airway smooth muscle (ASM) cells, and we sought to further 
investigate the importance of polyadenylation in inflammatory gene induction using 
a macrophage-like cell type. I used the RAW 264.7 murine macrophage cell line and 
stimulated with lipopolysaccharide (LPS) to induce an inflammatory response. While 
primary macrophages may have been an ideal choice for being more representative 
of true macrophage biology, the RAW 264.7 cell line was chosen for two main 
reasons. Firstly, at the time of beginning the project, the poly(A) tail test (PAT) 
protocol required high input RNA quantities, especially if a deadenylated 
counterpart of a sample needed to be generated (in excess of 20 µg of RNA). Such 
high yields of RNA are more manageable and feasible with a cell line. Secondly, cell 
lines offer greater reproducibility across different types of experiments. When trying 
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to assemble and integrate data from multiple different experiments into an overall 
picture of how polyadenylation is important in the overall process of inflammation, 
and how cordycepin’s effects are mediated (the subject of the next chapter), such 
reproducibility is very important. 
Experiments in this chapter aimed to establish a working inflammatory system using 
LPS as a stimulus in the RAW 264.7 macrophage-like cell line. The inflammatory 
response would be assessed by RT-qPCR to monitor mRNA levels of inflammatory 
genes. Polyadenylation over the course of the inflammatory response was assessed 
by using the poly(A) tail test (PAT). This was done on both total RNA samples and 
also nuclear RNA, to examine whether the initial poly(A) tail size was the subject of 
regulation. 
4.1 Developing the inflammatory system 
I used the RAW 264.7 murine macrophage cell line and stimulated with 
lipopolysaccharide (LPS) to induce an inflammatory response. The cells were 
cultured in DMEM + 10% FBS, which contributes to growth factor signalling in the 
cells. In order to determine to what extent this signalling (and other effects of the 
serum) would have on the inflammatory dynamics, I performed LPS stimulations on 
cells still in the growth medium, and also on cells whose medium was changed to 
DMEM + 0.5% FBS. RT-qPCR data shows that serum starvation leads to a stronger 
degree of induction of the inflammatory genes by LPS compared to cells for which 
medium was not changed (Figure 4.1). The degree of induction refers to the 
difference in mRNA levels between unstimulated and stimulated conditions. This can 
result from either a lowering of mRNA levels in unstimulated conditions or an 
increase in mRNA levels in stimulated conditions (or some combination of the two). 
For Tnf mRNA, the greater degree of induction in serum-starved cells was mainly 
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due to a decrease of mRNA levels under unstimulated conditions. For Cxcl2, 
however, higher mRNA levels in stimulated conditions were the main contributor to 
the stronger induction in serum-starved cells. I decided to use the method involving 
serum starvation for subsequent experiments due to the stronger induction. 
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Figure 4.1. Serum withdrawal prior to LPS stimulation results in a 
more pronounced response. 24 hours after seeding RAW 264.7 cells, 
one set of cells was stimulated with LPS for 2 hours (serum-replete), 
while a second set of cells had medium changed to DMEM + 0.5% 
FBS (serum-starved). A further 24 hours later, serum-starved cells 
were stimulated with 1 µg/ml LPS for 2 hours. RT-qPCR was done, 
error bars represent standard deviations across 3 technical 
replicates. 
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4.2 Time courses and poly(A) tails 
With a working inflammatory system established, I then did time course 
experiments to observe the expression profiles of inflammatory genes over time, 
after induction with LPS. To this end, RT-qPCR was done on samples from the time 
course in addition to PAT to assess the distribution of poly(A) tails (Figures 4.2 and 
4.3). Over a 2 hour period, all genes assessed showed an increase of 2-3 orders of 
magnitude in expression levels which remained elevated at the end of this period. 
RT-qPCR was also done for Tnf and Acod1 using primers specific for unspliced mRNA 
in order to gauge pre-mRNA levels (and thereby estimate transcription levels). Tnf 
pre-mRNA levels appeared to increase and plateau by 30 minutes for the entire 2 
hour period and mature mRNA levels followed a similar profile, with a slight 
decrease by 90 minutes. Acod1 pre-mRNA levels, in contrast, rose to peak at 70 
minutes and then declined greatly by 120 minutes. Although the Acod1 pre-mRNA 
levels had decreased greatly by 90 minutes (and further still by 120 minutes) from 
the peak at 70 minutes, the levels of mature Acod1 mRNA continued to increase 
throughout the whole 2 hour period. Hprt is shown as a control mRNA whose 
expression levels did not change, validating Rpl28 as a reference mRNA. 
Performing PAT on the RNA samples showed that Cxcl2 and Tnf have relatively long 
poly(A) tails that coincide with their induction, and steadily get shorter over time 
(Figure 4.3). This could reflect a situation in which a pulse of transcription produces 
a population of mRNAs with long, freshly produced poly(A) tails which are gradually 
deadenylated over time. In the case of Tnf, the PAT data show the highest 
proportion of mRNAs with long poly(A) tails at 30 minutes, an approximately equal 
spread of mRNAs over a range of tail sizes at 50 minutes, and then most mRNAs are 
deadenylated from 70 minutes onwards. However, the Tnf pre-mRNA levels remain 
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elevated at these later timepoints, indicating that transcription is ongoing. This 
suggests that new Tnf transcripts produced at later timepoints may be made with 
shorter poly(A) tails. 
   
Figure 4.2. LPS stimulation of RAW 264.7 cells induces expression of 
inflammatory genes. RAW 264.7 cells were stimulated with 1 µg/ml LPS for 
the indicated durations. RT-qPCR data obtained on the Qiagen Rotor-Gene Q 
platform show expression levels over the time course. Error bars represent 
standard deviations across 3 technical replicates. Data for 2 biological 
replicates are shown in separate graphs for each mRNA. Acod1 data was only 
obtained for one biological replicate. 
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Figure 4.2. (cont) LPS stimulation of RAW 264.7 cells induces expression of 
inflammatory genes.  
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    A 
Figure 4.3. Tnf and Cxcl2 poly(A) tails change in size over the course of their 
inductions by LPS. RAW 264.7 cells were stimulated with 1 µg/ml LPS for the 
indicated durations. RNA samples are the same as those analysed in Figure 4.2 
(replicate 2). (A) RT-qPCR data obtained on the Qiagen Rotor-Gene Q platform 
showing expression levels over the time course. These are the same data as 
those shown in Figure 4.2. (B) RNA samples were used for RL2-PAT, and 
products were run on an agarose gel. (C) Gel images were scanned using 
Quantity One software and profiles represented graphically. All data (including 
qPCR) are shown for a single biological replicate. qPCR error bars represent 
standard deviation across three technical replicates. * indicates artefactual 
bands. 
Deadenylated product sizes – Tnf: 215 bp. Cxcl2: 339 bp. Rpl28: 259 bp. 
B 
0’ 15’ 30’ 50’ 70’ 90’ 120’ 
Rpl28 
0 1 0 0 2 0 0 3 0 0
1
2
3
4
5
T n f
P o ly (A ) ta il le n g th /b p
R
e
la
ti
v
e
 f
r
e
q
u
e
n
c
y
3 0 '
5 0 '
7 0 '
9 0 '
1 2 0 '
C 
0 1 0 0 2 0 0 3 0 0
1
2
3
4
C x c l2
P o ly (A ) ta il le n g th /b p
R
e
la
ti
v
e
 f
r
e
q
u
e
n
c
y
3 0 '
5 0 '
7 0 '
9 0 '
1 2 0 '
0 1 0 0 2 0 0 3 0 0
2
4
6
8
R p l2 8
P o ly (A ) ta il le n g th /b p
R
e
la
ti
v
e
 f
r
e
q
u
e
n
c
y
0 '
1 5 '
3 0 '
5 0 '
7 0 '
9 0 '
1 2 0 '
0 3 0 6 0 9 0 1 2 0
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
T n f
T im e  a fte r L P S  a d d it io n /m in s
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
/R
p
l2
8
0 3 0 6 0 9 0 1 2 0
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
C x c l2
T im e  a fte r L P S  a d d it io n /m in s
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
/R
p
l2
8
Tnf 
600 bp 
500 bp 
400 bp 
300 bp 
200 bp 
0’ 15’ 30’ 50’ 70’ 90’ 120’ LPS 
700 bp 
800 bp 900 bp 
1000 bp 
* 
0’ 15’ 30’ 50’ 70’ 90’ 120’ 
Cxcl2 
* 
 112 
 
To test whether initial poly(A) tail size was variable over the course of the 
inflammatory response, I performed another time course experiment but nuclear 
and cytoplasmic fractions were separated prior to RNA isolation. Doing PAT on 
nuclear RNA should show the poly(A) tail distribution of newly synthesised RNA. PAT 
for Tnf shows that the poly(A) tail of cytoplasmic RNA is longer at 30 minutes and 
shorter afterwards (Figure 4.4), as had been observed in total RNA (Figure 4.3B and 
4.3C). PAT done for Tnf on nuclear RNA appeared to generate very little product, 
leading to weak signal on the gel.  
  
Figure 4.3. (cont) Tnf and Cxcl2 poly(A) tails change in size over the course of 
their inductions by LPS. (D) The Tnf PAT gel was loaded in the wrong order, so 
the image was altered to reorder the lanes. The original is shown alongside the 
altered image. * indicates artefactual bands. 
D 
Tnf – original gel image 
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Qualitatively, it appears that there is a band at 30 minutes corresponding to newly 
made RNA with a longer poly(A) tail compared to the PAT product for the 70 minute 
timepoint (Figure 4.4). This suggests that Tnf mRNA is made with a poly(A) tail 
whose length varies depending on what stage of the inflammatory response the cell 
is in. Notably, while PAT for cytoplasmic and total RNA samples shows that the 
poly(A) tail becomes shorter, and stays short, after 30 minutes of LPS treatment, this 
does not appear to be the case for nuclear RNA PAT. Tnf poly(A) tails of newly made 
mRNA appear to be long and short at 30 minutes, short only at 70 minutes, and long 
and short, again, at 120 minutes. This may indicate an oscillatory nature of the 
polyadenylation state of Tnf over the course of the inflammatory response. 
LPS 
Tnf 
400 bp 
300 bp 
200 bp 
0’ 30’ 70’ 120’ 0’ 30’ 70’ 120’ 
Cytoplasmic Nuclear 
Figure 4.4. Initial Tnf poly(A) tail size is variable. RAW 264.7 cells were 
stimulated with 1 µg/ml LPS for the indicated durations. Nuclear and cytoplasmic 
RNA was isolated from cells and RL2-PAT was done. PAT products were run on 
one agarose gel but different exposures were used for imaging cytoplasmic and 
nuclear lanes (images separated by a gap). PAT gel images were scanned using 
Quantity One software and profiles represented graphically. 
Deadenylated Tnf product size: 215 bp. 
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4.3 Discussion 
A working inflammatory model was established in the RAW 264.7 cells, as measured 
by levels of unspliced and mature mRNA of inflammatory genes. The poly(A) tails of 
Tnf and Cxcl2 were shown to change over the course of their inductions. For Tnf, the 
fact that the poly(A) tail becomes progressively shorter after the 30’ timepoint 
(Figure 4.3) even though unspliced levels of Tnf (i.e. pre-mRNA) remains elevated 
until at least 90’ (Figure 4.2) suggests that the initial tail size is changing. Indeed, PAT 
done for Tnf on nuclear RNA (representing newly transcribed mRNA) showed that 
Tnf mRNA made at 30’ had a greater proportion of long poly(A) tails than mRNA 
made at 70’ (Figure 4.4). I was unable to obtain data for Cxcl2 mRNA either for 
unspliced mRNA levels or nuclear PAT, and so there is insufficient data to make the 
same argument for Cxcl2. Additional replicates are needed for the nuclear PAT to 
confirm whether the initial Tnf poly(A) tail size is dynamic, and more mRNAs should 
be tested, particularly control mRNAs e.g. Rpl28 to verify that their initial poly(A) tail 
size remains constant while that of Tnf (and perhaps also those of other 
inflammatory mRNAs) are dynamic. 
However, the RAW 264.7 inflammatory system was successfully established and 
allowed reproducible inductions between replicates and measurement of poly(A) 
tails. While more data may be needed to validate the Tnf initial poly(A) tail size 
result, the idea that the initial poly(A) tail size varies is consistent with the qPCR data 
for mature and unspliced mRNA levels (which was shown across two biological 
replicates and validated against a control mRNA whose levels did not change). This 
represents a possibility of polyadenylation being involved in the regulation of such 
mRNAs. 
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5 Cordycepin and macrophages 
The caterpillar fungi Cordyceps or Ophiocordyceps are prized in Far Eastern 
traditional medicine and are used for the treatment of many ailments including 
kidney and heart conditions (Winkler 2010). The adenosine analogue cordycepin is 
derived from Cordyceps fungi and has been shown to have clear biological activities, 
including anti-inflammatory properties (H. Kim et al. 2011; Kondrashov et al. 2012; 
Ying et al. 2014; Jeong et al. 2010b). See section 1.3.3 for more detail. 
Our group previously observed anti-inflammatory effects of cordycepin in human 
airway smooth muscle (ASM) cells (Kondrashov et al. 2012). Having established the 
inflammatory system in RAW 264.7 cells, we sought to test cordycepin in these cells. 
Time courses were done as in the previous chapter with and without cordycepin and 
the effects of cordycepin on mRNA levels and polyadenylation were both assessed. 
Proper cleavage and polyadenylation is needed for efficient transcription 
termination. In ASM cells, cordycepin was found to cause defective cleavage and 
transcription termination, consistent with a role in interfering with polyadenylation. 
We sought to test whether such effects were also present in the RAW 264.7 cells. 
Experiments were also done to gain insight into cordycepin’s mechanism of action. 
In some studies, cordycepin has been reported to be active intracellularly 
(Kondrashov et al. 2012; Wong et al. 2010), while others report that effects of 
cordycepin on adenosine receptors are important. This was tested by assessing 
whether cordycepin’s effects were altered by inhibiting its import into the cell. 
Another experiment was done in which, prior to LPS stimulation, cells were either 
preincubated with cordycepin for a given time or preincubated for part of that time 
and then had the medium replaced with cordycepin-free medium. In the event that 
cordycepin’s effects are mediated extracellularly through adenosine receptors, any 
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effects of cordycepin should be lost or significantly reduced in cells for which the 
medium was replaced (whereas intracellular effects would persist). Cordycepin is 
metabolised by adenosine deaminase (ADA), resulting in its deamination to 3’-
deoxyinosine. The ADA inhibitor pentostatin was used to see whether inhibition of 
deamination of cordycepin would potentiate its effects (which would imply that 3’-
deoxyinosine is an inactive metabolite). LPS binding to Toll-like receptor 4 (TLR4) 
results in signalling that causes degradation of IκBα (NFKBIA). This then allows 
nuclear translocation of NF-κB, an important inflammatory transcription factor, and 
switching on of target genes (Lu, Yeh, and Ohashi 2008), as discussed in section 
1.3.2.1.3. It has been reported by several groups that cordycepin interferes with this 
process, while the data of other groups (including our own ASM data) suggests that 
this does not happen. To assess this, the degradation of IκBα was monitored in the 
presence and absence of cordycepin. 
5.1 Cordyceps fungal extracts 
Cordycepin is one of the metabolites present in Cordyceps fungi with a number of 
reported biological activities. We tested Cordyceps militaris and Ophiocordyceps 
sinensis ethanol extracts for anti-inflammatory potential, and also measured the 
concentration of cordycepin in the extracts. Both extracts were able to replicate the 
repressive effects of cordycepin on inflammatory gene expression in RAW 264.7 cells 
(Figure 5.1A) while control extracts from other fungi were not, with no reduction in 
Tnf or Il1b levels observed for treatments with P. ostreatus, A. bisporus, or F. 
velutipes extracts (Figure 5.1B). The level of cordycepin in the C. militaris extract was 
very similar to the stock concentration of cordycepin used for the cordycepin 
treatment, and both the cordycepin stock and C. militaris extract were used as 1000-
fold concentrates (so the same volume of each was used in the respective cell 
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treatments). Taken together, these findings strongly imply that cordycepin is the 
bioactive component of C. militaris. Strikingly, however, the level of cordycepin in 
the O. sinensis extract was 5 orders of magnitude lower (Table 5.1), despite 
exhibiting repressive effects on inflammatory gene expression. This clearly 
demonstrates that cordycepin is not the sole component that contributes to the 
anti-inflammatory potential of at least one of these fungi. 
Extract [Cordycepin] [3’-deoxyinosine] 
Coryceps militaris 22.72 ± 1.59 mM 12.37 ± 1.57 µM 
Ophiocordyceps sinensis 0.13 ± 0.01 µM 0.04 ± 0.003 µM 
 
  
Table 5.1. Cordyceps militaris extract contains significant quantities of 
cordycepin while Ophiocordyceps sinensis extract does not. 
Concentration of cordycepin and 3’-deoxyinosine was determined in 
the two fungal extracts by LC/MS. 
D
M
S
O
C
M
P
O
A
B
F
V
0 .0
0 .5
1 .0
1 .5
2 .0
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
/R
p
l2
8
T n f
Il1b
D
M
S
O
C
o
rd
y
C
M
 e
x
tr
a
c
t
O
S
 e
x
tr
a
c
t
0 .0
0 .5
1 .0
1 .5
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
/R
p
l2
8
T n f
Il1b
A 
Figure 5.1. Ethanol extracts from C. militaris and O. sinensis exhibited similar 
repressive effects to those of cordycepin. RAW 264.7 cells were treated with the 
indicated compound or extract for 1 hour prior to stimulation with LPS at 1 µg/ml 
for 1 hour. RT-qPCR was performed, error bars represent standard deviations 
across 3 technical replicates. Extracts used: Cordyceps militaris (CM), 
Ophiocordyceps sinensis (OS), Pleurotus ostreatus (PO), Agaricus bisporus (AB), 
and Flammulina velutipes (FV). 
B 
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5.2 Effects of purified cordycepin 
Our lab group previously observed anti-inflammatory effects of cordycepin in airway 
smooth muscle cells (Kondrashov et al. 2012). To assess whether these effects were 
also present in macrophages, we incubated RAW 264.7 cells with DMSO (control) or 
cordycepin prior to stimulating the cells with LPS to provoke an inflammatory 
response. Expression of inflammatory genes was then measured by RT-qPCR at a 
number of timepoints over a course of 2 hours. Inflammatory gene expression of 
assessed genes was found to be repressed by cordycepin (Figure 5.2), while 
housekeeping gene expression (Hprt and Gapdh) was unaffected. A third set of cells 
was also used in which cordycepin was added 10 minutes after LPS stimulation, in 
order to assess how fast or slow the effects of cordycepin were (Figure 5.3). The 
repressive effects of cordycepin for cells pretreated with cordycepin and cells 
treated with cordycepin after LPS addition were identical. Cordycepin’s observed 
effects are clearly very fast, and are thus likely to be primary in nature. 
The previous work on ASM cells indicated that cordycepin did not affect the 
unspliced mRNA levels of most inflammatory mRNAs assessed (Kondrashov et al. 
2012). In the RAW 264.7 cells, cordycepin was found to affect unspliced mRNA levels 
(Figure 5.4). Only two genes were assessed (Tnf and Acod1), but the result was 
observed over two replicates. 
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Figure 5.2. Cordycepin represses inflammatory gene expression. RAW 
264.7 cells were treated with DMSO or 20 µM cordycepin for an hour 
(DMSO and C-60 respectively) prior to 1 µg/ml LPS addition for the 
indicated durations. Data for DMSO series are the same as those shown 
in Figure 4.2. RT-qPCR was performed, error bars represent standard 
deviations across 3 technical replicates. Acod1 data was only obtained for 
one biological replicate. 
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Figure 5.2. (cont) Cordycepin represses inflammatory gene 
expression.  
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Figure 5.3. Administering cordycepin 10 
minutes after LPS causes the same 
repression as a 1 hour pretreatment.  
RAW 264.7 cells were treated with DMSO or 20 µM cordycepin for an hour 
(DMSO and C-60 respectively) prior to 1 µg/ml LPS addition for the 
indicated durations. Cells in the C+10 series had 20 µM cordycepin added 
10 minutes after addition of 1 µg/ml LPS. The 0’ timepoint for DMSO and 
C+10 was a single cell treatment, shared between both series. RT-qPCR was 
performed, error bars represent standard deviations across 3 technical 
replicates. 
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Figure 5.4. Cordycepin represses at the transcriptional level. See 
Figure 5.2 legend for experimental description. Error bars represent 
standard deviations across 3 technical replicates. Acod1 data are 
only available for 1 replicate. 
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Figure 5.5. Pentostatin potentiates cordycepin’s repressive effect on 
inflammatory gene expression. (A) RAW 264.7 cells were seeded in DMEM 
+ 10% FBS. After 24 hours, cells were treated with the indicated 
concentrations of cordycepin, with or without 1 nM pentostatin for 1 hour, 
at which point 1 µg/ml LPS was added to cells for a further 2 hours. RT-qPCR 
was performed, error bars represent standard deviations across 3 technical 
replicates. 
(B) As above, but 24 hours after seeding, medium was changed to DMEM + 
0.5% FBS. The experiment was then done 24 hours later. Error bars 
represent standard deviations across 3 biological replicates. 
Significant differences assessed by 2-way ANOVA followed by Sidak’s 
multiple comparisons test. *p<0.05, **p<0.01, ***p<0.001 
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The deamination of cordycepin by adenosine deaminase produces 3’-deoxyinosine 
as the breakdown product. To assess whether cordycepin (or a non-deaminated 
metabolite) was the active compound rather than 3’-deoxyinosine (or a metabolite 
of this compound), RAW 264.7 cells were incubated with cordycepin in the presence 
or absence of 1 nM pentostatin – an inhibitor of adenosine deaminase – prior to LPS 
stimulation. Pentostatin potentiated the repressive effects of cordycepin for all 
concentrations of cordycepin tested when cells were in DMEM + 10% FBS (Figure 
5.5A), suggesting that deamination of cordycepin reduces or may even abolish its 
anti-inflammatory capacity. However, when this was repeated with biological 
replicates in cells for which serum was withdrawn (i.e. cells for which the medium 
was changed to DMEM + 0.5% FBS 24 hours after seeding cells in DMEM + 10% FBS, 
and 24 hours prior to the experiment), significant differences were only observed for 
Il1b and not for Tnf (Figure 5.5B). It should also be noted that a significant decrease 
in Il1b levels was observed when treating with pentostatin in the absence of 
cordycepin, suggesting possible additive, independent effects.  
Stimulation of adenosine receptors with adenosine is known to cause anti-
inflammatory effects in macrophages (Haskó and Cronstein 2013), and it has been 
reported that some of cordycepin’s biological effects are also mediated through 
these receptors (Takahashi et al. 2012; Kadomatsu et al. 2012; Nakamura et al. 
2006). As an adenosine analogue, it is conceivable that cordycepin can act 
extracellularly as an adenosine receptor agonist. Our group has previously shown 
that inhibiting cordycepin import into the cell, by using an inhibitor of the adenosine 
transporter, abrogates its anti-inflammatory effects in airway smooth muscle cells 
(Kondrashov et al. 2012). Work in the Centre for Bioanalytical Science (Nottingham) 
showed that cordycepin itself is short-lived intracellularly, while it persists as 
cordycepin triphosphate in tissue culture cells and liver (Wahyu Utami and David 
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Barrett, unpublished data). Moreover, inhibition of the phosphorylation of 
cordycepin through inhibition of adenosine kinase also abrogates its anti-
inflammatory effects (Kondrashov et al. 2012). To address the question of whether 
cordycepin can act extracellularly, possibly through adenosine receptors, or whether 
it must be imported and phosphorylated, as is the case for airway smooth muscle 
cells, we performed similar experiments. RAW 264.7 cells were incubated with NBTI 
(adenosine transport inhibitor) or ITu (adenosine kinase inhibitor) or nothing 
(control) prior to addition of LPS together with DMSO, adenosine, or cordycepin. As 
had been the case with airway smooth muscle cells, it was found that NBTI or ITu 
treatment completely abolished cordycepin’s repressive effects on inflammatory 
gene expression in RAW 264.7 cells (Figure 5.6). These data indicate that cordycepin 
must be imported and phosphorylated to have its effects, and does not act 
extracellularly. 
The NBTI/ITu experiment also demonstrates distinct activities of cordycepin and 
adenosine. While adenosine was seen to repress Il1b mRNA levels, its repression of 
other mRNAs was much less than that of cordycepin, if there was even any 
repression at all. The repression of Il1b by adenosine was not relieved by NBTI or 
ITu, either. These data indicate that cordycepin and adenosine do not act in the 
same manner, and so cordycepin is unlikely to merely act as an adenosine analogue 
that mimics the effect of adenosine. 
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To further distinguish the effects of cordycepin from those of adenosine, 2 sets of 
RAW 264.7 cells were briefly exposed to DMSO, adenosine, or cordycepin before 
being washed with PBS and having medium replaced. 1 set then had DMSO, 
adenosine, or cordycepin added back to the original concentration (non-washed) 
while the other set did not (washed). 2 hours after this point, cells were stimulated 
with LPS. Cordycepin that is intracellular and stable should still be able to exert its 
effects on the cells, while any extracellular action, e.g. that of adenosine on 
adenosine receptors, should be lost. While effects of adenosine were lost, the 
repressive effects of cordycepin were retained, albeit to a lesser degree, in the cases 
of Acod1 and Tnf, but not for Cxcl2 (Figure 5.7). These data show that the effects of 
C
o
n
tr
o
l
N
B
T
I
IT
u
0 .0
0 .5
1 .0
1 .5
T n f
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
/R
p
l2
8
D M S O
A d o
C o rd y
C
o
n
tr
o
l
N
B
T
I
IT
u
0 .0
0 .5
1 .0
1 .5
2 .0
C x c l2
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
/R
p
l2
8
D M S O
A d o
C o rd y
C
o
n
tr
o
l
N
B
T
I
IT
u
0 .0
0 .5
1 .0
1 .5
I l1 b
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
/R
p
l2
8
D M S O
A d o
C o rd y
Figure 5.6. Inhibiting import of cordycepin or its phosphorylation abrogates 
its repression of inflammatory genes. RAW 264.7 cells were treated with 
nothing (control), 10 µM NBTI, or 100 nM ITu for 15 minutes, then stimulated 
with LPS at 1 µg/ml for 1 hour. RT-qPCR was performed, error bars represent 
standard deviations across 2 biological replicates. 
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cordycepin are more persistent than those of adenosine, making effects through 
adenosine receptors even less likely. This experiment, alone, cannot rule out a 
distinct extracellular mode of action, since it could be the case that extracellular 
effects had already triggered long-acting signalling pathways within the cell by the 
time the washing was done. However, when taken together with the results of the 
inhibition of cordycepin import and phosphorylation experiment (Figure 5.6), an 
intracellular mechanism of action becomes likely. It is possible that washed cells had 
lower levels of intracellular cordycepin than non-washed cells, which may account 
for the loss of repression of Cxcl2, rather than because extracellular effects were 
lost. Adenosine did not display particularly strong repression of inflammatory gene 
expression, but for Tnf and Cxcl2, the modest repression observed in non-washed 
cells was lost in the washed counterparts. It should be noted that Acod1 shows 
higher expression levels for DMSO treatment in washed cells than in non-washed 
cells. This highlights potential limitations of this experiment as a means for assessing 
changes in repressive capacity. 
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It is known that cordycepin is a polyadenylation inhibitor, and so effects on 
polyadenylation must be considered when assessing its mechanism. For this reason, 
I did PAT for Tnf – an inflammatory gene whose poly(A) tail size changes over the 
inflammatory response, and whose expression is repressed by cordycepin – on 
samples from the LPS time course in the presence and absence of cordycepin. It was 
found that the poly(A) tail is, indeed, shortened by cordycepin (Figure 5.8). While 
this does not indicate causality, it is clear that the effects of cordycepin on 
polyadenylation are present. 
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Figure 5.7. Cordycepin effects can be 
persistent. RAW 264.7 cells were 
treated with DMSO, 50 µM adenosine 
(ado), or 50 µM cordycepin (cordy), 
with 2 sets of cells per group, for 30 
minutes. All cells then had medium removed and were washed with PBS. 1 set 
of cells had fresh DMEM + 0.5% FBS added (termed ‘washed’), while the other 
set of cells also had the respective compound (DMSO, ado, or cordy) added at 
the original concentration (these cells were termed ‘non-washed’). A further 2 
hours later, cells were stimulated with LPS at 1 µg/ml for 1 hour. RT-qPCR was 
performed, error bars represent standard deviations across 2 biological 
replicates. 
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Figure 5.8. Cordycepin shortens the Tnf poly(A) tail. RAW 264.7 cells 
were treated either with DMSO or 20 µM cordycepin (C-60) for 1 hour 
prior to addition of 1 µg/ml LPS for the indicated durations. RNA was 
isolated and RL2 PAT performed to assess polyadenylation. Agarose 
gels were scanned in Quantity One and data presented graphically. 
N.B. Tnf (DMSO) gel image has been altered to reorder lanes – see Fig 
4.3D for original image. * indicates artefactual bands. 
Deadenylated Tnf product size: 215 bp. 
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Figure 5.9. Cordycepin causes defects in transcription termination and mRNA 
3’ cleavage. (A) RAW 264.7 cells were treated with DMSO or 20 µM cordycepin 
for an hour prior to 1 µg/ml LPS addition for the indicated durations (DMSO and 
C-60 respectively), or 20 µM cordycepin 10 minutes after 1 µg/ml LPS addition 
for the indicated durations (C+10). The 0’ timepoint for DMSO is used as the 
calibrator for both DMSO and C+10 series (the C+10 series does not have its own 
0’ timepoint). RNA was isolated and RT-qPCR performed. Error bars represent 
standard deviations across 3 biological replicates. 
Significant differences assessed by 2-way ANOVA followed by Dunnet’s multiple 
comparisons test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
(B) RT-qPCR primer locations for uncleaved and unterminated mRNA. 
AAAAAAA…AAA 5’ 3’ 
Correctly cleaved and 
terminated mRNA 
Cleavage site 
Poly(A) signal 
Uncleaved mRNA 
5’ 3’ 
Unterminated mRNA 
Primers for uncleaved mRNA Primers for unterminated mRNA 
5’ 3’ 
B 
A 
0
1
5
3
0
9
0
0
1
2
3
4
R p l2 8  u n c le a v e d /u n s p lic e d
R
e
la
ti
v
e
 c
le
a
v
a
g
e
 f
a
il
u
r
e
/A
U
D M S O
C -6 0
C + 1 0
* *
0
1
5
3
0
9
0
0
1
2
3
R p l2 8  re a d th ro u g h /u n s p lic e d
R
e
la
ti
v
e
 r
e
a
d
th
r
o
u
g
h
/A
U
D M S O
C -6 0
C + 1 0
0
1
5
3
0
9
0
0
5
1 0
2 0
3 0
4 0
T n f u n c le a v e d /u n s p lic e d
T im e  a fte r  L P S  a d d it io n /m in s
R
e
la
ti
v
e
 c
le
a
v
a
g
e
 f
a
il
u
r
e
/A
U
D M S O
C -6 0
C + 1 0
**
0
1
5
3
0
9
0
0
2
4
6
8
1 0
T n f re a d th ro u g h /u n s p lic e d
T im e  a fte r  L P S  a d d it io n /m in s
R
e
la
ti
v
e
 r
e
a
d
th
r
o
u
g
h
/A
U
D M S O
C -6 0
C + 1 0
**
****
***
 131 
Proper mRNA 3’ cleavage and polyadenylation is thought to be essential for efficient 
transcription termination (Luo, Johnson, and Bentley 2006; West, Proudfoot, and 
Dye 2008; Richard and Manley 2009). If cordycepin’s effects on polyadenylation 
include interfering with mRNA 3’ cleavage, it would be expected to lead to defective 
transcription termination. In order to measure this, we performed RT-qPCR using 
primers that amplified a region spanning the cleavage site, and primers that 
amplified a region 500-750 nt downstream of the cleavage site (Figure 5.9). These 
levels were then represented relative to the unspliced levels of the mRNA to gauge 
cleavage and termination efficiencies. Cordycepin caused an increase in the relative 
proportions of uncleaved transcripts for Rpl28 and an increase in both uncleaved 
and unterminated transcripts for Tnf (Figure 5.9). These data support a model for an 
intracellular mode of action of cordycepin, involving impairment of and interference 
with mRNA 3’ processing. The timepoints that were chosen (0’, 15’, 30’, 90’) allowed 
for assessment of both newly or recently made mRNA and also mRNA in the later 
stages of the induction. 
Assessment of cleavage and termination efficiencies also showed differences in 
cordycepin and adenosine treatments (Figure 5.10). Adenosine treatment, whether 
in washed or non-washed cells, did not change measured cleavage and termination 
efficiency. Cordycepin treatment, however, caused a significant decrease in cleavage 
and termination efficiencies – an effect that was still clearly observed in washed 
cells. In the time course, cordycepin affected both cleavage and termination for Tnf 
but only cleavage for Rpl28 (Figure 5.9). Data from the washing experiment, 
however, showed changes in both cleavage and termination efficiencies for both Tnf 
and Rpl28 in cordycepin-treated cells. Rpl28 expression levels are insensitive to 
cordycepin, but these data show that cordycepin, while having specific effects on 
final mRNA levels, may have more generalised effects on 3’ processing and 
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transcription termination, as was previously observed in airway smooth muscle cells 
(Kondrashov et al. 2012). 
 
Figure 5.10. The effects of cordycepin on mRNA 3’ processing are not 
shared by adenosine and are unlikely to be mediated extracellularly. RAW 
264.7 cells were treated with DMSO, 50 µM adenosine (ado), or 50 µM 
cordycepin (cordy), with 2 sets of cells per group, for 30 minutes. All cells 
then had medium removed and were washed with PBS. 1 set of cells had 
fresh DMEM + 0.5% FBS added (termed ‘washed’), while the other set of 
cells also had the respective compound (DMSO, ado, or cordy) added at the 
original concentration (these cells were termed ‘non-washed’). A further 2 
hours later, cells were stimulated with LPS at 1 µg/ml for 1 hour. RT-qPCR 
was performed, error bars represent standard deviations across 2 biological 
replicates. 
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To test whether cordycepin affected NF-κB signalling, an LPS time course was done 
in RAW 264.7 cells over a 30 minute period. Cells were treated with either DMSO or 
cordycepin for 1 hour prior to addition of LPS. Western blotting was then done on 
cell lysates for total IκBα. The DMSO series shows a band for IκBα in unstimulated 
cells and for a 5 minute LPS treatment (Figure 5.11). This band is almost completely 
lost, indicating degradation, in the 15 minute timepoint, and then reappeared in the 
30 minute sample. The degradation of IκBα was not at all prevented by cordycepin 
pretreatment. Further replicates are needed for verification, but these data suggest 
that cordycepin does not interfere with IκBα degradation. 
  
IκBα 
Symplekin 
DMSO 
30’ 15’ 5’ 0’ 
Cordy 
30’ 15’ 5’ 0’ 
1.00 1.35 0.14 0.69 1.00 1.01 0.07 0.15 
Figure 5.11. IκBα degradation is not prevented by cordycepin. RAW 
264.7 cells were treated with DMSO or cordycepin for an hour prior to 
LPS addition at 1 µg/ml for the indicated durations. Cells were then 
lysed and Western Blot performed. Relative IκBα levels for timepoints 
in each series (DMSO and cordy) are shown with the respective 0’ 
timepoint set to 1. Symplekin was used as a loading control. 
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5.3 Discussion 
Data in this chapter demonstrated the anti-inflammatory effects of cordycepin in 
RAW 264.7 cells. In general, more replicates are needed in order to be able to 
perform statistical analysis and confirm the conclusions that have (tentatively) been 
made here. 
Cordycepin is likely to be the main bioactive component (as far as anti-inflammatory 
effects are concerned) of C. militaris ethanol extract. O. sinensis extract, however, 
contained 5 orders of magnitude less cordycepin than the concentration of 
cordycepin in the C. militaris extract or purified cordycepin stock in DMSO. This 
suggests that other metabolites are more important in O. sinensis for mediating its 
anti-inflammatory effects. Data in Table 5.1 and Figure 5.1 are only for one 
biological replicate, however. To confirm these findings and further investigate, 
more replicates would be needed, and perhaps fungal samples from multiple 
sources. Additionally, a treatment of pure cordycepin should be used that matches 
the low cordycepin concentration in the O. sinensis extract to show that the low 
level of cordycepin in O. sinensis alone cannot account for its anti-inflammatory 
properties. 
Cordycepin decreased the expression of the assessed inflammatory genes and had 
identical effects when administered to cells ten minutes after addition of LPS rather 
than 1 hour beforehand (Figures 5.2 and 5.3). The fact that unspliced mRNA levels 
were decreased (Figure 5.4) suggests a transcriptional level of control by cordycepin. 
Since NF-κB is a key inflammatory transcription factor whose activation is 
downstream of LPS/TLR4 signalling in macrophages (see sections 1.3.2.1.1 and 
1.3.2.1.2), we assessed whether cordycepin interfered with the NF-κB pathway, as 
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others have reported (H. G. Kim et al. 2006; Y. Li et al. 2016; Jie Peng et al. 2015; 
Ying et al. 2014). This was done by detecting IκBα degradation following LPS 
stimulation in the presence and absence of cordycepin. Cordycepin did not impede 
the degradation of IκBα (Figure 5.11). Further replicates are needed to confirm this 
finding, however. 
Experiments with adenosine highlighted distinct activities of adenosine and 
cordycepin, showing that cordycepin is unlikely to simply act by mimicking the effect 
of adenosine. Cordycepin is likely to act intracellularly and require phosphorylation, 
since inhibition of the adenosine transporter and adenosine kinase abrogated its 
effects (Figure 5.6). The results of the washing experiment were entirely clear and 
seemed to sometimes contradict the results of the NBTI/ITu experiment. However, if 
cordycepin does act intracellularly, it is possible that non-washed cells accumulated 
more cordycepin within them than the washed cells. To monitor this variable, the 
experiment could be repeated with parallel sets of cells. At the end of the 
experiment, one set could be used for RT-qPCR (as we did), and the other set could 
be subjected to liquid chromatography-mass spectrometry analysis to determine 
cordycepin concentrations in washed and non-washed cells. Effects on 
polyadenylation by cordycepin were clearly observed (Figure 5.8), and were 
consistent with the observation that cordycepin caused defective mRNA cleavage 
and transcription termination (Figures 5.9 and 5.10). As such, valuable information 
was obtained for understanding molecular effects of cordycepin.  
 136 
6 High-throughput analysis of cordycepin-treated RAW 
264.7 cells 
Having observed by RT-qPCR that cordycepin treatment in RAW 264.7 cells led to 
downregulation of a number of inflammatory mRNAs (see previous chapter), we 
elected to perform high-throughput analysis to reveal genome-wide changes 
brought about by cordycepin. To assess changes in gene expression, a microarray 
analysis was performed followed by cluster analysis on the lists of RNAs whose levels 
were changed by cordycepin. In order to see whether cordycepin sensitivity 
correlated with mRNA stability or transcription rates, RNA-seq was performed on 
newly transcribed RNA (generated by pulse labelling) from RAW 264.7 cells. 
6.1 LPS and cordycepin treatments 
With polyadenylation implicated in inflammatory gene expression, and cordycepin, 
as a polyadenylation inhibitor, shown to inhibit expression of a number of 
inflammatory genes, we sought to assess the effect of cordycepin in a genome-wide 
manner through microarray analysis. RAW 264.7 cells were either pre-treated with 
DMSO or 20 µM cordycepin for an hour prior to either no further treatment or 
addition of 1 µg/ml LPS for one hour. At the end of the two hour period (1 hour 
DMSO/cordycepin plus 1 hour LPS/no LPS) RNA was isolated from cells and analysed 
by microarray. Cell conditions were named ‘D0’, ‘D60’, ‘C0’, and ‘C60’ – D means 
DMSO pre-treated, C means cordycepin pre-treated, 0 means NOT stimulated with 
LPS, 60 means LPS-stimulated. We compared expression in D60 vs D0 (i.e. LPS-
stimulated vs unstimulated, both without cordycepin) to show expression changes 
caused by LPS stimulation, and then compared C60 vs D60 (i.e. LPS-stimulated with 
cordycepin to LPS-stimulated without cordycepin) to show how those expression 
changes are affected. These two comparisons were then plotted against each other, 
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with genes whose expression levels were at least 2-fold changed in both 
comparisons considered, while other genes were disregarded (Figure 6.1). A Chi-
squared test showed that LPS and cordycepin treatments are not independent 
(p<2.2×10-16). Specifically, it appears that proportionately more RNAs that 
upregulated by LPS treatment are downregulated by cordycepin (94) than 
upregulated (30). Similarly, proportionately more RNAs that are downregulated by 
LPS treatment are upregulated by cordycepin (49) than downregulated (1). 
Additionally, performing gene ontology analysis on the list of genes most strongly 
downregulated in the LPS with cordycepin treatment compared to LPS alone 
revealed that immune and inflammatory gene clusters are the most significantly 
enriched (Table 6.1). 
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Gene Ontology Term Count 
Bonferroni-
corrected 
P-value 
Gene names 
Fold 
Enrichment 
mmu04060:Cytokine-
cytokine receptor 
interaction 
17 5.41E-08 
CSF3, IL6, TNF, CCL2, PDGFB, 
TNFRSF12A, CSF1, CCL5, IL7R, CCL4, 
CCL7, CXCL10, OSM, LOC100045000, 
IL12RB1, LOC100044675, IFNB1, 
IL10RA, IL1B 
7.0 
cytokine 13 7.07E-06 
CSF3, IL6, TNF, CCL2, CSF1, CCL5, 
CCL4, CCL7, CXCL10, OSM, 
LOC100045000, IFNB1, IL1B, 
CMTM5 
8.4 
GO:0005125~cytokine 
activity 
13 2.16E-05 
CSF3, IL6, TNF, CCL2, CSF1, CCL5, 
CCL4, CCL7, CXCL10, OSM, 
LOC100045000, IFNB1, IL1B, 
CMTM5 
7.8 
GO:0006955~immune 
response 
22 4.56E-04 
CSF3, IFIH1, IL6, CCL2, TNF, RSAD2, 
NLRP3, CCL5, IL7R, CCL4, CCL7, 
FOXP1, POLR3D, CXCL10, OSM, 
LOC100045000, ZGPAT, CLEC4E, 
SQSTM1, TICAM1, OASL1, IL1B, 
LIME1, CD300LB 
3.7 
GO:0006954~inflammatory 
response 
14 8.83E-04 
NFKBIZ, IL6, TNF, CCL2, CCL5, 
NLRP3, CCL4, CCL7, CXCL10, 
LOC100045000, CD44, TICAM1, 
IL1B, NOS2, PTAFR 
5.8 
Table 6.1. Immune and inflammatory GO terms are the most significantly 
enriched in genes downregulated by cordycepin.  
RAW 264.7 cells were treated with 1 µg/ml LPS for 1 hour after a 1 hour 
pretreatment with DMSO or cordycepin (D60 and C60 respectively). Gene 
expression levels from microarray data were then compared between the two 
treatments. Those genes whose levels were >2-fold decreased in C60 
compared to D60 were compiled into a list which was uploaded to DAVID for 
functional annotation. The 5 most significantly enriched GO terms are shown 
in the table. 
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Figure 6.1. 94 RNAs with a >2-fold increase after LPS treatment are >2-
fold downregulated by cordycepin. RAW 264.7 cells treated with DMSO 
for 2 hours (D0), or treated with 1 µg/ml LPS for 1 hour after a 1 hour 
pretreatment with DMSO or cordycepin (D60 and C60 respectively).  
Gene expression levels from microarray analysis were compared 
between D60 and D0 (showing the effect of LPS) and between C60 and 
D60 (showing the effect of cordycepin in LPS-treated cells), and log2(fold 
change) values calculated. These values were then plotted against each 
other for all expressed genes. Grey dots indicate RNAs that did not show 
a significant >2-fold change in one or both comparisons. Red dots are 
RNAs that are >2-fold changed in both comparisons, with numbers 
indicating the number of such RNAs in each quadrant. 
A Chi squared test showed that the two treatments are not independent 
(p<2.2×10-16). 
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6.2 Cordycepin sensitivity and mRNA kinetics 
Cordycepin inhibits both polyadenylation and transcription of inflammatory genes 
(Figures 5.4 and 5.8). In response to the inflammatory stimulus (LPS), inflammatory 
genes experience a large increase in transcription, and transcripts may be made with 
longer poly(A) tails for transient stabilisation of mRNAs that are otherwise unstable, 
as many inflammatory mRNAs are (P. Anderson 2010; Sanduja et al. 2012). If 
cordycepin’s inhibitory effects on polyadenylation and transcription, possibly 
through defective termination and mRNA 3’ processing, are responsible for its 
inhibition of inflammatory genes, then it may be the case that genes that have a 
high transcription rate and produce unstable mRNAs are sensitive to cordycepin. 
Information on which genes are cordycepin-sensitive is contained in the microarray 
data. RNA-seq data using 4-thiouridine-labelled RNA – i.e. RNA that was freshly 
transcribed within a short labelling period – from unstimulated RAW 264.7 cells 
(assumed to be at steady-state) was used to make inferences about mRNA 
transcription rates and stability. Consolidating the microarray and RNA-seq data 
allowed us to look for correlations between cordycepin-sensitivity and transcription 
rate or mRNA stability. No such correlation was observed, however (Figure 6.2).  
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6.3 Cordycepin and long noncoding RNAs 
Long noncoding RNAs (lncRNAs) are RNAs longer than 200 nt that do not code for 
protein, but can have regulatory roles and implications for health and disease 
(Wapinski and Chang 2011; Kung, Colognori, and Lee 2013). It has been reported 
that there exists a class of lncRNAs whose turnover is promoted by PABPN1 in a 
polyadenylation-dependent manner(Beaulieu et al. 2012). If cordycepin inhibits 
polyadenylation, it would be expected to stabilise these lncRNAs, which should 
therefore be enriched in the set of RNAs upregulated by cordycepin. To test this 
hypothesis, I looked at the changes in RNA levels from the microarray data between 
Figure 6.2. Cordycepin sensitivity is independent of mRNA stability and 
transcription rate. RAW 264.7 cells treated with 20 µM cordycepin (C0) or DMSO 
(D0) for 2 hours. Gene expression levels were compared between the two 
treatments and log2(fold change) values calculated. In a separate experiment, 
untreated RAW 264.7 cells (in DMEM + 0.5% FBS) were exposed to a 15 minute 4-
thiouridine labelling. RNA-seq was then performed and log2(fold change) values 
from the microarray plotted against the 4SU-labelled FPKM (transcription rate) 
and 4SU-labelled FPKM/total FPKM values from the RNA-seq data.Linear 
regressions (red lines) were fitted to all plots, and r
2
 values calculated. No 
significant correlation was observed. 
-4 -2 2 4
-0 .1
0 .1
0 .2
0 .3
C 0  v  D 0  s ta b ility
log 2 (F C )
L
a
b
e
ll
e
d
 F
P
K
M
/t
o
t
a
l 
F
P
K
M
r
2
= 0 .0 2 2 8 9
-4 -2 0 2 4
5 0
1 0 0
1 5 0
2 0 0
2 5 0
C 0  v  D 0  t ra n s c r ip t io n
log 2 (F C )
L
a
b
e
ll
e
d
 F
P
K
M
r
2
= 5 .7 7 5 e -5
 142 
the cordycepin-treated and non-cordycepin-treated cells (both in the absence of 
LPS). The RNAs were categorised into 3 classes: significantly upregulated by 
cordycepin, significantly downregulated by cordycepin, and unchanged. Significantly 
upregulated and downregulated RNAs were those that were at least 2-fold changed 
in the appropriate direction, and had an adjusted p-value < 0.01. All other RNAs 
were placed in the ‘unchanged’ category. The vast majority of RNAs were in the 
unchanged category (>20,000), while the upregulated and downregulated categories 
had 547 and 146 RNAs, respectively. In order to perform the comparison between 
categories with similar numbers of RNAs, a random selection of 500 RNAs were 
taken from the unchanged category. The numbers of lncRNAs in each category was 
determined and a Chi-squared test done to see whether the proportion of lncRNAs 
in a category is independent of cordycepin treatment. The test revealed that lncRNA 
proportion and cordycepin treatment are not independent, with a much higher 
proportion of lncRNAs observed in the upregulated category (Figure 6.3). These data 
support the hypothesis that cordycepin stabilises a class of lncRNAs whose 
degradation is enhanced by polyadenylation. It may be that some or all of these 
RNAs are involved in mediating cordycepin’s effects (i.e. they may regulate 
inflammation). 
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Figure 6.3. lncRNAs are enriched in RNAs that are upregulated by cordycepin 
treatment. RNA expression fold changes were calculated from microarray data 
between RAW 264.7 cells treated for 2 hours with 20 µM cordycepin (C0) or 
DMSO (D0). RNAs that were >2-fold increased or decreased in expression, with 
an adjusted p value < 0.01, were placed in the up and down categories 
respectively. From the remaining RNAs, a random selection of 500 RNAs with a 
log
2
(fold change) between -0.1 and 0.1 formed the unchanged category. 
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6.4 Discussion 
Data in this chapter showed that cordycepin did indeed cause widespread 
repression of inflammatory mRNAs, as seen in the cluster analysis of the microarray 
data (Table 6.1). In section 1.2.3.1, some possible models by which cordycepin 
might act were proposed. One was that inherently unstable mRNAs may depend on 
a poly(A) tail more for the limited stability they do have, and that inhibition of 
polyadenylation would have a particularly strong destabilising effect on such 
mRNAs. The lack of a correlation between stability and cordycepin sensitivity, 
however (Figure 6.2), does not support this model. Another suggested possibility 
was that cordycepin may arrest the cleavage complex, as observed in vitro 
(Zarkower and Wickens 1987), thereby sequestering 3’ processing factors. Genes for 
which transcription is taking place at a high rate (such as genes activated in the 
inflammatory response) would have high requirements for processing factors. A 
shortage of processing factors would affect transcription of such genes more than 
genes that are transcribed at a low rate (such that the availability of processing 
factors is not rate-limiting). However, the lack of a correlation between transcription 
rate and cordycepin (Figure 6.2) suggests this model does not apply. In the second 
model mentioned above, if a high need for processing factors arises through 
‘weaker’ cis elements defining the poly(A) site rather than simply due to high rates 
of transcription, then cordycepin-sensitive genes may be enriched in such cis 
elements. This could be investigated through further bioinformatic analysis of the 
data sets. 
Interestingly, lncRNAs are significantly enriched in RNAs upregulated by cordycepin 
treatment. There is a class of lncRNAs whose degradation is dependent on 
polyadenylation and whose levels are increased by PABPN1 knockdown (Beaulieu et 
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al. 2012). If cordycepin inhibits the polyadenylation of such lncRNAs, this would be 
expected to have a stabilising effect, which could account for the enrichment of 
lncRNAs in cordycepin-treated cells. If one or more of these lncRNAs affects the 
process of inflammation, cordycepin-mediated stabilisation of this/these lncRNA(s) 
could constitute part of the mechanism by which its anti-inflammatory effects are 
mediated. It would be interesting to assess whether the lncRNAs that are stabilised 
by cordycepin are the same as those whose levels are increased by PABPN1 
knockdown, ostensibly through reduced polyadenylation-dependent degradation. 
This assessment was not carried out in this thesis as the work done by Beaulieu et al 
was performed in human cells while my data were generated from experiments in 
murine cells. 
While data in this chapter did not support any of the proposed hypotheses to 
explain cordycepin’s effects, a clear genome-wide anti-inflammatory effect of 
cordycepin was shown to exist in RAW 264.7 cells. 
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7 Cordycepin in a rat model of osteoarthritis 
Osteoarthritis (OA) is a degenerative joint disease. While classically viewed as a non-
inflammatory form of arthritis, evidence shows that inflammation can play a role in 
disease progression. Key features of the disease include remodelling of subchondral 
bone (bone under the cartilage) and degradation and loss of articular cartilage. As 
the previous two chapters show, cordycepin has widespread anti-inflammatory 
effects in RAW 264.7 cells. Furthermore, it has been reported that cordycepin shifts 
the balance of bone formation and degradation (F. Wang et al. 2015; Dou et al. 
2016), and that it also reduced overactive cytokine production in chondrocytes from 
OA patients (Ying et al. 2014). For these reasons, cordycepin treatment was used in 
a rat model of osteoarthritis in order to see if it had any effect on pain behaviour in 
affected animals (this work was done by James Burston in Victoria Chapman’s 
research group at the University of Nottingham). In order to see whether cordycepin 
affected mRNA levels of inflammatory genes or had effects on polyadenylation, RNA 
was isolated from the synovia of rats in the OA model and analysed by RT-qPCR and 
3’ end labelling. 
7.1 Pain behaviour – work done by James Burston 
Using the monosodium iodoacetate (MIA) chemically induced model of 
osteoarthritis in rats, cordycepin (administered orally) was assessed for its capacity 
to alter the pain behaviour of the animals. Animals had a saline (control) or MIA 
injection into the knee of a hind limb (day 0), and were then fed with DMSO (vehicle) 
or cordycepin every other day over the course of 14 days, during which time pain 
behaviour was assessed. Pain associated with the site of damage was measured 
through weight bearing asymmetry – animals were placed in a chamber that forced 
them to stand on their hind limbs, and the difference in weight borne by the leg with 
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the injury (ipsilateral) and the other leg (contralateral) was measured. Allodynia 
(pain caused by stimuli that do not normally cause pain) was measured by paw 
withdrawal threshold (PWT) – animals were placed in a cage in which the bottoms of 
their paws could have force applied by Von Frey filaments. The force applied was 
increased until the PWT was reached i.e. the force that caused the animal to 
withdraw its paw. The saline + vehicle group showed equal weight bearing over the 
course of the 14 days, while the MIA + vehicle group placed much more weight on 
their uninjured (contralateral) side (Figure 7.1). The MIA + cordycepin group also 
placed more weight on the contralateral limb than the saline + vehicle group, but 
placed significantly more weight on their ipsilateral side than the MIA + vehicle 
group in 3 of the 4 timepoints after day 0. The PWT of the saline + vehicle group 
remained constant over the 14 day period, while that of the MIA + vehicle group had 
dropped markedly by day 3, with no recovery observed over the remaining period. 
The MIA + cordycepin group experienced the same drop in PWT, with no differences 
between these groups at day 3 or day 7. At days 10 and 14, however, the PWT of the 
MIA + cordycepin group was significantly higher than that of the MIA + vehicle 
group. Together, these data show that cordycepin reduces pain behaviour in the 
MIA rat model of osteoarthritis. 
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Figure 7.1. Cordycepin alters pain behaviour in a rat osteoarthritic 
model. MIA or saline was injected into the knee of one hind limb of rats 
on day 0. MIA rats were then fed 20 mg/kg cordycepin or DMSO (vehicle) 
every other day. Saline rats were fed DMSO every other day. Pain 
behaviour was then assessed through weight bearing asymmetry and paw 
withdrawal threshold upon application of pressure to the paw using Von 
Frey filaments. 
p<0.05, ** p<0.01, *** p<0.001 between MIA groups and saline control. 
# p<0.05, ## p<0.01, ### p<0.001 Between MIA + vehicle group and MIA 
+ cordycepin group. 
N = 6-8 animals per group. 
Data courtesy of James Burston and Victoria Chapman (University of 
Nottingham, School of Life Sciences) 
Saline + vehicle MIA + vehicle MIA + cordycepin 
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7.2 Analysing rat RNA 
At the end of the 14 day period over which the pain behaviour experiments were 
done, the rats were killed and tissues chilled. Since cordycepin affects RNA levels in 
cell culture, we sought to assess expression of inflammatory genes between the 
different treatment groups. In order to do this, we had to first isolate the RNA from 
the tissues. Using a column based kit was unsuccessful and resulted in the synovia 
being wasted. We therefore decided to use spare synovia from animals in other 
experiments (which would otherwise have been discarded) as our tissues on which 
to test different RNA isolation methods. Using TRIzol yielded enough RNA to work 
with, but, when run on a gel, it was found to be degraded. This may have occurred 
due to contaminating RNases in the workflow or degradation experienced in the lag 
time between killing the animal and chilling the tissue (in this case, the time was 19 
minutes). Another possible explanation was that the decay occurred during the lysis 
procedure, with the denaturing reagents either being insufficient in quantity or not 
penetrating the tissue quickly enough. In the case of contaminating RNases being 
present, incubating the RNA at 37°C should further degrade the RNA. This was 
carried out, but no further degradation was observed (Figure 7.2). Upon repeating 
the entire RNA isolation process with a synovium that was chilled much sooner after 
killing the animal (2 minutes), the RNA was found to be intact, and incubation at 
37°C did not lead to any degradation. The degradation that was originally observed 
was therefore probably due to the tissue not being chilled soon enough after the 
animal was killed. The amount of lysis reagent (TRizol) was not changed, so this was 
unlikely to have been the cause of the problem before. RNA was then successfully 
isolated using TRIzol from the remaining ipsilateral synovia, and RT-qPCR was carried 
out to measure inflammatory gene expression in the synovia. No significant 
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differences were observed in the expression levels of the assessed genes between 
the three treatment groups (Figure 7.3). 
  
Positive 
control 
Synovial RNA 
TRIzol (2’) 
0’ 0’ 30’ 30’ 
Figure 7.2. After killing the rat, the synovium must be quickly removed 
and chilled to avoid RNA degradation. RNA was isolated from the synovia 
of rats using TRIzol. 19’ and 2’ refer to the time elapsed between killing 
the rat from which the synovium was taken and removing and chilling the 
synovium. Positive control is RNA isolated from RAW 264.7 cells known to 
be intact. RNA samples were then either incubated for 30’ at 37°C or not 
to check for presence of RNases in the workflow. All RNA samples were 
then run on an agarose gel to assess integrity. 
Positive 
control 
Synovial RNA 
TRIzol (19’) 
0’ 0’ 30’ 30’ 
28S rRNA 
18S rRNA 
Degraded 
RNA 
Duration 
at 37°C 
Duration 
at 37°C 
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Since cordycepin is a polyadenylation inhibitor, and has been shown to shorten 
global poly(A) tails in a number of cell types(Kondrashov et al. 2012), we decided to 
determine whether cordycepin was having any such effect on the level of the entire 
tissue. Briefly, 5'-[32P] pCp was ligated to the 3’ end of RNA samples, a cocktail of 
RNases was added to digest all non-poly(A) RNA, and resulting RNA was run on a 
urea-TBE PAGE gel. A phosphor screen was then exposed to the gel and imaged on a 
phosphorimager. Doing so revealed no differences in global poly(A) tail lengths 
between the treatment groups (Figure 7.4). While cordycepin inhibits inflammatory 
gene expression in RAW 264.7 cells and inhibits global polyadenylation in a number 
of cell types, it appears that its effects on pain behaviour in the rat osteoarthritis 
model are not dependent on these phenomena occurring within the synovium, 
unless such effects already took place at an earlier, unobserved time. 
Figure 7.3. No significant differences observed in assessed 
inflammatory gene mRNA levels in rat ipsilateral synovia between 
treatment groups. MIA or saline was injected into the knee of one hind 
limb of rats on day 0. MIA rats were then fed 20 mg/kg cordycepin or 
DMSO (vehicle) every other day. Saline rats were fed DMSO every other 
day. RNA was extracted from rat ipsilateral synovia using TRIzol. RT-qPCR 
was performed, error bars represent standard deviations across 2 
animals per group. 
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7.3 Discussion 
Data in this chapter show that OA pain behaviour in a rat model of the disease is 
significantly altered by orally administered cordycepin. When isolating RNA from 
animal tissues (or at least from the synovium), the tissue must be chilled very soon 
after killing the animal in order to prevent degradation of RNA. Analysis of RNA from 
rats in the OA study did not reveal any significant differences in mRNA levels of 
cytokines assessed, nor did it show any differences in total poly(A) tail sizes between 
rats in different treatment groups. However, the finding that pain behaviour in the 
OA rat model is altered by cordycepin is a very promising start to the investigation of 
cordycepin as a lead compound for new OA therapeutics. 
  
Figure 7.4. No global poly(A) tail length differences were 
observed between rat groups in ipsilateral synovial RNA 
samples. MIA or saline was injected into the knee of one hind 
limb of rats on day 0. MIA rats were then fed 20 mg/kg 
cordycepin or DMSO (vehicle) every other day. Saline rats were 
fed DMSO every other day. RNA was extracted from rat 
ipsilateral synovia using TRIzol. [5'-32P]Cytidine 3',5'-
bis(phosphate) was ligated to the 3’ end of RNA samples, a 
cocktail of RNases was added to digest all non-poly(A) RNA, and 
resulting RNA was run on a urea-TBE PAGE gel. The gel was 
incubated at -80°C with a phosphor screen for > 5 days and 
then imaged on a GE Storm 825 phosphorimager. 
Saline+V MIA +C MIA +V 
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8 Discussion and conclusions 
During the course of this project, a working inflammatory model was established in 
the RAW 264.7 murine macrophage cell line. In this system, the poly(A) tail was 
found to be dynamic, with the initial poly(A) tail size of Tnf becoming longer 
following lipopolysaccharide (LPS) stimulation. Anti-inflammatory effects of 
cordycepin were observed in the system on a genome-wide scale, and mechanistic 
insight was gained into how cordycepin’s effects are mediated. Pain-alleviating 
properties of cordycepin in a rat model of osteoarthritis (OA) warrant further 
investigation into its use as a therapeutic. 
8.1 Advances in poly(A) tail measurements 
Chapter 3 was concerned with method development and troubleshooting. 
Previously, the method used for the poly(A) tail test (PAT) involved a high input RNA 
quantity, an unreliable deadenylation step, and an inefficient ligation. Optimisation 
was done that addressed all of these issues, resulting in a considerably improved 
method. In addition, higher PCR bands following PAT that often appeared on gels 
were identified as artefactual multimers. These could be removed by running the 
PAT products on a fully denaturing TBE-urea PAGE gel – a finding that should prove 
useful. Attempts to perform TAIL-seq were not ultimately successful in yielding 
usable data. Using the starting method, provided to us by the authors of the original 
TAIL-seq paper (Chang et al. 2014), we were unable to even generate a library. After 
further attempts and troubleshooting, the method was improved, most notably in 
the ligation efficiency, and a library was generated. Sequencing data from the library 
showed poly(A) tails and uridylation but 3’ UTRs were too short (suggesting too 
great a degree of RNase T1 digestion) and counts were too low. As mentioned, 
however, considerable improvements were made, and further refinement should 
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yield usable data. Presently, work is being done in the group to develop an altered 
version of TAIL-seq termed quanTAIL-seq. The method aims to address inefficiencies 
in the TAIL-seq workflow that should yield libraries from which better quality data 
can be obtained. When quanTAIL seq is fully developed, usable poly(A) tail data 
should be obtainable. 
8.2 Polyadenylation in the inflammatory response 
An inflammatory system was successfully established in which LPS was used as a 
stimulus to induce an inflammatory response in RAW 264.7 cells. It was found that 
withdrawal of serum from the medium 24 hours prior to addition of LPS resulted in a 
greater degree of induction (Figure 4.1), and so this was done as standard in all 
experiments thereafter. It should be noted that many other groups do not withdraw 
serum prior to LPS induction (H. G. Kim et al. 2006; Y. Li et al. 2016; Shin, Lee, et al. 
2009), and so the absence of growth factor signalling in our cells cf. the presence of 
it in theirs should be borne in mind when comparing data. 
Once the system was established, the improved PAT procedure was applied to 
analyse poly(A) tail size changes over the inflammatory response. As can be seen in 
Figure 4.3, the Tnf and Cxcl2 poly(A) tails change are variable while that of Rpl28 
remains constant. The Tnf poly(A) tail shortens much faster than that of Cxcl2. PAT 
performed on nuclear RNA (Figure 4.4) confirmed that the initial poly(A) tail of Tnf 
was variable in size at different timepoints. However, the change is relatively 
modest, only observed in one replicate, and data is needed to show that a control 
mRNA (e.g. Rpl28 does not change). It should also be noted that the initial poly(A) 
tail size difference (Figure 4.4) was inferred from PAT performed on nuclear RNA, 
assumed to be newly synthesised. Using an independent method of isolating newly 
synthesised RNA, like 4-thiouridine labelling, followed by PAT would support the 
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idea that initial poly(A) tail size is variable. Also, nuclear PAT was only done for Tnf. 
PAT data to show that initial tail size does not change for a control mRNA is needed 
to confirm the validity of the finding. Since the poly(A) tail size of Tnf in total RNA 
changes so quickly, it may be that a greater proportion of Tnf mRNA is made with a 
longer poly(A) tail earlier on in the time course. Repeating the time course with 
more timepoints across multiple replicates and with control mRNAs for reference 
would be worthwhile. However, the indication that initial poly(A) tail size is variable 
is interesting and this may represent a means for regulation of the inflammatory 
response. Regulation at the level of polyadenylation is a phenomenon that we have 
observed in the serum response in NIH-3T3 mouse fibroblasts (Singhania et al, 
manuscript under review). A similar phenomenon may exist in the inflammatory 
response. 
8.3 Mechanistic insight into cordycepin’s mode of action 
Anti-inflammatory effects of cordycepin are well documented, and a range of 
mechanisms have been proposed to explain its effects. This project confirms 
previous findings that cordycepin has anti-inflammatory effects. Given that the 
effects of C. militaris extract and cordycepin were very similar (Figure 5.1), and that 
the concentration of cordycepin in the C. militaris was almost the same as in the 
cordycepin stock (Table 5.1), it stands to reason that cordycepin is likely to be the 
active component of C. militaris. This was not the case for O. sinensis extract, in 
which the cordycepin concentration was 5 orders of magnitude lower, but anti-
inflammatory effects were still observed, and so cordycepin is unlikely to be the 
active compound in this fungus. 
Contrary to data obtained in ASM cells (Kondrashov et al. 2012), there appear to be 
effects at the transcriptional level (Figure 5.4). A decrease in transcription may be a 
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result of interfering with NF-B signalling, but cordycepin did not impede the 
degradation of IB (Figure 5.11) suggesting that this is not the case. Other 
explanations include effects on polyadenylation causing decreased transcription 
termination efficiency (Figure 5.9 and 5.10) leading to inefficient recycling of 
transcriptional machinery (Mapendano et al. 2010), or that cordycepin may arrest 
the mRNA 3’ cleavage complex as it does in vitro (Zarkower and Wickens 1987). If 
the cleavage complex is arrested, thus sequestering processing factors, generation 
of transcripts with high processing factor requirements could be limited by the 
availability of factors. In both cases (inefficient recycling of transcriptional machinery 
or lack of availability of processing factors), genes being transcribed at high rates 
would be expected to be most affected. However, the idea that cordycepin affects 
those mRNAs that are transcribed at high rates is inconsistent with the observation 
that no correlation was observed between transcription rate and cordycepin 
sensitivity (Figure 6.2). Alternatively (or additionally), cordycepin’s mechanism may 
include effects on signal transduction – there is evidence that it inhibits AKT 
phosphorylation (H. G. Kim et al. 2006) which may decrease NF-κB activation 
(Rajaram et al. 2006; Dan et al. 2008). Co-administration of cordycepin and 
pentostatin (inhibitor of adenosine deaminase) potentiated cordycepin’s repressive 
effects on inflammatory mRNA levels (Figure 5.5A), suggesting that deamination of 
cordycepin reduces its activity. However, such effects were less clear in cells from 
which serum had been withdrawn (Figure 5.5B). This observation may have arisen 
due to the presence of adenosine deaminase in the serum, such that potentiation of 
cordycepin’s effects through prevention of its deamination may become less 
pronounced in the absence of serum (since there would be less adenosine 
deaminase available to deaminate the cordycepin). The effects of cordycepin were 
abrogated by inhibiting either the adenosine transporter or adenosine kinase using 
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S-(4-Nitrobenzyl)-6-thioinosine (NBTI) or 5-Iodotubericidin (ITu) respectively (Figure 
5.6). This outcome strongly suggests that cordycepin must be imported and 
phosphorylated in order to elicit its anti-inflammatory effects, and therefore that its 
effects are intracellular. Since effects of cordycepin on adenosine receptors have 
been reported (Kadomatsu et al. 2012; Kitamura et al. 2011; Nakamura et al. 2006), 
we sought to test whether extracellular effects of cordycepin in the RAW 264.7 
system were present, although the NBTI/ITu experiment suggested that they were 
not. Repressive effects of adenosine were observed for Il1b, but were much lower 
than those of cordycepin for other mRNAs (Figure 5.6), suggesting that the two 
compounds function in different ways. NBTI or ITu should not alter the effects of 
adenosine if it acts extracellularly, so repression of Il1b mRNA should be maintained 
in the presence of either inhibitor. The data were too variable to confirm this, 
however. 
To distinguish the effects of cordycepin and adenosine, we conducted the washing 
experiment (Figure 5.7), but the results were inconclusive. A different experiment 
could be done in which the effects of cordycepin are simply compared in the 
presence and absence of adenosine receptor antagonists. The ability or inability of 
adenosine receptor antagonists to relieve cordycepin-mediated repression of 
inflammatory gene expression would include or exclude adenosine receptors 
respectively in cordycepin’s mode of action. The antagonists would need to have a 
higher affinity for the recptor(s) than cordycepin in order for the experiment to 
provide an answer, however.  
The poly(A) tail size of Tnf was found to be elongated in response to LPS stimulation 
(Figure 4.3), and a size increase is present in the initial poly(A) tail size (Figure 4.4). 
Furthermore, cordycepin-treated cells display a much more modest increase in 
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poly(A) tail size after LPS stimulation. This shows that effects of cordycepin on 
polyadenylation are present, consistent with an intracellular mode of action. Further 
work would be required to establish whether the shorter poly(A) tail has a role in 
mediating cordycepin’s effects, or whether it is merely a consequence of its effects. 
Cordycepin was found to have no effect on the breakdown of IκBα (Figure 5.11). 
This is at odds with findings from Peng et al (Jie Peng et al. 2015). This could be due 
to the differences in timings – they used a 24 hour incubation with LPS, while my 
observations of IκBα levels were within a 30 minute window after addition of LPS, 
and so signalling events would be at different stages. Kim et al, who also used LPS as 
a stimulus in RAW 264.7 cells, reported that cordycepin treatment decreased 
phosphorylation of IκB after 2.5 hours of LPS stimulation. Their paper does not show 
total IκBα levels, which is what my data show, and so I cannot directly compare their 
data to mine. Also, without knowing total IκBα levels, decreased signal of p-IκBα 
could be explained either by decreased phosphorylation (as Kim et al conclude) or 
increased degradation of the protein entirely. My observation that IκBα degradation 
is not prevented by cordycepin suggests that NF-κB translocation into the nucleus 
would be unimpeded, while Kim et al show that NF-κB translocation is inhibited by 
cordycepin (H. G. Kim et al. 2006). When measuring this, Kim et al used a longer LPS 
stimulation (2.5 hours). It would be interesting to repeat my experiments across a 
broader range of timepoints in order to better understand the timings of 
cordycepin’s reported effects. It would also be informative to assess localisation of 
NF- κB, as well as phosphorylation of IκBα and activation of upstream members of 
the pathway including IκB kinases (IKKs). In this way, a more complete picture would 
be obtained regarding the effects of cordycepin on NF-κB signalling (none of which 
were detected in my experiment). It should be noted that the localisation of NF-κB is 
not the only means to its regulation. Posttranslational mechanisms including 
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phosphorylation and acetylation of NF-κB subunits also play roles (Karin and Ben-
Neriah 2000; Christian, Smith, and Carmody 2016) which may be affected by 
cordycepin. Phosphorylation of p65 is an important activating modification in NF-κB 
signalling (see section 1.3.2.1.2 for more detail), and Li et al show this to be reduced 
by cordycepin (Y. Li et al. 2016). Such posttranslational modifications could also be 
assessed in a broader investigation into the effects of cordycepin on NF-κB 
signalling. 
8.4 High throughput analysis of cordycepin’s effects 
Genome-wide analysis by microarray showed that immune and inflammatory gene 
clusters are the most significantly enriched in the list of genes downregulated by 
cordycepin treatment compared to LPS alone. If intrinsically unstable mRNAs, which 
many inflammatory mRNAs are (P. Anderson 2010; Stumpo, Lai, and Blackshear 
2010), were made with short poly(A) tails due to cordycepin treatment, this might 
explain why they are particularly sensitive to cordycepin. Since removal of the 
poly(A) tail is generally the first and rate-limiting step of mRNA decay (C.-Y. A. Chen 
and Shyu 2011), the loss of the poly(A) tail could leave unstable mRNAs susceptible 
to fast decay. However, no significant correlation was observed between mRNA 
stability and fold change after cordycepin treatment (Figure 6.2). If cordycepin 
arrests the cleavage complex as it has been shown to do in vitro (Zarkower and 
Wickens 1987), this could lead to a decreased availability of 3’ processing factors to 
such an extent that they become rate-limiting for transcripts with high processing 
factor requirements. High processing factor requirements could arise from genes 
with such a high transcription rate that the sheer number of transcripts being made 
requires a correspondingly high number of processing factors. Alternatively, such a 
requirement could exist in mRNAs with inefficient poly(A) signals (PASs) due to 
suboptimal cis elements. Figure 6.2 shows that no correlation was observed 
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between transcription rate and cordycepin sensitivity, and so this model does not fit 
either. To test whether there is a link between the efficiency or “strength” of poly(A) 
sites and cordycepin sensitivity from the microarray data, a bioinformatic approach 
could be used. However, preliminary analysis by project students of microarray data 
for cordycepin treatment in NIH-3T3 cells indicates that such a link is unlikely to 
exist. The arrested cleavage complex that forms the basis of the model has only 
been detected in vitro. It would be worthwhile investigating whether the 
stabilisation of the complex by cordycepin is a phenomenon that occurs in 
cordycepin-treated cells. Microarray analysis revealed an enrichment of long 
noncoding RNAs (lncRNAs) in cordycepin-treated cells (Figure 6.3). Given that there 
is a class of lncRNAs whose nuclear degradation is enhanced by polyadenylation 
(Beaulieu et al. 2012), this enrichment is consistent with a model in which 
cordycepin inhibits polyadenylation. If cordycepin inhibits polyadenylation of these 
lncRNAs, such RNAs would be expected to become stabilised (since their 
degradation is dependent upon polyadenylation). As mentioned previously, 
cordycepin causes repression of inflammatory genes at the transcriptional level, as 
inferred from unspliced mRNA levels (Figure 5.4). Cordycepin’s anti-inflammatory 
effects are very fast, since the addition of cordycepin 10 minutes after the addition 
of LPS or 60 minutes before led to virtually the same degree of repression of 
inflammatory mRNAs (Figure 5.3). This indicates that the anti-inflammatory effects 
are mediated very quickly, and unlikely to occur through a slow secondary process of 
altering transcription of a transcription factor. Rather, the effects are likely to be 
mediated either through a primary effect or through a fast secondary effect. This 
could be through effects on polyadenylation or effects on signal transduction e.g. 
AKT inhibition, as Kim et al claim is integral to cordycepin’s activities (H. G. Kim et al. 
2006). The observation that a set of lncRNAs are stabilised by cordycepin presents 
 161 
another explanation: if such lncRNAs regulate inflammation, whether by directly 
regulating inflammatory gene expression or modulating signal transduction, then 
their stabilisation by cordycepin could be responsible for the observed effects. Such 
a secondary effect could be quick enough to fit the data, since, in this model, 
cordycepin stabilises RNAs that have already been transcribed. Investigation into the 
potential involvement of the cordycepin-stabilised lncRNAs in mediating anti-
inflammatory effects would be worthwhile. 
To address the question of whether cordycepin’s acts through effects on 
polyadenylation or not, inhibition of polyadenylation in other ways would be worth 
attempting to see whether this replicates cordycepin’s effects. However, our 
attempts so far to perform knockdown of poly(A) polymerases (PAPs) in RAW 264.7 
cells have been unsuccessful. Alternatively, other unrelated polyadenylation 
inhibitors could be used, or perhaps expression of a dominant negative PAP mutant.  
8.5 Demonstrated therapeutic potential of cordycepin in osteoarthritis 
Cordycepin has been successfully used as an anti-inflammatory compound in a 
number of animal models of disease and injury (X. Yang et al. 2015; M. Chen et al. 
2012; H. Kim et al. 2011; Cheng et al. 2011). During this project, work done by James 
Burston (School of Life Sciences, University of Nottingham) showed that orally 
administered cordycepin alleviated pain behaviour in a rat model of osteoarthritis 
(Figure 7.1). No differences in poly(A) tail size between rat treatment groups were 
observed in synovial RNA, however (Figure 7.4), nor were there differences in the 
mRNA levels of cytokines that were assessed (Figure 7.3). If cordycepin has effects 
on polyadenylation in vivo, there are several possibilities that would account for our 
not detecting them. We may have been looking at the wrong time or in the wrong 
tissue. Also, it could be that total poly(A) tail size is unchanged but specific mRNAs 
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do experience changes. In this case, a more targeted approach of doing PAT on the 
rat RNA for specific mRNAs would be appropriate. Tnf may be one such mRNA, since 
its poly(A) tail was affected by cordycepin in RAW 264.7 cells (Figure 5.8). 
Alternatively, a high throughput method like TAIL-seq could be used to observe 
genome-wide poly(A) landscape changes between animals, but at much greater 
expense. If RNA from multiple tissues and at multiple stages in the disease model 
were to be analysed, the expense of using TAIL-seq would certainly become 
prohibitive. 
Limited data notwithstanding, the effects of cordycepin on pain behaviour in the rat 
OA model represent a promising start into an assessment of cordycepin’s suitability 
as a lead compound for the development of new OA treatments. These findings are 
complemented by evidence of its anti-inflammatory effects in chondrocytes from OA 
patients (Ying et al. 2014). The ability of cordycepin to overcome impairment of 
osteogenesis and inhibit osteoclastogenesis (F. Wang et al. 2015; Dou et al. 2016) 
suggests a potential to shift the balance of bone destruction and formation. Changes 
in subchondral bone over the course of OA in the rat model may therefore be worth 
monitoring between cordycepin and non-cordycepin treated animals. Finally, as a 
compound with demonstrated anti-inflammatory effects, cordycepin would be 
worth testing in rheumatoid arthritis (RA) – a disease with a more inflammatory 
nature. Anti-TNF therapies have been highly successful in the treatment of RA (P. C. 
Taylor, Taylor, and Feldmann 2009; Brennan et al. 1989), and cordycepin represses 
TNF levels, both at the level of mRNA – as has been observed in this project – and 
protein (Shin, Lee, et al. 2009; Jie Peng et al. 2015). However, anti-TNF biologics 
have their shortcomings, including heightened risk of infections and loss of efficacy 
over time (Askling and Dixon 2008; Neovius et al. 2015; P. C. Taylor, Taylor, and 
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Feldmann 2009). Cordycepin’s broad anti-inflammatory action may mean it has 
potential for the development of new RA treatment options. 
In summary, this project provides insight into the effects of cordycepin, both at the 
transcriptomic and molecular level. In the context of inflammation, Tnf was found to 
have a dynamic poly(A) tail size in response to LPS stimulation, and this was true of 
the initial poly(A) tail size i.e. Tnf was made with a poly(A) tail of different size at 
different points in the inflammatory response. Cordycepin was shown to be anti-
inflammatory and, in addition to reducing levels of inflammatory mRNAs, shortened 
the Tnf poly(A) tail. This effect, along with a stabilisation of lncRNAs, provide 
potential leads to be followed to discover the role of inhibiting polyadenylation in 
mediating cordycepin’s observed effects. Improved and emerging poly(A) tail 
measurement techniques will doubtless play a role in such investigation. Lastly, 
promising animal data support further research into the potential use of cordycepin 
as a therapeutic agent. 
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